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Abstract  
 
 
Genetic and epigenetic mechanisms play vital roles in the initiation and progression of cancer. 
The motivation of the work reported here is thus to support research in this area, by 
investigating genetic and epigenetic mechanisms and the inter-relationships between them 
through provision of a platform (in-house biomedical resource (StatEpigen)) for data collation 
and analysis. StatEpigen is targeted initially to collating information on colon cancer and the 
basic aim of this project is to enhance, evaluate and ensure robustness of this resource.  
 
Elements involved in building towards a more comprehensive ‘picture of needs’ to date include: 
a comparative study of available epigenetic/epigenomic biomedical resources, manual 
augmentation of StatEpigen database resource and an in-depth analysis of a set of germline 
mutated colon cancer genes from the phylogenetic perspective, to link resource provision to the 
experimental base and address key bioinformatics questions.  
 
Comparative study has confirmed the current importance of epigenetic studies and provided 
information on resources that may offer integration potential for StatEpigen. Manual data 
augmentation (15% contribution to the current datasource, URL: http://statepigen.sci-
sym.dcu.ie/) permitted assessment of the data curation process itself, and also motivation and 
planning for some degree of future automation. The in-depth genetic analysis addressed a 
specific-research question relating to the suitability of the murine model as a reference organism 
for colon cancer in humans. Analysis of the mouse parallel (following 180 MY of independent 
evolution) revealed that some genes can not be used as suitable cancer model for humans.  This 
finding provided stimulus for developed analyses (e.g. through StatEpigen) of related epigenetic 
characteristics and genetic-epigenetic interactions that are influential in the initiation and 
progression of the disease.  
 
A future focus for StatEpigen includes exploitation of the data already gathered, as well as tool 
development for automation of the data augmentation process.  
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  Chapter 1 
Introduction 
1.1 Background to Epigenetics 
In any assessment of data resource requirements, a clear overview of current availability 
is required. This is true also for the field of ‘epigenetics’, which has attracted 
considerable attention over the last decade (especially after the completion of Human 
Genome Project) (Human Genome Management Information System, 2013). 
 
Epigenetics is concerned with the study of heritable and reversible changes in gene 
expression or cellular phenotype that occur without corresponding alteration in the 
DNA sequence – “epi” from the Greek meaning over (–genetics). Epigenetic changes 
occur due to mechanisms such as DNA methylation, histone modification (methylation/ 
demethylation, acetylation/ deacetylation, phosphorylation, ubiquitylation and 
sumoylation) and small regulatory RNA changes (Goldberg et al. 2007, Fernberg 2004). 
Gene silencing, genomic imprinting, X-chromosome inactivation are processes that 
utilize epigenetic processes.  
 
DNA methylation is addition of methyl group (–CH3) to the 5 position of the cytosine 
pyrimidine ring or the number 6 nitrogen of the adenine purine ring (cytosine and 
adenine are two of the four bases of DNA).  In most of the cases, addition of methyl 
marks leads to repression of gene activity. In mammals, methylation is found sparsely 
but globally, distributed in definite CpG sequences throughout the entire genome, with 
the exception of CpG islands (CpG-rich regions of around 1kb that represent 
approximately 1% of genome, and often located around the promoters of housekeeping 
genes). DNA methylation patterns that extend beyond CpG methylation are also 
observed in different animals (Bird 2002, Lister et al. 2009). 
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Histone (protein components of chromatin around which DNA can wind for compaction 
and gene regulation) modification occurs when the binding of epigenetic factors to 
histone ‘tails’ alter the extent of wrapping of DNA around histones and thus allows the 
gene/s (in the DNA) to be switched on or off. Molecules that bind to histones include 
methyl, acetyl, phosphate groups and ubiquitin and sumo proteins (Esteller 2011). The 
attachment of these molecules to histones alters DNA activity in different ways. DNA 
methylation and histone modifications (explained in more detail in Chapter 3) are two 
of the best understood mechanisms of epigenetic modifications to date. Genomic 
imprinting is also an important epigenetic phenomenon whereby inherited genes are 
‘imprinted’ due to one copy of the gene being epigenetically marked or imprinted in 
either the egg or the sperm. Thus the allelic expression of an imprinted gene depends on 
whether it is inherited maternally or paternally. Imprinted expression can also vary 
between tissues, developmental stages and species (Reik and Walter 2001). Gene 
silencing is the “switching off” of a gene that can be triggered by any of the epigenetic 
events mentioned earlier and is an epigenetic process of gene regulation. 
  
To summarize, epigenetic events have the potential to reprogramme genomes without 
any genetic modification. The term “epigenetics” was coined by Conrad Waddington in 
early 1940s to describe ‘environmental effects on the phenotype’ but the molecular 
comprehension was delayed for around half a century (House 2010). The role of 
epigenetics in diseases is highlighted by genetically identical (monozygotic) twins that 
can develop distinctly different disease profiles and life projections later in their lives 
(also called twin discordance phenomenon, Fraga et al. 2005, Baranzin et al. 2010). In 
recent years, ‘epigenetics’ has grown into one of the most dynamic areas of biological 
research.  
 
Epigenetic studies are also new and core to the investigation of human development, 
moving focus from the way in which genes and gene products bring the phenotype into 
being, towards a focus on the mechanism through which cells become committed to a 
particular structure or function and the way in which these features are transmitted in 
cell lineages. Epigenetics is thus important not only for its practical applications, e.g., in 
cancer treatment, but also for gaining a greater understanding of the way in which 
heredity and evolution occur, since non- DNA inheritance systems may be involved 
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(Jablonka and Lamb 2002). In terms of involvement in the etiology1 of human disease, 
the role of epigenetics is increasingly recognised (e.g. Jiang et al. 2004, Feinberg et al. 
(2004 and 2006) and more recently, Rodenheiser and Mann (2006), Steinmann et al. 
2009 and many others), these are described in detail in the following section. 
 
Epigenetics in Human Diseases 
Many studies have been conducted to explore the role of epigenetics in the occurrence 
of different diseases or conditions. Genetic, epigenetic and environmental factors are 
likely to contribute to the pathogenesis of the diseases. Some diseases or conditions for 
which knowledge of epigenetic factors are acquired are: cancer (Esteller 2011), auto 
immune disorders (Quintero-Ronderos and Montoya-Ortiz 2012), schizophrenia (Deng 
2010), autism (Grafodatskaya 2010) and aging (Susana 2010), where DNA methylation 
and histone modification are the predominant epigenetic mechanisms involved. 
Similarly, Prader Willi Syndrome (when genes derived from father) /Angelman 
Syndrome (when same genes derived from mother) (Adams 2008); Beckwith-
Wiedeman syndrome (BWS: typically characterised by excessive growth caused by 
under-expression of a growth-suppressing gene and over-expression of a growth-
promoting gene, both found on chromosome 11) are found to involve genomic 
imprinting phenomenon (Reik and Walter 2001). Additionally, other 
diseases/conditions, e.g. diabetes, neurobiological disorders and cardiovascular 
diseases, stress-related disorders (Post traumatic stress disorder), muscular degeneration 
and many more are also studied currently for possible epigenetic links. 
 
Epigenetic Inheritance  
Since epigenetic events are heritable, transgenerational epigenetic inheritance can be 
studied (similar to Lamarck’s original evolutionary theories, Lamarck 1914). Indeed, 
studies have recently emerged in epigenetics research that examine (i) epigenetic 
inheritance in descendants (even up to a number of generations) resulting from 
epigenetic changes in parents (Eaxinger and Whitelaw 2010), as well as (ii) testing the 
evolutionary implications of epigenetic inheritance (Jablonka and Lamb 1995) and (iii) 
the analyses of environmental factors and their impact on epigenetic events. The thrifty 
phenotype hypothesis (Hales and Barker 1992) that says that the reduced fetal growth in 
                                                 
1 Study of causes of disease (Footnotes occur as superscripted numbers throughout the thesis) 
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limited supply of nutrients is associated with a number of chronic conditions later in life 
has motivated thrifty epigenotype hypothesis (Stöger 2008). 
1.2 Animal Reference Models  
Animal models are in use for different human diseases, to understand the etiology and 
pathogenesis of diseases – they provide a vital cornerstone for modern medicine. 
Currently animal models are also used for epigenetic studies and transgenerational 
epigenetic study, as described in more detail in the following section. The diseases in 
mouse and human might not be entirely equivocal, at the phenotypic, epigenetic or 
genotypic level. It would be desirable to test for the existence of measurable differences 
between model organisms before using them as the ‘disease models’. 
 
Animal Reference Models for diseases  
 
For different diseases (e.g. cancer, COPD, pneumonia, asthma, pulmonary 
hypertension, lung disease, rheumatoid arthritis) animals are used as references. The 
most common animal used in human disease studies is the mouse. The major 
advantages of using mouse are that, it is small in size (ease of handling),  has a rapid 
reproductive rate/ short life span (possibility of studying several generations over a 
fairly short period of time), and has a high level of genetic similarity to human (78% 
identity at the protein coding level, Waterston et al. (2002)). While the disadvantages 
include the differences between mouse strains - studies suggest that more than 1 strain 
of mouse is used per study to control for strain variation (Rivera and Tessarollo 2008). 
Some diseases in mouse offer a completely different phenotype than human e.g. Asthma 
and fibrosis (Rivera and Tessarollo 2008). Other animals used as models for human 
include chimpanzee for modelling hepatitis C, monkeys for modelling polio and guinea 
pig for modelling diabetes and tuberculosis (Rivera and Tessarollo 2008). 
 
Animal Reference Models for epigenetic studies 
 
For epigenetic studies (particularly maternal nutrition based epigenetic studies), rodents, 
and specifically mouse, are commonly used. For environmental epigenetic studies and 
analyses of the phenotypic outcome, (e.g. how maternal diet can alter epigenetic and 
accompanying phenotypic response in the offspring), Agouti viable yellow (Avy) and 
axin 1 fused (Axin1Fu) mice are used most notably. These mice have a well-
characterized locus whose methylation pattern governs dramatic phenotypic outcomes 
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which makes them suitable for such study (Rosenfeld 2010). However, other strains of 
rats and mice, sheep, and Japanese macaques are also used to study the epigenetic effect 
of maternal diet on offspring. Similarly, for transgenerational animal studies, again 
Agouti viable yellow (Avy) and axin 1 fused (Axin1Fu) mice, rats and other strains of 
mice are also used. For methyl-deficient dietary animal studies, different strains of rats 
and mice are used (Rosenfeld 2010). 
1.3 Cancer Focus 
Cancer as a set of disease types - classification  
Cancer (or neoplasm) is a generic term for group of over 100 diseases, characterized by 
abnormal, uncontrolled cell growth. It is the leading cause of death worldwide, resulting 
in over seven million fatalities each year (Ferlay et al. 2010). At advanced stage, cancer 
cells can spread to other parts of body/organs through blood and lymph systems. This 
process is termed ‘metastasis’ (and is a fatal stage).  
 
Cancers are named for the organ or type of cell in which they start, e.g. cancer 
beginning in colon is called colon cancer. However, cancer can be broadly classified2 
as: 
Carcinoma: Cancer that begins in skin or in tissues that line/cover internal organs. 
Sarcoma:   Cancer that begins in bone, cartilage, fat, muscle, blood vessels, or other 
          connective or supportive tissue. 
Leukaemia: Cancer that starts in blood-forming tissue such as the bone marrow and 
           causes large numbers of abnormal blood cells to be produced and enter the 
           blood stream. 
Lymphoma and myeloma: Cancers that begin in the cells of the immune system. 
Central nervous system cancers: Cancers that begin in the tissues of the brain and 
spinal cord.  
The word tumour is used as a synonym for cancer sometimes, but benign tumours are 
not cancerous, this is true only for malignant tumours. Lung, breast, prostrate, colon, 
stomach, liver cancers are the most common forms of cancers. Regardless of the tissue 
of origin, cancer essentially arises from a single cell. The transformation from a single 
normal cell into a tumour cell is a multistage process, typically a progression from a 
                                                 
2 Source of information : www.cancer.gov  
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pre-cancerous lesion to malignant tumours. The cause can be attributed to interaction 
between genetic factors and different carcinogenic factors, namely physical carcinogens 
(e.g. ultraviolet and ionizing radiation), chemical carcinogens (e.g. asbestos, 
components of tobacco smoke, aflatoxin3, arsenic), and biological carcinogens (e.g. 
infection from certain pathogens). The carcinogens might have some role to play in 
alterations of the genetic and epigenetics variety. Thus it can be said that, at a  
molecular level, the genetic and epigenetic factors and the interaction between them can 
cause cancer. Many current studies back the genetic-epigenetic interaction for the 
etiology of cancer (Sawan et al. 2008, You and Jones 2012).  Aging is also considered 
as one of the causes of cancer. More detail on the interaction between genetic and 
epigenetic factors is given in Chapter 3.  
Colon cancer focus  
 
Colon cancer (also known as colorectal cancer, CRC or bowel cancer, characterized by, 
rectal bleeding and anaemia that sometimes is associated with weight loss and changes 
in bowel habits), is the third most common cancer in males and second in females 
(Ferley et al. 2008).  Because of its high incidence, there is a lot of research on this form 
of cancer and there is ample data available.  
 
To study the incidence and pathogenesis of cancer from available data resources, colon 
cancer was selected as the starting point and is the focus of this thesis. From this work 
future research can expand into additional cancer types. The aim of this work is to use 
the genetic (mutation events) and epigenetic data and the interactions between them 
from existing literature. Specifically, the statistical relationship between the genetic and 
epigenetic events by curating the information, and collecting it in a suitable data 
resource (StatEpigen Knowledge Management System (Barat and Ruskin 2010)) so that 
it can be fed into different modelling software being developed in our research group. 
This will allow the modelling software to use real patient data to check the validity of 
the model itself. The database can also be used by other researchers as it is made 
available via the web portal http://statepigen.sci-sym.dcu.ie/, one example of how this 
data can be used is outlined in Chapter 4 and has been published (Morgan et al. 2012). 
StatEpigen Knowledge Management System is our in-house biomedical database 
                                                 
3 A food contaminant 
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resource and is currently specific to colon cancer genetic and its associated epigenetic 
factors. This database intends to incorporate other cancer types in future.  
1.4 Knowledge Mining  
Since knowledge mining (data mining) is an important part of the knowledge discovery 
process, the genetic and epigenetic information are nowadays made available in 
database resources. More details on this are in Chapter 2. For in-house StatEpigen 
database as well, in addition of using the StatEpigen data in modelling software, it can 
also be used for data mining and valuable information can be extracted from the 
process. The results from this analysis will however be more accurate, with more 
information/data in the database. More is given on this and is in Chapter 5.   
 
Parallel genetic resource development  
 
The database can benefit from the links to /incorporation of addition of genetic 
resources (e.g. COSMIC, Wellcome trust). Information gathered from parallel research 
efforts on genetics, which can be linked to genetic and epigenetic events and their 
interactions, can be added continuously. Additionally, genetic and epigenetic data 
gathered for animal models of human diseases (e.g. cancer) can also be drawn upon.  
 
Key Requirements 
 
The efficient augmentation of the StatEpigen database is the key requirement for now. 
This will enable improved accuracy for data mining analyses based on the data as well 
as enable precise evaluation of cancer models. The manual augmentation process is 
currently implemented which is time consuming, although accurate. This needs to be 
automated / semi- automated in the near future for increased efficiency. 
1.5 Thesis scope – Aims and Achievements 
This thesis comprises five chapters. Chapter 1 provides the background information in 
the form of a general introduction to the field while Chapter 3 is focused on cancer and 
its causative agents, namely genetic and epigenetic factors, at a molecular level.  
 
In general, the objective of this research is to understand the role of genetic and 
epigenetic factors and the interactions between them. To be specific, the aim is to 
streamline (via data curation of scientific literature and augment it manually in 
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StatEpigen database) the knowledge that we have at present in scattered form (in the 
form of literature from various fields), and make it usable to extract valuable 
information (via data mining). The database is made available to the scientific 
community via webportal http://statepigen.sci-sym.dcu.ie/ and is currently also being 
used to feed different modelling software being developed in the computing lab (which 
enable testing of the software with real patient data).   
 
The data curation process currently is manual and during this project, 15% of the 
current data content (genes 728, mutations 150, and epigenetic events 318) was 
contributed to the database. As the project aims for an upgrade of the current system in 
future, some integrable database resources are also explored along with automatic 
source provision for StatEpigen KMS, (Chapter 2). Furthermore, the current availability 
of epigenetic resources (published in Shakya et al. 2012) in addition to genetic 
resources are also examined while assessing the data resource requirement. A 
framework for upgrading the current system is also proposed (explained with a 
schematic diagram and a flowchart), which is available in Chapter 5. Some results from 
an exploratory data analysis are also provided in this chapter. Besides this, genetic 
analysis of colon cancer genes is also carried out from phylogenetic perspective (in 
Chapter 4). This analysis identified differences between human and mouse and 
presented us with 17 genes that are positively selected (with respect to site and lineage 
specific analyses, Morgan et al. 2012) which can be further explored for epigenetic 
events occurring at specific sites with StatEpigen data. Given the importance in cancer 
of genetic - epigenetic interactions and their synergies, such analyses contribute both to 
current knowledge and future discovery. 
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2 Chapter 2 
Biomedical, Epigenetic Resources and StatEpigen 
2.1 Introduction 
In this chapter, we present a comparative survey of available biomedical resources 
including in particular, those recording epigenetic information. Cancer-related 
epigenetic resources are investigated, including specialized options, which include an 
in-house specific database resource StatEpigen (Barat and Ruskin 2010), focussed on 
colon cancer in its initial inception. Some content of this chapter, (Section 2.4), has 
appeared as a recent publication, (Shakya et al. 2012)4. 
Completed in 2003, the Human Genome Project (HGP, a 13 year project), led to the 
identification of more than 20,000 genes and determined the 3 billion chemical base 
pairs of human DNA. In the past decade, the tremendous advances in medical 
technologies, corresponding development in computer power, storage capacity, inter-
connectivity and cost effectiveness, has led to an explosive growth in generation and 
collection of all aspects of biomedical data, allied with the importance of Bioinformatics 
as a field (Choudhary et al. 2011). Data warehousing (Marakas 2003), as a way of 
dealing with large dataset size, combines databases across an entire enterprise, whereas 
independent or federated systems seek to integrate multiple autonomous databases into 
a single federation, with constituent databases interconnected via a network and often 
geographically decentralised, (Heimbigner and McLeod 1985, Sheth and Larson 1990, 
Devlin 2012). An example includes many bioinformatics data sources linked by the 
Entrez Life Sciences search engine.5  
 
                                                 
4 In Epigenetics Volume 7, Issue 9. 
5 Managed by the U.S. National Library of Medicine, NIH, Maryland, USA . 
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From patient records to information from pharmaceutical studies, specific disease 
research, and different ‘omics’ studies, biomedical data cover a wide range of data. 
Well-known examples of the latter include genomics, proteomics and transcriptomics. 
Resource types can be classified by two key features; firstly, the means or method by 
which access is provided to entities; secondly, the nature of the entities themselves. The 
repository or web service that provides access to these data is a vital component of 
biomedical data resourcing (Tenenbaum et al. 2011). In general, resource providers, 
(such as PubMeth and MutationDB) review research papers from the domain and mine 
these for information relevant to the scientific audience.  Typically, non-profit research 
institutes, such as the Sanger Institute, University of California Santa Cruz (UCSC), 
National Center for Biotechnology Information (NCBI) – National Institute of Health 
(NIH), European Molecular Biology Laboratory (EMBL), European Bioinformatics 
Institute (EBI) and so on, make such data publicly available over the internet for 
analysis.  
 
Biological/biomedical databases themselves are a primary biomedical resource, 
providing data directly on biological quantities, and these co-exist alongside secondary 
and composite resources. Examples of primary databases include those containing 
information on sequence or structure alone, e.g. SwissProt, PIR (protein sequences), 
Genbank and DDBJ (genome sequences). Secondary resources contain derived 
information from primary sources; examples include eMOTIF (Stanford), SCOP 
(Cambridge) while composite resources typically draw information from a variety of 
different databases, such as those of the NCBI genome browser. Here, an overview of 
the principal biomedical resources is provided according to the data mining approach, 
the resource type and scale. 
 
As outlined in Chapter 1 and, in particular, following completion of the Human Genome 
Project, increased attention has been paid to those processes that lead to heritable 
changes in gene expression, (during development or across generations), without 
altering the nucleotide sequence within the DNA. Both epigenetics and epigenomics, 
(the genome-wide distribution of epigenetic changes), have become major areas of 
research focus. Principal epigenetic phenomena encompass DNA methylation, histone 
modification (acetylation/deacetylation, methylation/demethylation, phosphorylation, 
ubiquitylation and sumoylation) while processes utilizing epigenetics include gene 
  
Chapter-2                   Biomedical, Epigenetic Resources and StatEpigen 
 
11 
 
silencing, genomic imprinting, X-chromosome inactivation (also called lyonization), 
bookmarking. Recently-launched large-scale initiatives include IHEC (the International 
Human Epigenome Consortium)6, with plans to map up to 1,000 reference epigenomes 
within a decade, and the Human Epigenome Project (HEP)7, that aims to identify, 
catalogue and interpret genome-wide DNA methylation patterns of all human genes in 
all major tissues (Novik et al. 2002), amongst others. In summarising publicly-available 
biomedical resources here, the particular focus is thus on those that deal with 
epigenomic/epigenetic research. In addition, we assess the data mining capabilities, 
intrinsic to or accessed by these resources, and comment on their adequacy.  
2.2 Knowledge Discovery and Data Mining  
Data mining (broadly the application of algorithms for extracting patterns from data), is 
a major step in the so-called Knowledge Discovery from Data (KDD) process. Pre and 
post-processing of data and pattern extraction are typical steps (Fayyad et al. 1996). The 
KDD process is interactive and iterative, involving numerous steps as illustrated in 
Figure 2.1. The challenges include both social and technical factors, (different 
hardware, software platforms and automation), (Dasu and Johnson 2003), together with 
acquisition of metadata, and establishment of quality metrics. 
  
                                                 
6 Paris, France (February 2010) 
7 Multinational project  (Wellcome Trust Sanger: UK, Epigenomics AG: Germany/ USA, The Centre 
National de Genotypage: France), http://www.epigenome.org/  
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Figure 2.1: Flowchart illustrating the knowledge discovery process 
 
 
Data mining can be categorised into predictive (supervised learning), and descriptive 
(unsupervised learning), methods, covering a range of subtypes (Breiman et al. 1984, 
Groth and Lewis 1998 and Kerr et al. 2008). Semi-supervised learning incorporates a 
combination of both and is an important current direction for research in this area.  
2.2.1 Biomedical Resource Groups: Data Mining 
 
Attempting to present an overview of the spectrum of biomedical resources and 
corresponding analysis capabilities is far from trivial. As illustration, PubMed is the 
U.S. National Library of Medicine’s (NLM) web-based interface to MEDLINE, the 
premier bibliographic index to journal articles in the Life Sciences. MEDLINE includes 
citations from over 4600 of the worlds leading biomedical journals from 1966 to 
present, with even older citations (back to 1951, OLDMEDLINE). A typical 
classification of biomedical resources is to identify parameters or measures targeted and 
the analyses offered, but as new resources or extended provision come online, this needs 
to be continually revisited. Broad categories are highlighted below.  
 
Data preparation (Data collection + 
integration) 
Data pre- processing (Data derivation / merger, Data cleaning, 
normalizing, consistency checks etc.) 
Study Definition (articulating a 
goal, choosing a dependent 
variable or output, specifying the 
data fields) 
Identify exceptions 
in the data /group 
similar data 
Supervised 
Learning?  
 
Yes No 
Dimensionality Reduction 
(PCA, Factor analysis and so on) 
Exploration of existing data mining 
tools, determination of appropriate 
tool, Application and Analysis. 
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Text Mining 
Text mining is heavily dependent on diverse knowledge sources, in part because of the 
complex nomenclature of the biomedical sciences. The two most important controlled 
vocabularies currently are MeSH8 (Medical Subject Headings) and GO (Gene 
Ontology)9. MeSH, a list of standardised vocabulary used by NLM10, is one of the 
vocabularies in the UMLS11 Metathesaurus, a large, multipurpose and multi lingual 
vocabulary database that contains information on biomedical concepts. MeSH contains 
a hierarchical set of controlled vocabulary items taken from medicine, chemistry and 
genomics and now also includes the names of substances with pharmacological action. 
There are close to 300,000 items in MeSH and annotations also provide a rich set of 
metadata, describing articles, as well as a map of the entire biomedical field. GO 
consists of three sub-vocabularies and describes gene products in terms of their 
associated biological processes, cellular components, and molecular functions. PubMed 
articles are indexed using these vocabulary items, which also helps to find articles, 
relevant to the user’s search, but using different terms for the same concepts. 
 
Data Integration and Web Mining 
Another major category of resource provision looks at integration and web mining of 
data. The UMLS (Unified Medical Language System)12 is a set of files and software 
that bring together many health and biomedical vocabularies and standards to enable 
interoperability between computer systems. UMLS can be used to enhance or develop 
applications, such as electronic health records, classification tools, dictionaries and 
language translators. The purpose is the development of computer systems, which 
‘understand’ the meaning of biomedical language (Lindberg et al. 1993 and more 
recently FactSheet, UMLS). The three tools used by UMLS are (i) Metathesaurus, (ii) 
Semantic Network and (iii) SPECIALIST Lexicon. 
 
A number of other recent initiatives in data integration also exist. One is the semantic 
data integration environment that is part of the Biomedical Informatics Research 
Network (BIRN) project (Astakhov et al. 2005). Here, each participating institution 
maintains storage of their experimental or computationally-derived data while a 
                                                 
8 http://www.nlm.nih.gov/mesh/MBrowser.html  
9 http://www.geneontology.org/ 
10 National Library of Medicine (U.S.) 
11 Unified Medical Language System 
12 http://www.nlm.nih.gov/research/umls/ 
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mediator-based data integration system performs semantic integration across the 
databases. This enables researchers to perform analysis based on larger and broader 
datasets than would be available from any single institution’s data.  The aim is a cyber 
infrastructure for biomedical research that supports advance data acquisition, storage, 
management, integration, mining visualisation and other computing and information 
processing services over the Internet. Healthgrid technology also is an emerging trend, 
where these grid infrastructures comprise applications, services or middleware 
components that deal with the specific data processing problems. This technology is an 
integration of bio-medical knowledge, imaging, computational tools, and other 
technologies in diagnosis and treatment (Healthgrid 2004).  
 
Improvements can also be made in web searching for biomedical information. 
Currently, although the web provides easier and more comprehensive access to 
information than do physical environments, it cannot provide an accurate and efficient 
response to user requirements, since machines are not able to interpret and contextualise 
information in the form of natural language. Web mining is expected to improve 
efficient access to information, substituting traditional methods of content-based and 
collaborative recommendation systems, with the new trend in using technologies such 
as intelligent software agents, (Ferber 1999), fuzzy linguistic techniques (Herrera and 
Herrera-Viedma 1998, Morales-del-Castillo et al. 2010), and semantic web technologies 
(Berners-Lee et al. 2001, Lassila and Hendler 2007). A filtering and recommendation 
system that applies a fuzzy linguistic approach, based on semantic web technologies, to 
identify key user information has been reported in (Morales-del-Castillo et al. 2010), 
and facilitates retrieval of information from large repositories as required.  
 
In addition to the diverse set of biomedical resources, generated by the research 
community itself, there are now an increasing number of shared electronic resources. 
The Biomedical Resource Ontology (BRO) has been developed to enable semantic 
resource annotation in the context of discovery on the Internet, (Tenenbaum et al. 
2011). Bioportal, a web repository for biomedical ontologies and data resources offers 
researchers and clinicians access to the web for important biomedical ontologies, (Noy 
et al. 2009), while biomedical/scientific web communities are also being built by 
different groups to share targeted resources. Examples include Alzforum13, (which has 
                                                 
13   www.alzforum.org 
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over 4600 networked researchers seeking the cure for Alzheimer’s), and the 
Schizophrenia Forum14, amongst others. The caBIG® (Cancer Biomedical Information 
Grid)15, is a similar information network, enabling all constituencies in the cancer 
community - researchers, physicians, and patients - to share data and knowledge. The 
aim of caBIG is to provide a framework for creating, communicating, and sharing 
bioinformatics tools, data and research results, while using shared applications, data 
standards and data models. Similarly, a number of biological resources are available 
now as part of the W3C Resource Description Framework (RDF) triples. Gene ontology 
(GOs), ChEBI (Chemical Entities of Biological Interest) and SNOMED CT 
(Systematized Nomenclature of Medicine - Clinical Terms) are well-known ontology 
examples.  
 
Semantic Wikis (Anmueller 2005, Oren 2006), represent another type of effort to 
develop collaborative annotation and knowledge management systems. Gene Wiki, 
(Huss et al. 2008), WikiProteins (Mons et al. 2008), and BOWiki are just some of the 
examples. The Science Collaboration Framework (SCF), (Das et al. 2008), (based on a 
semantically-aware content management system), aims to leverage existing knowledge 
repositories, using annotated information available on the semantic web. 
 
2.3 Genetic/ Genomic Resources in Brief 
These resources are categorized into gateways, genetic databases and mutation 
databases for ease of classification as follows. For our genetic analysis work, (Chapter 
4), Ensembl genomes (Section 2.3.1) and UniProtKB/Swiss-Prot (protein sequence) 
databases were extensively used. The link between hereditary (for e.g. HNPCC, Chapter 
4) as well as sporadic diseases (e.g. sporadic cancer caused by mutation, triggered by 
carcinogen, i.e. epigenetic event in molecular form) to genetics and epigenetics as 
evident by current researches (Chapter 3), links all of these, at some level.  
 
2.3.1 Gateways 
 
                                                 
14 www.schizophreniaforum.org 
15 https://cabig.nci.nih.gov/ 
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Currently, the most widely-used genome browsers are: Ensembl, NCBI Map Viewer 
and UCSC16 although others are also available. Ensembl is a European initiative while 
NCBI and UCSC are U.S. based. These genome browsers act as gateways to 
metadatabase connections. 
Ensembl Genomes17, automatically annotates the genome, integrates this annotation 
with other available biological data and makes this publicly available. The database is 
for vertebrates and other eukaryotic species. The latest (12th) release18 brings the total 
genomes available to 335. Ensembl is a major joint project between EMBL - EBI and 
the Wellcome Trust Sanger Institute, targeting development of a software system to 
produce and maintain automatic annotation of selected eukaryotic genomes. The latest 
release also continues to display a joint gene set based on the merger achieved between 
the automatic annotation from Ensembl and the manually curated annotation from 
HAVANA (Human and Vertebrate Analysis and Annotation) group at Sanger. The 
CCDS (Consensus Coding Sequence, Pruitt et al. 2009) is a consensus project between 
the European Bioinformatics Institute (EBI), the Wellcome Trust Sanger Institute 
(WTSI), the National Center for Biotechnology Information (NCBI), and the University 
of California at Santa Cruz (UCSC) and tracks identical protein annotations on the 
reference mouse and human genomes with a stable identifier (CCDS ID), ensuring that 
these are consistently represented on the NCBI, Ensembl, and UCSC Genome 
Browsers19. Ensembl is powered by Biomart20, a query-oriented data management 
system (Hubbard et al. 2005). Biomart can be used with any data type and is 
particularly suited for providing ‘data-mining’ type searches of complex descriptive 
data. It has powered many other databases, including those of ICGC (International 
Cancer Genome Consortium), HGNC (HUGO Gene Nomenclature Committee), the 
Gene Expression Atlas, COSMIC, Intogen (Integrative OncoGenomics), amongst 
others. In addition, the Biomart plug-in has been used by many third party software 
including Bioclipse, BioExtract, Galaxy, Cytoscape, and biomaRt-BioConductor. It 
should be noted that, Cytoscape is also used as a graphical data visualisation tool in 
StatEpigen.  
                                                 
16 http://www.ensembl.org/index.html, http://www.ncbi.nlm.nih.gov/, http://genome.ucsc.edu/  
17 http://www.ensembl.org/index.html  
18 Version 65, Dec. 2011 
19 If both CCDS, Vega / HAVANA entry and Ensembl entry for a gene agree, it is said to have a golden 
transcript. 
20 http://www.biomart.org/  
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Entrez Gene is NCBI’s repository for gene-specific information. NCBI provides search 
engine forms to query the data in Entrez along with eUtils (Entrez Programming 
Utilities)21, for more direct access to query results. The E-Utils use a fixed URL syntax 
that translates a standard set of input parameters into the values necessary for various 
NCBI software components to search and retrieve requested data. The E-Utils are 
therefore the structured interface to the Entrez system, which currently incorporates 38 
databases storing data, which includes nucleotide and protein sequences, gene records, 
three-dimensional molecular structures, and biomedical literature.  
The UCSC Genome Browser contains the reference sequence and working draft 
assemblies for a large collection of genomes. It also provides portals to the ENCODE 
(Encyclopaedia of DNA Elements) and Neanderthal projects22. 
2.3.2 Genetic Databases  
 
Global efforts for gene annotation include HGNC (HUGO Gene Nomenclature 
Committee)23, the only worldwide authority that assigns standardised nomenclature to 
human genes. This has assigned unique gene symbols and names to more than 31,000 
human genes, of which over 19,000 are related to protein coding.  Genenames.org is a 
curated online repository of HGNC-approved gene nomenclature and associated 
resources including genomic, proteomic and phenotypic information links, as well as 
dedicated gene family pages.  
OMIM (Online Mendelian Inheritance in Man)24 is a database of human genes and 
inherited traits and disorders25 and provides a comprehensive and authoritative, 
compendium of human genes and genetic phenotypes. The full-text, referenced 
overviews in OMIM contain information on all known Mendelian disorders and over 
12,000 genes. OMIM focuses on the relationship between phenotype and genotype and 
NCBI/ Entrez links are provided from all cited references within each OMIM entry. 
                                                 
21 http://www.ncbi.nlm.nih.gov/books/NBK25497/#chapter2.Introduction  
22 Project to sequence the Neanderthal genome. 
23 Jointly funded by US NHGRI(National Human Genome Research Institute) and the Wellcome 
Trust (UK) 
24 Housed/maintained  at NCBI 
25 Maintained by Johns Hopkins University and collaborators 
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Genecards26, is an integrated database of human genes that provides concise genome 
related information on all known and predicted human genes. It extracts and integrates a 
carefully selected subset of gene related transcriptomic, genetic, proteomic, functional 
and disease information, from dozens of relevant sources. The information is 
automatically mined and integrated from a variety of data sources, resulting in a web-
based card for each of the 7000 human genes that currently have an approved gene 
symbol published by the HUGO/GDB nomenclature committee. The aim is to provide 
immediate current knowledge on a given gene. Source databases, mined for this 
information, include SWISS-PROT, OMIM, Gene Atlas and GDB. This composite 
database27 aims to integrate information fragments, scattered over a variety of 
specialised databases into a coherent picture. Genecards is a freely accessible web 
resource that offers one hypertext card for each of the genes in the database and the 
recent version features both novel infrastructure and an improved search engine, which 
uses a persistent object/relational model, powerful tools, such as GeneAlaCart and 
GeneDecks. GeneALaCart is provided to produce tabulated annotations for the gene set 
and enable complex analysis. 
2.3.3 Mutation DBs 
 
A resource group with specific focus on mutation includes Mutation View (Minoshima 
et al. 2001) a multi-server/ client database system, which allows the users to 
systematically integrate information including genetic, molecular, biological and 
clinical findings of each disease. This enables chromosome ideograms to be generated 
for diseases, with OMIM document links for the mapped regions.  
 
UMD (Universal Mutation Database), (Beroud et al. 2005), is a locus- specific database 
(LSDB) of mutations and their association with clinical and biological data. The 
database includes most genes and provides a large set of new analysis tools. Currently, 
there are new features to integrate non-coding sequences, clinical data, pictures, 
monoclonal antibodies and polymorphic markers (SNPs). UMD was developed as 
generic software to create locus specific databases (LSDBs) with the 4(th) Dimension 
(R) package from ACI28, rather than the more popular MySQL and PHP, but has  
                                                 
26 http://www.genecards.org/  
27 Developed and maintained by Crown Human Genome Centre ,Weizmann Institute of Science, 
Israel  
28 www.4D.com  
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comparable capability. Other mutation-related biomedical resources are tabulated, in 
brief, Table 2.1. 
 
Table 2.1: Genomic Mutation Resources 
 
Name Resource Content Additional Comments 
IDBases29 Locus specific database 
for immunodeficiency-
causing mutations 
Currently 122 public databases are maintained and 3 under 
construction; aim is to establish database for every 
immunodeficiency or provide links to those maintained by others. 
KinMutBase30 Disease-causing mutations 
in protein kinase domains 
Database contains 582 mutations in 20 tyrosine kinase domains 
and 13 serine/threonine kinase domains. Database refers 1790 
cases from 1322 families. 
SH2Base31 Pathogenic SH2 (Src 
Homology 2) domain 
mutations 
Genome wide search for disease-causing-mutations in the SH2 
domains revealed 8 genes, mutations of which cause 9 distinct 
phenotypes. 
Mutation DB32 Locus specific mutation 
for different genes.  
Human genome variation society (HGVS) maintained.  Provides 
HGNC gene symbol, OMIM number and the corresponding URL. 
HGMD 
33(Human Gene 
Mutation 
Database) 
Comprehensive data on 
human inherited disease 
mutations 
Provided by Biobase34, compilation enables quick access to both 
single mutation queries and advanced search applications, 
applicable in human genetics research, diagnostics and personal 
genomics applications. 
2.4 Epigenetic Resources and StatEpigen 
The Human Epigenetics Project marks a further major step, following the Human 
Genome Project35, driving much current ongoing research. Ongoing epigenetics and 
epigenomics research ranges from small-scale laboratory work to many large-scale 
project initiatives, with corresponding data made available via different epigenetic 
databases. 
                                                 
29 http://bioinf.uta.fi/base_root/  
30 http://bioinf.uta.fi/KinMutBase/   
31 http://bioinf.uta.fi/SH2base/ 
32 http://www.hgvs.org/dblist/glsdb.html 
33 http://www.hgmd.org/ 
34 http://www.biobase-international.com/  
35 http://www.genome.gov/12011238 
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As outlined in Chapter 1, epigenetic abnormalities have been found to be causative 
factors of cancer, genetic disorders and paediatric syndromes, as well as contributory 
factors of autoimmune diseases and ageing (Rodenhiser and Mann 2006). The recent 
intensive research on cancer-epigenetics (Sharma et al. 2010, Esteller 2011) has also led 
to discovery of many epigenetic markers that play an important role in disease 
initiation. As a consequence, cancer-related epigenetic resources still dominate the 
landscape at the current time, compared to those for other diseases/conditions 
(autoimmune diseases, psychotic diseases, Chapter 1).  
 
Two of the large-scale project initiatives for cancer research include ICGC 
(International Cancer Genome Consortium)36 and TCGA (The Cancer Genome Atlas)37. 
Genomic and epigenomic changes that occur in various types of cancer are being 
investigated by the ICGC. The goal is to obtain a comprehensive description of 
genomic, transcriptomic and epigenomic changes in 50 different tumour types and/or 
subtypes. Many samples from one tumour type or subtype would be analyzed in detail 
to provide crucial insights on genetic-epigenetic links. With respect to TCGA 
comprehensive sequencing, characterization and analysis of the genomic changes in 
various cancers has been achieved and the intent is to chart the genomic changes 
involved in more than 20 types of cancers.  
 
The non-genetic inheritance phenomenon (epigenetic changes, Chapter 1; molecular 
details, Chapter 3), occur due to mechanisms such as DNA methylation, histone 
modifications and regulatory RNA changes while gene silencing, genomic imprinting, 
X-chromosome inactivation utilize epigenetics. Many epigenetic resources 
incorporating different epigenetic signatures have been observed in the survey, although 
unsurprisingly, less comprehensive than genetic/genomic resources. A brief summary of 
each is presented below. Other available epigenetic resources and available tools for 
epigenetic research gathered from the survey are tabulated in Appendix I, Table A and 
Table B respectively. 
 
 
                                                 
36 http://www.icgc.org/ 
37 http://cancergenome.nih.gov/ 
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2.4.1 Methylation signatures38 
The significant databases observed in our survey, with methylation signatures are 
PubMeth39 (a cancer methylation database), MethDB (experimentally confirmed DNA 
methylation data, Grunau et al. 2001), MethPrimerDB40, MethyCancer (He et al. 2008) 
and Methylogix41 
 
and are maintained as of the writing of this thesis.  
 
PubMeth, provides a sorted, annotated and summarized overview of genes, reported to 
be methylated in various cancers, with user query based on gene or cancer type. This 
database draws on text-mining of Medline/PubMed abstracts, combined with manual 
annotation of pre-selected abstracts. The text mining approach in PubMeth is fast and 
intelligent, enabling search of multiple aliases and textual variants of these aliases, and 
querying of multiple key wordlists simultaneously. It also provides the facility to 
browse a pre-computed gene list, without having to query the database directly.  
 
MethDB is general, more sample-oriented and not optimized to cancer-related queries. 
The database is designed to store and annotate information on the occurrence of 
methylated cytosines in DNA. It currently contains 19,905 methylation content data 
items and 5,382 methylation patterns or profiles for 48 species, 1,511 individuals, 198 
tissues and cell lines and 79 phenotypes. It also has a public online submission system 
available. The resource forms part of an integrated network of biological databases 
through DAS (Distributed Annotation System), enabling the epigenetic data to be 
viewed as a layer in the human genome, and is also connected to Ensembl (for DNA 
sequences with available MethDB data aligned to NCBI Refseq).  
 
A subset resource, MethPrimerDB, is a database of primer sequences used in PCR-
based methylation methods. It relies on submissions by users and administrators that 
guarantee the required quality of the database but not necessarily its completeness. To 
date, there are 29 primer sets. In 2006, the MethBLAST feature was added to 
MethPrimerDB oligonucleotide sequences. Further updates since 2006, however, are 
not found for this resource.  
                                                 
38  DNA methylation, addition of a methyl group to the cytosine base 
39  http://matrix.ugent.be/pubmeth/ 
40 http://medgen.ugent.be/methprimerdb/ 
41 http://www.methylogix.com/genetics/database.shtml.htm 
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MethyCancer is a disease-oriented database, specifically of human DNA methylation 
and cancer that aims to integrate methylation databases and has developed a meta-data 
format for data standardization, with manual curation still being used for noisy data. 
Four main types of data are included in MethyCancer, namely, (i) CGI clones and 
global CGI predictions, (ii) DNA methylation data, (iii) Cancer information, genes and 
mutations and (iv) Correlations of DNA methylation, gene expression and cancer. 
MethyView, a visualization tool from MethyCancer, is used to facilitate the browsing of 
methylation data in the context of existing human genome annotations. A search engine 
to query different data types and interactions from the MethyCancer database provides 
simple keyword search and also offers advanced options namely, “methylation,” 
“gene,” “cancer,” “clone” and “repeat” searches. For example, Methylation search 
enables the user to specify and combine query options, such as methylation type 
(pattern, profile, content and domain), data source (BIG/ UHN, MethDB, HEP, 
Columbia University), experimental methods, sample information (tissue, sex, age and 
phenotype) and chromosomal positions.  
  
Methylogix provides a high density DNA methylation database of human chromosomes 
21 and 22, a CpG island DNA methylation database for male germ cells (enabling 
comprehensive analysis of DNA methylation variation between and within the germ 
lines of normal males), and a targeted DNA methylation database of late-onset 
Alzheimer disease. Similarly, Methtools is a collection of software tools for handling 
and analysis of DNA methylation data, generated by the bisulfite genomic sequencing 
method.  
2.4.2 Genomic Imprinting 
Genomic imprinting (described in Section 1.1.1) related significant database resources 
are the Geneimprint database42, imprinted gene and parent-of-origin effect database 
(Glaser et al. 2006) and mouse gene imprinting database43 (with genomic imprinting 
information for the model organism: mouse)  
 
The Geneimprint database includes genes and related information on genomic 
imprinting for different animals including humans and gathered from NCBI. Genes are  
                                                 
42 http://www.geneimprint.com/site/genes-by-species 
43 http://www.mousebook.org/about.php 
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listed by species and sorted by chromosomal location, name and imprinting status and 
are provided through the web-interface. Similarly, an imprinted gene and parent-of-
origin effect database presents imprinted genes and related effects. This consists of two 
sections: (i) catalogue of current literature on imprinted genes in humans and animals 
and (ii) catalogue of reports of parental origin of de novo mutations in humans alone. 
The addition of (ii), showing a parent-of-origin effect, expands the scope of the database 
and provides a useful tool for examining parental origin trends for different types of 
spontaneous mutations. This second section currently includes more than 1,700 
mutations, found in 59 different disorders. The 85 imprinted genes are described in 152 
entries from several mammalian species. In addition, more than 300 other entries 
describe a range of reported parent-of-origin effects in animals. A further resource, 
containing information on mouse gene imprinting, also includes an imprinting 
catalogue, as well as chromosome anomalies on mutant mouse lines. This represents 
integration of curated information from the MRC Harwell stock resource and other 
Harwell databases, with additional information from external data resources such as 
IMSR (International Mouse Strain Resource).  
2.4.3 Histone and chromatin-related resources 
 
The most significant example reported is the Histone database, which is an inclusive 
resource for the analysis of chromatin structure and function. Nucleosomes (through 
various core histone post-translational modifications and incorporation of diverse 
histone variants), can serve as epigenetic markers to control processes such as gene 
expression and recombination. The Histone Sequence Database is a curated collection, 
assembled from major public databases, of sequences and structures of histones and 
non-histone proteins containing histone folds. A substantial increase in the number of 
sequences and taxonomic coverage for histone and histone fold-containing proteins is 
available. The database also provides comprehensive multiple sequence alignments for 
each of the four core histones (H2A, H2B, H3 and H4), the linker histones (H1/ H5) and 
the archaeal histones. Also included is current information on solved histone fold-
containing structures. This resource is maintained by the National Human Genome 
Research Institute.  
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Chromatin.us44 (another webportal) includes information on chromatin proteins, 
histones and nucleosome structures and non-histone chromatin protein structures, and 
provides links to the Protein Data Bank (PDB) site (which provides further details on 
these). ReplicationDomain45 is an online database for storing, sharing and visualizing 
DNA replication timing and transcription data, along with other numerical epigenetic 
data types. Data are typically obtained from DNA microarrays or DNA sequencing. 
2.4.4 Gene silencing 
Gene silencing is an epigenetic process of gene regulation that generally is used to 
describe the “switching off” of a gene by mechanism other than genetic modification 
(Chapter 1). This phenomenon has also been well-reported in the literature. Collected 
papers are available on Bio-Tech Info-Net46. Similarly, RNA induced epigenetics related 
papers on imprinting by noncoding RNAs are collated47. 
2.4.5 Other Epigenetic Database Resources 
Evolution of epigenetic resources is still in its early stages, with provision associated 
with several specific research efforts and groups. Nevertheless, in line with 
genetic/genomic data examples, efforts are being made to connect information, even as 
new targets are emerging. Some other biomedical resources that relate to epigenetic 
phenomena are also noted. The Epigenetics Database48 (includes all known epigenetics 
genes/proteins discovered to date), the Epigenie49, the Epigenetics Antibody Database 
50
, Unigene 51 are some other examples.  
 
The Epigenetics Database is arranged in hierarchical format, based upon gene ontology. 
While still in its developmental (ß) phase, it is expected that future developments will 
include user-submitted meta-data, which will be freely available for use in database and 
flat file format. Some sites, e.g., Epigenie, also provide bioinformatics tools (e.g., CpG 
Viewer, CpG and GC Plotter and tools for CpG Island detection). NCBI supported 
efforts include the Epigenetics Antibody Database, providing antibody information for 
researchers working in the field of epigenetics/epigenomics, and Unigene, containing 
                                                 
44 http://www.chromatin.us/chrom.html 
45 http://www.replicationdomain.com/ 
46http://www.biotech-info.net/gene_silencing.html#silencing 
47 http://www.euchromatin.com/RNAepi.htm 
48 http://www.epidna.com/database.php 
49 http://www.epigenie.com/Epigenetics-Research-Products.html 
50 http://www.antibodyresource.com/antibody-database.html 
51 http://www.ncbi.nlm.nih.gov/sites/entrez?db=unigene 
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same locus-of-origin transcription sequences, protein similarities, gene expression, 
cDNA clone reagents, genomic location and associated epigenetic information. NARNA, 
supported by Newcastle University, incorporates relationships between epigenetic 
events, DNA methylation, gene imprinting and X-chromosome inactivation with natural 
antisense RNAs.  
2.4.6 Large Scale Epigenetic Project Initiatives 
 
European project initiatives including HEP 
A number of European initiatives exist for centralized projects on DNA methylation. 
The Human Epigenome Project (HEP52), will provide an epigenetic resource of 
chromosomal DNA methylation reference profiles in human tissues and cell lines. Other 
initiatives include chromatin profiling (HEROIC, High-Throughput Epigenetic 
Regulatory Organization in Chromatin), treatment of neoplastic disease (EPITRON, 
EPIgenetic TReatment Of Neoplastic Disease53), and the SMARTER initiative54, which 
aim to develop small inhibitors of chromatin-modifying enzymes. Another effort to 
provide structure to the epigenetic research landscape in Europe is that of the Epigenetic 
Network of Excellence, now known as Epigenesys, which aims to advance epigenetics 
toward Systems Biology55.  
 
Roadmap epigenomics program 
The Roadmap Epigenomics Program (also known as Epigenomics Roadmap initiative), 
launched by NIH (2008), seeks to create a series of epigenome maps to study epigenetic 
mechanisms, develop new epigenetic analytics, generate a repository and long-term data 
archive, standardize procedures and practices in epigenomics and support new 
technologies for these. As part of the $190 million, five-year initiative, the Roadmap 
Epigenomics Mapping Consortium56 was formed to provide a public database for 
human epigenomics data, the Human Epigenome Atlas57. The current release, 
Epigenome Atlas Release 7, includes human reference epigenomes and the results of 
their integrative and comparative analyses. 
 
                                                 
52 http://www.epigenome.org/ 
53 http://www.epitron.eu/ 
54 http://www.smarter-chromatin.eu/ 
55 http://www.epigenesys.eu/ 
56 http://www.roadmapepigenomics.org/ 
57 http://www.genboree.org/epigenomeatlas/index.rhtml 
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The NIH Roadmap Epigenomics Program has also established IHEC, (the International 
Human Epigenome Consortium)58, which aims to coordinate epigenome mapping and 
characterization worldwide, in order to ensure high data quality standards, coordination 
of data storage, management and analysis and free access to the epigenomes produced. 
To attain substantial coverage of the human epigenome, IHEC aims to decipher at least 
1,000 epigenomes within the next 7–10 years. Officially launched in Paris (Jan 2010), 
with an initial (first phase) budget target of $130 million, IHEC intends to coordinate 
the mapping of epigenomes from not only the NIH’s Epigenomics Mapping Consortium 
but also from international efforts such as the European Epigenome Network of 
Excellence, the Danish National Research Foundation Centre for Epigenetics, and the 
Australian Epigenetic Alliance. The IHEC web portal provides links to databases, such 
as GEO, Array Express and DDBJ, where epigenetic sequencing data will be made 
available.  
 
Another significant large-scale program in epigenetics is the Encyclopaedia of DNA 
Elements (ENCODE)59, which is supported by the ENCODE Consortium, an 
international collaboration of research groups funded by the National Human Genome 
Research Institute (NHGRI). This initiative aims to identify all functional elements, 
both at the protein and RNA levels, and regulatory elements that control cells and 
circumstances in which a gene is active, in the human genome sequence.  
 
ICGC 
Genomic changes that occur in various types of cancer are being investigated by the 
International Cancer Genome Consortium (ICGC)60. The goal is to obtain a 
comprehensive description of genomic, transcriptomic and epigenomic changes in 50 
different tumour types and/or subtypes. Many samples from one tumour type or subtype 
will be analyzed in detail so that this initiative promises to provide crucial insights on 
genetic-epigenetic links.  
2.4.7 StatEpigen Database Resource 
StatEpigen is an in-house developed epigenetic database resource (Barat, Ruskin 2010). 
This database currently incorporates information on cancer epigenetic data, curated 
                                                 
58 http://www.ihec-epigenomes.org/ 
59 http://genome.ucsc.edu/ENCODE/ 
60 http://icgc.org/  
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from published scientific literature. Initially, the database has focussed on curation of 
colon cancer epigenetic data, although the aim is to add data in other types of cancer in 
future. The database also gives correlation between different epigenetic determinants of 
cancer. Statistical measures and correlations or associations between a particular 
epigenetic event, found in a particular cancer phenotype are related to other molecular 
events which comprise known cancer signatures.  
 
Since the primary aim of this project focuses on further development of StatEpigen 
database resource, the literature survey assisted in finding other database resources that 
can be integrated with StatEpigen database (Table 2.2). Following is the comparative 
study of some epigenetic resources that incorporate methylation signatures and can be 
integrated to in-house database, StatEpigen in future. Besides these, COSMIC database 
from Sanger Institute which provides data on somatic and germline mutation of cancer 
prone genes can also be integrated (Wellcome Trust Sanger Institute). 
  
 
Table 2.2: Epigenetic resources with methylation signatures (integrable to StatEpigen database) 
 
S.N. Databases  Database of: Comments: 
1 PubMeth Cancer methylation database Only cancer related DNA 
methylation considered. 
2 MethDB Experimentally confirmed DNA 
methylation data 
Aims to store all data about DNA 
methylation, not specific to 
cancer only. 
3 MethPrimerDB Primer sequences used in PCR 
based methylation data 
Method of methylation focussed 
database, has data on mouse, 
human and rat,  methylation data. 
4 MethyCancer Cancer related DNA methylation Human DNA methylation and 
cancer related database –Chinese 
initiative. Also integrated to 
HEP, MethDB, Columbia and 
BIG/UHN. 
5 Methylogix DNA methylation database of 
human chromosomes 21 and 22 + 
germcells. 
High density human 
chromosomes 21 and 22 and 
germcells only considered. 
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2.5 Discussion and Conclusion 
This chapter presented a summary landscape review of the biomedical literature, with 
the major focus on epigenetic resources. The intention was to check for developments in 
epigenetic sector, whether it has paralleled the developments in genetic sector, since the 
former became a target area of research after the human genome project. The genetic 
and epigenetic biomedical resources, surveyed here, are numerous and range from 
small- to large-scale. There is considerable ongoing integration and new links are still 
being forged. As with many newly identified research targets, early-stage resources are 
often found to be very specific and are supported locally, and this is still the case for 
much of epigenetic data. Many such databases and their software tools are accessible 
publicly from academic/ research institutions, while some others are commercially 
available, Appendix I, Table A. Quality assurance, effective annotation and overall 
management are still major issues, but appropriate analysis must also keep pace and  
currently is typically uneven, Appendix I, Table B. Clearly, the generation of a 
centralised repository for epigenetics-related data is desirable, and currently lacking, but 
new technologies offer increased potential for processing solutions down the line.  
 
Some major initiatives to ensure quality and standards for genetic and epigenetic 
research do exist, such as IHEC, HEP61 as described in this literature review. These will 
also lead to development of suitable data mining tools, with improved technology, 
where those currently available for epigenetic/epigenomic analyses are limited, and 
predominantly sequence oriented, ranging from sequence identification, through PCR 
and initial pattern matching, Appendix I, Table B. 
 
In general, survey results indicate that relational database management systems are still 
preferred and support most available data mining options, with MySQL as open source 
and data query achieved via form submission. Biomart, as noted earlier, is also widely-
used and relies on a query-oriented data management system. These preferences are 
likely to change, with hybrid and object-oriented systems becoming much more general. 
 
                                                 
61 http://www.epigenome.org/  
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3 Chapter 3 
Cancer, Genetic and Epigenetic Factors, and StatEpigen 
3.1 Introduction 
This Chapter explores cancer and its etiology at molecular level, starting with cancer 
staging which determines the level of cancer progression in a cancer patient. Cancer 
Staging describes the extent or severity of a cancer diagnosis based on information 
about the tumour62 (www.cancer.gov). Staging helps plan the treatment, identify a 
clinical trial suitable to the patient and can also be used to estimate the prognosis (likely 
outcome or course of the disease). The common elements considered in most staging 
systems are: 
• Location of the primary tumour,  
• Tumour size and number of tumours,  
• Spread of cancer into lymph nodes,  
• Cell type and tumour grade (how closely the cancer cells resemble normal 
tissue)  
• Presence or absence of metastasis (the spread of the cancer).  
 
The TNM system is one of the most commonly used staging systems. It is based on the 
extent of the tumour (T), the extent of spread to the lymph nodes (N), and the presence 
of metastasis (M). A number is added to each letter to indicate the size or extent of the 
tumour and the extent of spread. Table 3.1 below shows the indications used for TNM 
staging. 
 
 
                                                 
62 Abnormal growth of tissue resulting from uncontrolled, progressive multiplication of cells and 
serving no physiological function. 
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Table 3.1:  Tables showing the indications used for TNM staging (Source: www.cancer.gov, National 
Cancer Institute website) 
 
Primary Tumour (T) 
TX Primary tumour can not be evaluated 
T0 No evidence of primary tumour 
Tis Carcinoma in situ (early cancer that has not spread to neighbouring tissue) 
T1, T2, T3, T4 Size and/or extent of the primary tumour 
 
Regional Lymph Nodes (N)  
NX Regional lymph nodes can not be evaluated 
N0 No regional lymph node involvement (no cancer found in the lymph nodes) 
N1, N2, N3 Involvement of regional lymph nodes (number and/or extent of spread) 
 
Distant Metastasis (M)  
MX Distant metastasis can not be evaluated 
M0 No distant metastasis (cancer has not spread to other parts of the body) 
M1 Distant metastasis (cancer has spread to distant parts of the body) 
 
For example, prostate cancer T2 N0 M0 means that the tumour is located only in the 
prostate and has not spread to the lymph nodes or any other part of the body. Similarly, 
breast cancer T3 N2 M0 refers to a large tumour that has spread outside the breast to 
nearby lymph nodes, but not to other parts of the body.  
 
For many cancers, TNM combinations correspond to one of five stages. Criteria for 
stages differ for different types of cancer. For example, colon cancer T3 N0 M0 is stage 
II; however, bladder cancer T3 N0 M0 is stage III. Table 3.2 below shows what each 
stage means. 
 
Table 3.2:  Cancer stages and definitions (Source: www.cancer.gov, National Cancer Institute website) 
 
Stage  Definition 
Stage 0 
Carcinoma in situ (early cancer that is present only in the layer of cells in 
which it began). 
Stage I, II, and III 
Higher numbers indicate more extensive disease: greater tumour size, and/or 
spread of the cancer to nearby lymph nodes and/or organs adjacent to the 
primary tumour. 
Stage IV The cancer has spread to another organ. 
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Cancers of the blood or bone marrow and most types of leukaemia, do not have a clear-
cut staging system yet. 
The summary staging system is used for all types of cancer. The categories are: 
1. In situ - early cancer that is present only in the layer of cells in which it began.  
2. Localized - cancer that is limited to the organ in which it began, without 
evidence of spread.  
3. Regional - cancer that has spread beyond the original (primary) site to nearby 
lymph nodes or organs and tissues.  
4. Distant - cancer that has spread from the primary site to distant organs or distant 
lymph nodes.  
5. Unknown - cases for which there is not enough information to indicate a clearly 
described stage.  
3.2 Genetic and Epigenetic Factors in Cancers 
Cancer arises through the accumulation of multiple genetic and epigenetic changes 
(Feinberg 2004). Environmental components such as growth factors and hormones 
(Coffey 2001, Michels 2005, Giovannucci 2003) and changes in diet and life history 
that result in mismatch between ancestral and current environments are also found to 
increase the risk of cancers, (Jemal et al. 2011). This could be due to the impact of 
environmental components, diet and life history, in the genetic and epigenetic events.  
3.2.1 Key Genetic Effects 
 
Genetic changes or mutations are any permanent change/damage of DNA sequence of 
the genome such that the genetic message carried by that gene is altered. Genetic 
changes could be somatic or germline (hereditary) mutations of specific genes. Somatic 
mutations (changes in DNA sequence) are sporadic, that occur in cells other than germ 
cells, whereas germline mutations are mutations that are heritable in the lineage of germ 
cells. Mutations can cause (genetic) diseases, changes in enzyme activity, nutritional 
requirements, antibiotic susceptibility, morphology, antigenicity and other properties of 
cells. The most common type of mutation is a single base alteration or point mutation 
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that can be either a transition63 or transversion64. Other mutation types are classified 
according to the effect they have on the structure of the genes’ protein product. These 
include: silent (where new codon specifies same amino acid), missense (new codon 
specifies different amino acid), nonsense (new codon is stop codon), frameshift 
(deletion or addition of a base), large segment deletion (unequal crossover in meiosis), 
splice donor or acceptor and triplet repeat expansion (Fischer and Reichert 2009).  
 
Alterations in 3 types of genes, proto-oncogenes, tumour-suppressor genes and stability 
genes are responsible for tumorigenesis. Of the estimated 20-25,000 genes in human 
genome, currently more than 1% of human genes are known to play a role in the 
development of cancer (Cancer Gene Census, Sanger Institute). A single gene cannot 
cause cancer as there are multiple mechanisms for protection. Cancer is caused only 
when several genes are defective. Therefore, mutated cancer genes can be thought of as 
contributing to rather than causing cancer (Vogelstein and Kinzler 2004).  
 
Oncogenes are mutated forms of normal genes called proto-oncogenes. Oncogenes 
cause the normal cells to grow out of control and become cancerous (Adamson 1987, 
Weinstein and Joe 2006). Often, proto-oncogenes encode proteins that function to 
stimulate cell division, inhibit cell differentiation, and stop cell death (all of these 
processes being important for normal human development and for the maintenance of 
tissues and organs). However, oncogenes typically exhibit increased production of 
these proteins, thus leading to increased cell division, decreased cell differentiation, and 
inhibition of cell death; taken together, these phenotypes define cancer cells. Oncogene 
activations can result from gene amplifications, chromosomal translocations or from 
subtle intragenic mutations affecting crucial residues which regulate the activity of gene 
product (Vogelstein and Kinzler 2004). Some studies have suggested that cancer cells 
may rely heavily on certain oncogenic mutations than others for their growth, 
proliferation and survival. This concept is termed as “oncogene addiction” (Weinstein 
and Joe 2006). Therefore, by aiming at those specific oncogenes, it is believed that it 
might be possible to target cancer cells, in spite of other mutations. These oncogenes are 
thus currently a major molecular target for anti-cancer drug design. 
                                                 
63 Point mutation that changes a purine nucleotide to another purine (A-G) or pyrimidine 
nucleotide to another pyrimidine (C-T). 
64 A base-pair substitution mutation in which a purine is replaced by pyrimidine (e.g. A → C), and 
vice versa (e.g. T → G) 
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Tumour suppressor genes encode proteins that normally slow down cell division, repair 
DNA damage and trigger apoptosis. Mutations in tumour suppressor genes reduce the 
gene activity which leads to uncontrolled growth of cells, leading to cancer. Gene 
inactivation is caused from missense mutations at residues that are essential for its 
activity, from mutations that result in a truncated protein, from different deletions or 
insertions or from epigenetic silencing.  
 
Both the tumour-suppressor gene and oncogene mutations ultimately result in driving 
the neoplastic process by increasing tumour cell number through the stimulation of cell 
birth, inhibition of cell death or cell cycle arrest (i.e. at the physiological level, the 
mutations result in increase of tumour cells). Stability genes (caretaker genes) on the 
other hand, when mutated, promote tumorigenesis in a different manner. These genes 
when inactivated trigger other genes to be mutated at a higher rate (Friedberg 2003). 
Stability genes include the mismatch repair (MMR), nucleotide-excision repair (NER) 
and base-excision repair (BER) genes that are responsible for repairing minor mistakes 
during normal DNA replication or are induced by exposure to mutagenic agents. 
Stability genes also control processes involving large portions of chromosomes, such as 
those responsible for mitotic recombination and chromosomal segregation (e.g. BRCA1, 
ATM) (Vogelstein and Kinzler 2004). Mutations in these 3 types of genes lead to 
hereditary predisposition to cancer if it occurs in germline cells or to sporadic tumours 
if occurs in somatic cells. 
3.2.2 Pathways 
 
Vogelstein and Kinzler, (2004) suggest focussing on pathways, the 3 groups of gene 
follow rather than the genes themselves, the reasons being: 
1. Fewer numbers of pathways than the genes themselves. Studies have shown that 
mutations within a pathway obey an ‘exclusivity principle’; that is, only one of 
many genes is generally mutated in any single tumour, exactly as predicted if the 
functional effect of each mutation was similar (e.g. Rb pathway with mutations 
in any one of Rb, p16, CDK4 and Cyclin D1 genes (Sherr 2000, Ichimura 2000, 
Ortega et al. 2002, and Classon and Harlow 2002)).  
2. There are more than one ways to disrupt a pathway, all of which have similar 
effect/consequence (e.g. p53 pathway- which can be disrupted by point mutation 
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of p53 gene; the same effect can be achieved with amplification of the MDM2 
gene and infection with DNA tumour virus whose products bind to p53 and 
functionally inactivate it). 
These instances suggest that, pathways rather than individual genes govern the course of 
tumorigenesis and the targeted therapeutics can be effective against a broad range of 
cancers in future (Vogelstein and Kinzler 2004) .  
3.2.3 Epigenetic Factors 
 
As per the current knowledge on epigenetic involvement in cancer and suggested  
complementary role of genetics and epigenetic in the etiology of the same, (Feinberg 
2004, Sawan et al. 2008, You and Jones 2012) it would be sensible to look into the 
epigenetic mechanism for some of the major epigenetic events at this stage. 
 
DNA Methylation  
As defined in chapter 1, DNA methylation refers to the modification of DNA by 
addition of a methyl group to the cytosine base (C). It is found to be the most stable, 
heritable and well conserved epigenetic change. Introduced and maintained by a family 
of enzymes called DNA Methyl Transferases (DNMT) (Doerfler et al. 1990), DNA 
methylation can induce "epigenetic silencing" or the loss of expression of tumour 
suppressor genes, causing normal cells to be transformed into cancer cells; it is the first 
and most common epigenetic alteration to be observed during cancer initiation (Egger et 
al. 2004, Feinberg and Tycko 2004). Epigenetic alterations involving DNA methylation 
can lead to cancer by various mechanisms. Hypomethylation of DNA can result in 
genome instability (Qu et al. 1999), hypermethylation in gene promoters causes 
heritable silencing and therefore inactivation of tumour suppressor genes.  Similarly, 
methylated CpG sites are “hotspots” for C->T transition mutations caused by 
spontaneous hydrolytic deamination (Rideout et al. 1990). Methylation of CpG sites 
also increases the binding of some chemical carcinogens to DNA and increases the rate 
of UV induced mutations. Methylation as a cause of mutation is also reported by Mazin 
(1994) and the relationship between these two events is investigated by many, including 
Xia (2012).  
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DNA methylation, in general, occurs at CpG dinucleotide sites, and a majority of CpG 
cytosines are methylated (in mammals). However, there are clusters of DNA near 
promoter regions that have higher concentrations of CpG sites (also known as CpG 
islands) that are unmethylated in normal cells. These CpG islands become highly 
methylated in cancer cells, thereby causing unexpected or unlikely genes to be silenced 
or to be switched off (transcriptional silencing). This abnormality is the trademark 
epigenetic change that occurs in tumours and takes place early in cancer development 
(Jones & Baylin, 2002, Egger et al., 2004). Subsequently, it has been found that, 
hypermethylation of CpG islands can cause tumours by shutting off tumour-suppressor 
genes (e.g. MGMT, p16INK4a, hMLH1, p14ARF), forging the genetic-epigenetic link 
again (Esteller 2007). In fact, CpG island hypermethylation may be more common in 
human cancer than DNA sequence mutations. 
 
Histone Modification 
Histones are alkaline proteins (found in eukaryotic cell nuclei), around which DNA 
wraps to form nucleosomes. There are 5 major families of histones: H1/H5, H2A, H2B, 
H3 and H4. Histones H2A, H2B, H3 and H4 are called core histones and two of these 
each, when wrapped by DNA double helix, forms a single nucleosome unit. The H1 and 
H5 are linker histones that bind the nucleosomes (H1 in humans), (Youngson 2006). 
Histone modifications lead to gene expression or inactivation (Kouzarides 2007). A 
direct link also exists between DNA methylation and histone modification, since a 
number of proteins involved in DNA methylation (e.g. DNMTs and MBDs (Methyl 
CpG-Binding Domain proteins)) directly interact with histone modifying enzymes, such 
as Histone Methyltransferases (HMTs) and Histone Deacetylases (HDACs) (Fuks 
2005). 
 
Other Epigenetic Phenomena 
Genomic Imprinting is an inheritance process that is independent of classical Mendelian 
inheritance and is a genetic phenomenon by which genes are expressed in the parent-of-
origin-specific manner.  X-chromosome inactivation is a process in which, one out of 
two copies of X-chromosomes available in female mammals is inactivated. This process 
is also called lyonization. All of these processes are epigenetic processes, and thought to 
be contributing to the cancer initiation and progression.  
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3.2.4 Genetic- Epigenetic mechanisms in Cancer 
 
Cancer was traditionally considered as a genetic disorder, however, after completion of 
human genome project, the role of epigenetics in cancer came to light (Feinberg 2004, 
Sharma et al. 2009). Current researches show cancer as an outcome of genetic-
epigenetic interactions and there is increasing evidence that these two mechanisms are 
complementary (Mazin 1994, Duncan et al. 2012). The cross-talk between genome and 
epigenome is shown to be involved in cancer (Sawan et al. 2008, You and Jones 2012). 
 
Feinberg (2004) suggested his hypothesis on genetic –epigenetic interplay in the 
initiation of cancer. He suggested, with regard to the role of epigenetics in cancer 
initiation and progression, it is possible that genetic mutation initiates the cancer and 
epigenetic change promotes its progression. It is also possible that epigenetic processes 
may be linked directly to initiation or may be responsible for ‘priming’ cells to the next 
mutagenic event that is involved in cellular transformation after this. Hence both genetic 
and epigenetic events may be co-involved in cancer progression. In fact, some literature 
(e.g. Ogino et al. 2006) suggest that, some genetic/epigenetic factors have a synergistic 
effect on the occurrence of colon cancer. Some notable publications are Rideout et al. 
(1990), Mazin (1994), Denissenko et al. (1997), which suggest that methylation events 
trigger mutation events. On the contrary, there are some other publications which 
suggest the opposite, i.e. mutation induces methylation, (Poole et al. 2012, Duncan et 
al. 2012). Thus genetic events can not be treated in isolation to epigenetic events 
without exploring possible relations, and related or co-occurring changes.  
3.3 StatEpigen database Resource 
StatEpigen Knowledge Management System (Section 2.4.7, Barat and Ruskin 2010), is 
our in-house epigenetic database resource. The uniqueness of this resource is that, it 
provides selected information on different genetic and epigenetic factors responsible for 
colon cancer, curated from different literature. The aim of the database is to provide a 
platform to explore how epigenetic events, (such as CpG island hyper and 
hypomethylation, different histone modifications, loss of heterozygocity etc.), are 
correlated with (i)each other,  (ii)other molecular events namely gene expression, 
(iii)different types of mutations and polymorphisms, (iv)other more complex molecular 
signatures such as MSI (Microsatellite Instability), CIN (Chromosomal Instability), and 
  
Chapter-3          Cancer, Genetic & Epigenetic Factors and StatEpigen 
 
37 
 
CIMP (CpG Island Methylator Phenotype) (v)simultaneous molecular events, i.e. 
combinations of event types occuring simultaneously in the same samples. To address 
these objectives in data evaluation, the following types of datasets are targeted:  
1. Molecular events and their frequency of occurrence,  with the phenotype of 
analysed samples (Simple molecular events) being provided, 
2. Molecular events and their frequency of occurrence in sample subsets, 
characterised by another molecular event (occuring in all analysed samples of a 
subset of given phenotype). These events are referred to as ‘conditional events’ 
and are an important feature for StatEpigen database resource. 
3.3.1 Structure and curation of data  
 
The database basically contains the two types of records, given in bullet points above. 
The data after manual curation is stored in MySQL database.  
 
Database Structure and Tables  
The database itself is a phenotype-focused resource, with genetic and epigenetic data 
available for an extensive phenotype range. To date, data on more than 100 colon cancer 
cell lines are available on StatEpigen. Similarly, information on 728 genes, 318 
epigenetic events, 579 genetic events, and 150 mutations is also available, with 5768 
simple molecular events and 2952 conditional events detailed to-date65.  
 
The data is basically stored in database objects called ‘Tables’. The major tables in 
current use (there are other tables as well for future addition of events or cancer types – 
but not in use currently) in StatEpigen database are : "Reference", "Cell-State", "Event" 
, "Gene", "single_rel", "double_rel", "pathology ". Reference tables store information on 
the references that one uses during data curtain process, Cell-State table stores, 
histology, subhistology, Origin, Cell-Line information, event table stores information on 
different events that are in curated till now, (Note: same type of event may have 
different different event-IDs depending on any specific details on it, e.g. 
Hypermethylation occurring in promoter region and exon2 are recorded as two different 
events). Similarly, Gene table records information on gene (e.g. UniProt and Entrez ID, 
HGNC symbol, full name), the single and double relation tables - record information on 
curated single and double relation information (the frequency of occurrence of that 
                                                 
65 http://statepigen.sci-sym.dcu.ie/  
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event, sample no. are some notable columns in the table ).  These tables are ‘relational 
tables’ and are linked to each other with their ‘keys’.  
 
Data Curation 
Data curation process firstly involves the selection of suitable literature. It involves 
filtering Pubmed database with keywords related to genetic and epigenetic events (e.g. 
hypermethylation, mutation). The selected papers are collected, scanned manually and if 
suitable are curated. The process involves curation of phenotypes, genes and molecular 
events and simple and conditional events. The phenotypes to look for are – Histology, 
subhistology, dysplasia, origin, cell-lines and pathology. Similarly, for genes, if HGNC 
(HUGO Gene Nomenclature Committee) approved gene name appears in a paper and it 
is a new entry, the curator needs to add all the details (pharmagkb site66 can be used for 
gene details). If duplicate names are given, HGNC name is found and details are 
entered. For molecular events, the curator needs to look for events as shown in Table 
3.3, (where this table is truncated for ease) curate any, that are found, according to the 
single or double relation available in the paper and augment the data in StatEpigen. To 
understand how the process works, an example of a simple event curation is given 
below. 
  
                                                 
66 http://www.pharmgkb.org/  
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Table 3.3: Type event table (truncated) to show different epigenetic events incorporated in StatEpigen 
database 
 
Type_
event 
Description Corresponding 
Name_Events 
Description 
 
1 Epigenetic 
events 
+Meth_CpGisland CpG island hyper-methylation 
-Meth_ CpGisland CpGisland hypo-methylation 
LOI Loss of imprinting.  
H3Ac Histone 3 acetylation 
H4Ac Histone 4 acetylation 
H3PhS10 Phosphorylation of threonine 10 on histone 3 
H3MeK4 Methylation of lysine 4 on histone 3 
H3MeK9 Methylation of lysine 9 on histone 3 
2 Mutations mutation Mutations.   
The Details field of the db table event will serve to 
annotate what kind of mutation is this:  
‘missense’; 
‘antisense’ 
‘frameshift’ 
‘silent’ 
 Or, for example, Details=‘germline 
polymorphism Single Nucleotide Polymorphism - the variation of a single 
base pair in the DNA among the individuals of the same 
species. 
3 Expression, 
both at the 
levels of 
mRNA or 
proteins 
gene_expression Both expression of genes and presence of proteins. 
mir_expression Expression of miRNAs 
4 Correspondi
ng to 
multiple 
events 
MSI Microsatellite Instability. Description in the adjacent 
column. 
CIMP CpG island methylator phenotype. The promoters of a 
group of genes are methylated in the same time. 
LOH Allelic loss in more than one loci 
5 Combined:  combined with 2 distinct events taking place simultaneously 
6 Diverse: 
events that do 
not 
correspond to 
neither of the 
other classes 
MMR_defective Inherited mutation in a mismatch-repair genes (MLH and 
MSH gene family) 
activation Activation of a protein 
phosphorylation Phosphorylation of a protein 
translocation Translocation of a protein from one to another cell 
compartment 
 
Supposing the literature includes the contents given in the text below: 
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P16 methylation of tumour and/or serum of 51 colorectal cancers and 10 adenoma 
patients, and 10 healthy volunteers was detected with conventional MSP or IP-MSP. IP-
MSP detected p16 methylation from 0.5pg/mul of the cell lysate. The sensitivity of IP-
MSP for detecting serum p16 methylation in 27 patients with tumours characterized 
by p16 methylation was significantly higher than that with conventional method (81% 
versus 59%), particularly in Stage II patients (91% versus 45%). IP-MSP detected no 
p16 hypermethylation in sera of adenoma patients and volunteers (Sakamoto et al. 
2010). 
After the curation of phenotypes and the molecular events from this extract, use of this 
information to form a Single Relation (or Simple Event record) is shown below. Four 
potential Single Relations are found in the text: 
1. p16 methylation  was detected in 81% of the 27 serum samples from patients 
with tumours. 
2. p16 methylation was detected in 91% of the serum samples from patients with 
tumours in Stage II. 
3. p16 methylation was not detected in sera of adenoma patients. 
4. p16 methylation was not detected in sera of volunteers.  
 
In the second potential Single Relation, there is no indication on how many samples 
from tumours in stage II were available. For this reason, the information is incomplete 
and this will not be used further to create a Single Relation record. 
 
For the remaining three statements, the ID_CELL_STATES of sera from tumours, 
adenomas and healthy volunteers are queried into the database to find, 75, 62 and 88 
respectively. Further, the ID_EVENT for p16 methylation was queried as ID_EVENT 
=17. In addition, the article from which this text is extracted was given ID_REF=257.  
 
The extract gives the frequencies of sample positive for p16 methylation hence 
Level=’YES’ in all the 3 cases. 
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The SQL code to add data is (with comments in red and double hyphen): 
INSERT INTO single_rel (REF_ID_REF, EVENT_ID_EVENT, 
CELL_STATE_ID_CELL_STATE, clinpath, Percent_Tumors, Nb_Tumors, 
Quantified, Unit_ID_UNIT, Level) VALUES 
 
(257, 17, 75, NULL, 0.81, 27, NULL, NULL, ‘YES’),  
-- the sera from carcinoma patients 
(257, 17, 62, NULL, 0,    10, NULL, NULL, ‘YES’),  
-- no samples positive for p16 methylation in the sera from adenoma 
patients 
(257, 17, 88, NULL, 0,    10, NULL, NULL, ‘YES’),  
-- no samples positive for p16 methylation in the sera from healthy 
subjects 
 
It is to be noted that the curator has to be careful here not to confuse Level ‘YES’, 
which indicates that the samples counted are those with positive outcome for the 
methylation, with the null frequency (Percent_Tumours =0) of positive samples in the 
ten samples analysed. After manual curation, these data are incorporated into the  
purpose –built database implemented in MySQL. 
 
This is one of the simplest examples of data curation. As can be seen, manual data 
curation is a time consuming process, hence, automation/ semi-automation of this 
process in future is desirable.  
 
Interface  
The data is provided to the user via web-based user interface. The URL is 
http://statepigen.sci-sym.dcu.ie. The data can be accessed with straightforward querying 
and results are displayed. The user interface employs a design implemented in PHP, 
Javascript, HTML and CSS (Barat and Ruskin 2010).  
 
Querying 
Different querying facilities are available in StatEpigen. It can be queried: (a) in a 
gene/molecular event- centric manner, (b) in a phenotype – centric manner or both, (c) 
Additional options to carry out phenotype-centric StatEpigen querying, according to 
most frequent histologies and subhistologies, clinicopathological factors and cell lines.  
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Graphics 
The graphical data visualisation facility is provided via the Cytoscape tool67 and data 
integration facility via ‘print statistics’ tab. Full details are provided in (Barat and 
Ruskin 2010). 
3.4 Summary 
This chapter explains the role of genetic and epigenetic factors and their inter-
relationship for cancer initiation and progression, as revealed by current research in the 
last decade. It also explains the need for database resources such as StatEpigen in the 
current context, as a specialised add-on resource and gives a brief description (and 
examples) of its main features, i.e. how it can be used and what it offers. 
 
                                                 
67 http://www.cytoscape.org/ 
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4 Chapter 4 
Evolutionary Analysis of CRC genes 
4.1 Introduction 
A genetic study of colon cancer from an evolutionary perspective has been carried out 
with the molecular evolution group in Sci-Sym centre (http://sci-sym.dcu.ie/). This 
allowed exploration of, not only the genetic influences in initiation of the human 
disease, (Section 4.1.1) but also the inheritance features (Section 4.1.2) and 
human/animal parallels (Section 4.1.3), the inhibitory factors intrinsic to selection 
(Section  4.1.4 and 4.1 below), and the type of damage that can be attributable to 
various causes.  
 
Traditionally, cancers have been considered as ‘selectively neutral’ from evolutionary 
point of view. Most cancer victims are at the post reproductive stage of their life, but 
juveniles may also be affected. In particular, the proposal that lethal cancers in juveniles 
played a significant role in the evolution of complex animals was put forward, by 
Graham in the Cancer Selection hypothesis (1992). He postulated that cancer killed 
numerous juveniles and concluded that the resulting accumulation of defences against 
the disease promoted the emergence of complexity and hence development of complex 
animals from simpler multicellular ancestors. The presence of neoplasias across the 
animal kingdom from molluscs to mammals highlights the ancestry of cancer as a 
disease (O’Connell 2010). This hypothesis thus tightly intertwines cancer with 
evolution and life history, and specifically proposes that cancer is a by-product of novel 
adaptation – a standpoint gaining considerable support from data and most recently 
reviewed by Zimmer (2007). It is highly possible that an anticancer adaptation (cancer 
selection in action) has evolved for survival in many environments (e.g. dark skin in 
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Africans, Jablonski and Chaplin (2010)). Cancer selection can be summarised as 
selection to prevent/ postpone deaths due to cancer and it is a key line of investigation 
in current cancer research.  
 
To maintain the genetic stability and survival of an organism, certain mechanisms exist 
that function in co-ordination, for example DNA damage pathways, signal transduction 
mechanisms (e.g. Wnt signalling pathway), DNA mismatch repair pathways to mention 
but a few (O’Driscoll, 2008). These and all other pathways should work in perfect 
coordination for the survival of the organism and to reduce deleterious mutations. If one 
or more genes malfunction, uncontrolled or cancerous growth can result. Organisms that 
have survived must have evolved “anticancer mechanisms” or ‘tumour suppressor genes 
through the process of adaptive evolution (O’Connell, 2010). Our objective is to analyse 
empirical cancer data from completed genomes for signatures of this adaptive evolution 
and to use this as a proxy for evidence of cancer selection. In particular, we want to 
contrast medically relevant species, specifically mouse and human and their ancestral 
lineages for evidence of lineage specific variations that may lead to better modelling of 
human colon cancer in rodents (Massaad et al. 1992, Chen et al. 2012).  
 
In this chapter, we would thus like to know - if mouse CRC orthologs68 have undergone 
any positive selection, as compared to humans, (mice have higher metabolic rates and 
have undergone 180 million years (MY) of independent evolution). Given the strong 
tendency for using murine models for human disease, a positive answer to this question 
means that such models for colon cancer may be less reliable. Therefore this analysis 
has predictive power in determining which models mimic the human disease more 
closely. In addition to answering this question, (which is important from an 
evolutionary medicine perspective in order to access instances where mouse may not be 
effective model for the human disease phenotype), analysis of all other lineages may be 
used to frame these results in the context of all mammals. In consequence, in this study, 
not only the human and mouse lineages, but all lineages leading to extant species in our 
new dataset are analysed, which allows us to gain a greater understanding of the level of 
lineage-specific functional shift that has occurred in CRC associated genes. Moreover, it 
                                                 
68 genes in different species which originated from a common ancestor , often with similar function 
i.e. genes resulting from speciation events. 
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allows us to site these hereditary mutations and their relationships within the broader 
context of factors initiating and progressing the disease. 
4.1.1  Genes, Pathways and Colon cancer 
 
As discussed in Chapter 3, cancer occurs due to changes in genetic and epigenetic 
factors and the interactions between them. Genetic changes can be of two types - 
somatic mutations (causing sporadic cancers) or germline mutations (causing hereditary 
cancers) that could have been triggered due to epigenetic events (Toyota and Suzuki 
2010). Advances in genome technology have now made it possible to screen the entire 
cancer genome for cancer specific/linked mutations with the hope of ultimately gaining 
a better understanding of cancer as a genetic disease. However, studies have also 
suggested that a large number of infrequently mutated cancer genes function within a 
relatively small number of signalling pathways that cooperate (by aberrant 
activation/deactivation) to induce disease(s). This means that, it is easier to target the 
signalling pathways themselves rather than the individual gene/ protein (Frank 2012). A 
recent finding has suggested that, Wnt signalling pathways behave aberrantly due to 
epigenetic deregulation of pathway inhibitors (Costa et al. 2010), which could be true 
for other signalling pathways as well. It is possible that the deregulation in pathways 
can then trigger mutation, which can then lead to uncontrolled cell growth. 
 
For the evolutionary analysis carried out in this chapter, germline mutated colon cancer 
genes have been chosen for investigation (StatEpigen database also holds CRC data 
predominantly currently) which are described in more detail in Materials and methods 
section (section 4.2). The aim of this chapter is to test the hypothesis that genes 
involved in hereditary colorectal cancers have signatures of adaptive evolution. This 
results chapter has been published (Morgan et al. 2012). 
4.1.2 Hereditary forms of CRC 
 
Colon cancer can be hereditary (around 20% of cases) or non-hereditary (sporadic) 
accounting for around 80% of cases, (Fearnhead et al. 2002). Both HNPCC (Hereditary 
Non-Polyposis Colorectal Cancer, also known as Lynch Syndrome) and FAP (Familial 
Adenomatous Polyposis) are examples of hereditary colon cancer with HNPCC alone 
accounting for 3% of all colon cancer cases, (Strate and Syngal 2005). HNPCC is a 
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hereditary predisposition for developing cancer of the colon and endometrium, together 
with other organs. The genes found to be linked with HNPCC are: MLH1, PMS2, 
MSH2, MSH6, and PMS1, all of which are members of the MMR DNA repair pathway 
(Strate and Syngal 2005). Missense mutations of the mismatch repair gene MLH1 have 
been identified in patients with HNPCC. A large number of MLH1 alterations are 
located in the C-terminal domain that is responsible for constitutive dimerization69 
together with the PMS2 gene (Kosinski et al. 2010). Other studies have shown MSI to 
be the molecular fingerprint of a deficient mismatch repair system and that 
approximately 15% of CRCs display MSI owing to the epigenetic silencing (Section 
1.1.1) of MLH1 or a germline mutation in one of the mismatch repair genes, MLH1, 
MSH2, MSH6 and PMS2 (Vilar and Gruber 2010). The mismatch repair endonuclease 
PMS2 is known to interact with MLH1 and is a component of the postreplicative DNA 
mismatch repair system (MMR). PMS2 is recruited to cleave damaged DNA, this 
recruitment being triggered by the binding of MSH2 and MSH6 proteins to dsDNA 
mismatches followed by the recruitment of MLH1 (Figure 4.1). PMS1 is also involved 
in the repair of DNA mismatches, and it can form heterodimers with MLH1. 
                                            
Figure 4.1: DNA mismatch repair pathway showing interaction between MMR genes. MHS6 combines 
with MSH2 to form the active protein complex that is capable of mismatch recognition. MLH1 acts as a 
heterodimer in conjunction with PMS2, PMS1 (Taken from Figure 1, Morgan et al. 2012). 
                                                 
69 The chemical reaction joining two molecular subunits, resulting in the formation of a single 
dimer. 
  
Chapter-4                          Evolutionary Analysis of CRC genes 
 
 
47 
 
Other hereditary CRC syndromes are known, such as FAP, AAPC, which are associated 
with defects in DNA mismatch repair genes as well as tumour suppressor genes (Strate 
and Syngal 2005). 
4.1.3 Mouse Modelling for Human CRC  
 
Modelling using the mouse as reference for different human diseases and drug treatment 
has a considerable history (e.g. Hanna et al. 2007, Section 1.2). Mouse models of 
colorectal and intestinal cancers do exist and are defined as experimental systems in 
which mice are genetically manipulated or challenged with chemicals to develop 
malignancies in the gastrointestinal tract. There include mouse models used for 
HNPCC, FAP, and inflammation related colon cancer (Baker et al. 1996, Groden et al. 
1991, Berg et al. 1996). There is literature that compares mouse and human with regard 
to several other aspects of cancer (e.g. Massaad et al. 1992 and many others), but 
comparison of the molecular evolution of colon cancer orthologs has, until our 
publication, Morgan et al. (2012), not been documented.  
 
Mouse has many desirable features to be a ‘disease model’ (Section 1.2). At the 
genomic level, mouse protein coding sequences share 78.5% sequence identity with 
their human counterparts (Waterston et al. 2002). With such high levels of sequence 
identity, it may seem reasonable to expect that many orthologs between mouse and 
human would have conserved functions between the two species. However, this 
assumption may have failed to consider the probability for divergence due to ~180 
million years (MY) of independent evolution, (Benton and Donoghue 2007). Another 
issue is the difference between the species in terms of their germline generation times, 
and indeed within the mouse species in terms of their natural versus artificial 
reproductive/germline generation times. Mice are bred in labs at faster rates than their 
wild cousins. It has been argued that such manipulations may have altered the 
evolutionary trade-off faced by mice, so that they are rewarded for investing energy in 
growing quickly and reproducing rapidly (Zimmer 2007). Therefore, artificial selection 
may be selecting negatively with respect to cancer defences (Zimmer 2007).  
 
In particular, some cancer related genes such as Fatty Acid Synthase (FAS), and the 
entire BRCA/Fanconi anaemia pathway have undergone intense evolutionary changes in 
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human, making them significantly different from their counterparts in mice, (O’Connell 
and McInerney 2005, O’Connell 2010). A further example of ortholog divergence 
between human and mouse is the TDP1 gene, (required in Topo1-DNA complex repair 
with protein sequence similarity of 81%). A point mutation from an A-> G at position 
1478 in human TDP1 is linked to a disorder known as SCAN1 (resulting in cerebellar 
atrophy and peripheral neuropathy). However, this mutation in mice does not result in 
the same condition/phenotype (Hirano et al. 2007). Similarly, BRCA1 is known to be 
heavily associated with breast cancer in humans, with BRCA1+/- women having a 50% 
risk of developing breast cancer, while BRCA+/- mice do not show increased 
susceptibility to this cancer, (Hakem et al. 1996). Also, specific mutations in any of the 
genes BCL10, PKLR and SGCA in humans result in disease, but the same mutations in 
the mouse homologs do not result in phenotypic change to a disease state, (Gao and 
Zhang 2003).  These clearly observed differences in phenotype could potentially be the 
result of protein functional shifts (adaptive evolution) in cancer-associated genes in 
either the human or mouse lineages (or indeed their ancestral lineages).  
 
Given these observations, the specific phylogenetic study presented here aimed to 
address the research question as mentioned in Page 44.: “Can mouse be used as a model 
organism for human colon cancer, despite undergoing 180 MY of independent 
evolution?” . 
4.1.4 Theory of Molecular evolution 
 
To set the scene for the practical study, we briefly elaborate on the theory of molecular 
evolution and the role played by positive selection. The neutral theory of molecular 
evolution, (Kimura 1968) states that the vast majority of evolutionary changes at the 
molecular level are caused by random drift of selectively neutral mutants. It was 
received by some as an argument against Darwin's theory of evolution by natural 
selection but Kimura (1983) maintained that the two theories are compatible. It is 
emphasised that, the theory does not deny the role of natural selection in determining 
the course of adaptive evolution (Kimura 1986). However, the theory attributes a large 
role to genetic drift and neglects other important forms of selection that occur in 
genomes, e.g. variation of selective pressure over time or punctuated selection. The 
development of the nearly neutral theory to accommodate the acceptance and spread of 
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slightly deleterious mutations in a population was an important step forward in the 
understanding of molecular evolutionary patterns (Ohta 1973, Ohta and Gillespie 1996). 
The neutralist – selectionist debate continued for almost last half century but during the 
last couple of decades, remarkable progress has been made in the study of molecular 
evolution, due to the development of new statistical methods, advances in 
computational technology and availability of sequence data. In particular, phylogenetic 
analysis of DNA or protein sequences has become a powerful tool for study of 
molecular evolution. This has enabled quantification of adaptive evolution that helped 
resolve the debate. Adaptive evolution is the modern synthesis of the process that 
Darwin originally described in his observations of adaptive radiations of bird 
morphologies (Darwin 1859).  
 
Positive selection is generally described as retention and spread of advantageous 
mutations throughout a population (Yang 1998) and has long been considered 
synonymous with protein functional shift. Recent studies using these codon models of 
evolution in an ML (Maximum Likelihood) framework have combined evolutionary 
predictions of positive selection with biochemical verification of functional affects of 
these substitutions (Levasseur et al. 2006, Moury Simon 2011, Loughran et al. 2012), 
and thus support the link between positive selection and protein functional shift. Details 
on this are also given in (Morgan et al. 2012) which publishes this phylogenetic study. 
Some important driving forces for positive selection are external mechanisms, such as 
adaptation to different ecological niches, and response to disease, along with more 
internal mechanisms, such as co-evolution and compensatory mutations. All of these 
driving forces are relevant to analyses being carried out in fundamental CRC research 
(e.g. MacColl 2011).  
 
Mathematically, at the molecular level, the ratio of nonsynonymous (amino-acid 
altering) substitutions per nonsynonymous site (dN) to synonymous (silent) 
substitutions per synonymous site (dS) is known as ω, and indicates the selective 
pressure at work in that sequence. If ω > 1 it signifies positive selective pressure, ω = 1 
signifies neutral evolution, while ω < 1 indicates purifying selective pressure, (Yang 
1998).   
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i.e.   ω =  

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  … Eq. 4.1 
 
 ω  > 1                   => Positive selection / Adaptive Evolution 
 ω = 1                    => Neutral Evolution 
 ω < 1                    => Purifying/Negative Selective Pressure  
 
An ω > 1 means that nonsynonymous mutations offer a fitness advantages to the protein 
(and its carrier) and have higher fixation probabilities than synonymous mutations 
(synonymous mutations in this context are assumed to be a measure of the background 
rate of genetic drift). Previous studies (Arbiza et al. 2006, Kosiol et al. 2008) have 
assessed the level of positive selection present in mammal genomes under a Bayesian 
framework and estimated 5%-9% of genes in mammals are under positive selection, this 
provides us with a reference or “expected level” of positive selection for our analysis of 
mammal CRC genes.  
 
In this chapter we apply a Maximum Likelihood method based on codon models of 
evolution to assess the selective pressures across our dataset (Yang 2007). These 
methods are far more robust than alternatives such as the sliding window approach 
(Schmid and Yang 2008). However, they do suffer from limitations and have strict 
criteria in terms of dataset size for statistical robustness (Bush 2001, Wong et al. 2004).  
 
Another feature of sequence evolution that can negatively impact on a selective pressure 
analysis is recombination. In previous work by Anisimova et al. (2003), to evaluate the 
robustness of the Likelihood Ratio Tests (LRTs) simulations were performed, the 
results showed that type 1 error rates can be up to 90% with relatively high rates of 
recombination in protein coding sequences resulting in the misinterpretation of 
recombination as positive selection. We have incorporated a test for recombination for 
all genes in the dataset prior to the ML selective pressure analysis as described below. 
4.2 Materials and Methods 
This section explains materials/ resources used and different methods implemented for 
the required analyses under different sub-sections as follows.  
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4.2.1 Selection of germline mutated genes and their orthologs 
 
For the investigation, 22 germline-mutated genes, known to be involved in the onset of 
CRC were selected from the Cancer Gene Census at the Sanger Institute (Futreal et al. 
2004). The complete list of genes used for this analysis is provided in Table 4.1 (along 
with their corresponding Ensembl Identifier, the associated cancer syndrome, the 
tumour types observed, the pathways they are involved in and the corresponding 
references). Some of these genes and their association with HNPCC are described in 
Section 4.1.2 in more detail. 
 
Other genes, APC (Syndrome: FAP, pathway: APC), CDH1 (Syndrome: Familial 
gastric carcinoma, pathway: APC), VHL (Syndrome: Von Hippel-Lindau Syndrome, 
pathway: HIF1), TP53 (Syndrome: Li_Fraumeni syndrome, pathway: p53), STK11 
(Syndrome: Peutz-Jeghers syndrome, pathway: PI3K), PTEN (Syndrome: Cowden 
syndrome, pathway: PI3K), are some examples of tumour-suppressor genes. These 
genes when inactivated, can cause cancer. Mutation/ alteration of stability genes on the 
other hand, promotes tumorigenesis by removing the maintenance of stability, namely 
loss of control of pathways such as MMR (mismatch repair), NER (Nucleotide-excision 
repair) and BER (Base excision repair). Gene MUTYH (causing Attenuated polyposis) 
is involved in the BER pathway while MSH6 gene (causing HNPCC) is involved in the 
MMR (DNA mismatch repair) pathway (Table1, Vogelstein and Kinzler, 2004). Some 
of the pathways that are related to colorectal cancer are involved in DNA damage 
control pathways and the Wnt pathway (APC gene mutation). In general, most of the 
cancer genes can be grouped into 12 critical pathways including: apoptosis, DNA 
damage control, invasion, cell cycle signalling, KRAS signalling, and TGF-beta 
signalling amongst others (Vogelstein and Kinzler 2004). 
 
Gene TP53 is found to be involved in P53 signalling pathway (cellular DNA damage 
response pathway) and acts as a hub-protein (Liu and Kulesz-Martin 2001). Some 
genes, such as TP53, KRAS, and APC are involved in cancer with great frequency, up to 
100% of cancers; these are referred in certain literature to as "mountains" (Wood et al. 
2007). Thousands of other genes are involved in cancer but are found at very low 
frequency, fewer than 5%; these genes are referred to as "hills" (Wood et al. 2007). 
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Collectively, however, the hills are also required for, and in some cases drive, the 
carcinogenesis (Wood et al. 2007).  
 
Single gene orthologs were identified for these 22 genes across a set of high coverage 
(>6X coverage) vertebrate genomes (using Compara data from Ensembl) (Hubbard and 
Barker 2002, Hubbard and Andrews 2005). The 21 species analysed were selected 
based on the genome coverage. These included representatives from 3 of the 4 main 
lineages of Eutheria (placental mammals), namely Afrotheria (e.g. elephants and 
manatees), Euarchontoglires (includes Primates, Rodents and Glires), and 
Laurasiatheria (e.g. cows, horses, and bats), as well as outgroup species such as 
platypus, zebrafish, and zebra finch. Details for the complete dataset (genes and species 
used) are provided in Appendix II, Table A. Here, the black boxes imply that, the 
corresponding orthologous gene is not available in Ensembl database for that species.  
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Table 4.1: List of colon cancer genes used and their associated disease and genomic features 
 
Gene Ensembl Identifier Taxa  Number 
Alignment 
 Length Syndrome Tumour Types Observed Pathway(s) References 
APC ENSG00000134982 20 9177 Familial adenomatous  Polyposis (FAP) 
Colon, thyroid, stomach, 
intestine APC 
[Vogelstein and Kinzler 2004, 
Markowitz and Bertagnolli 2009] 
ATM ENSG00000149311 18 9189 Ataxia telangiectasia (A-T) 
 Leukaemia, lymphoma, 
colorectal CIN [Vogelstein and Kinzler 2004] 
BHD ENSG00000154803 20 1737 Birt-Hogg-Dube 
syndrome Renal, colon 
AMPK, mTOR, 
STAT 
[Vogelstein and Kinzler 2004, 
Toro et al. 2008] 
BMPR1A ENSG00000107779 19 1596 Juvenile polyposis Gastrointestinal SMAD [Vogelstein and Kinzler 2004] 
CDH1 ENSG00000039068 15 2649 Familial gastric 
carcinoma Stomach APC [Vogelstein and Kinzler 2004 ] 
MADH4 ENSG00000141646 16 1656 Juvenile polyposis Gastrointestinal SMAD 
[Vogelstein and Kinzler 2004, 
Markowitz and Bertagnolli 2009 
(SMAD4)] 
MET ENSG00000105976 21 4146 
Hereditary papillary 
renal 
 cell carcinoma  
(HPRCC) 
Kidney, colorectal 
RAS, PI3K, 
STAT,  
Beta-catenin, 
Notch 
[Vogelstein and Kinzler 2004, De 
Oliveira et al. 2009] 
MLH1 ENSG00000076242 19 2274 
Hereditary non-
polyposis 
 colon cancer 
(HNPCC) 
Colon, uterus 
 
 
MMR [Vogelstein and Kinzler 2009, Markowitz and Bertagnolli 2009] 
MSH2 ENSG00000095002 18 2802 
Hereditary non-
polyposis  
colon cancer 
(HNPCC) 
Colon, uterus MMR [Vogelstein and Kinzler 2004,  Markowitz and Bertagnolli 2009] 
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MSH6 ENSG00000116062 19 4101 
Hereditary non-
polyposis  
colon cancer 
(HNPCC) 
Colon, uterus MMR [Vogelstein and Kinzler 2004, Markowitz and Bertagnolli 2009] 
MUTYH ENSG00000132781 21 1569 Attenuated Polyposis Colon BER [Vogelstein and Kinzler 2004,  Markowitz and Bertagnolli 2009] 
NF1 ENSG00000196712 17 8523 Neurofibromatosis type I Neurofibroma, colon RTK 
[Vogelstein and Kinzler 2004, 
Cacev et al. 2005] 
PMS1 ENSG00000064933 20 2799 
Hereditary non-
polyposis 
 colon cancer 
(HNPCC) 
Colon, uterus MMR [Päivi et al. 2001] 
PMS2 ENSG00000122512 21 2592 
Hereditary non-
polyposis  
colon cancer 
(HNPCC) 
Colon, uterus MMR [Vogelstein and Kinzler 2004] 
PTEN ENSG00000171862 18 1209 Cowden syndrome  Hamartoma, glioma, uteru, 
colorectum PI3K 
[Vogelstein and Kinzler 2004,  
Markowitz and Bertagnolli 2009] 
SDHB ENSG00000117118 18 840 
Hereditary 
paraganglioma, 
Carney–Stratakis 
Paragangliomas, 
pheochromocytomas, 
gastrointestinal 
HIF1 [Vogelstein and Kinzler 2004,  Pasini et al. 2007] 
SDHC ENSG00000143252 16 507 
Hereditary 
paraganglioma, 
Carney–Stratakis 
Paragangliomas, 
pheochromocytomas, 
gastrointestinal 
HIF1 [Vogelstein and Kinzler 2004,  Pasini et al. 2007] 
STK11 ENSG00000118046 18 1320 Peutz-Jeghers 
syndrome 
 Intestinal, ovarian, 
pancreatic, colorectal PI3K 
[Vogelstein and Kinzler 2004, 
Slattery et al. 2010] 
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Table 4.1 Detail on each of the 22 genes analyzed, HGNC approved gene symbols and Ensembl gene unique identifiers (IDs). The total number of species analyzed for each gene, 
the overall length of alignment in base pairs, the syndrome, tumour type observed and pathway involved are also given. Additionally, references citing alternative gene names are 
also identified. 
 
TP53 ENSG00000141510 16 1185 Li-Fraumeni 
syndrome/sarcoma 
Breast, sarcoma, adrenal, 
brain, colorectal p53 
[Vogelstein and Kinzler 2004, 
Markowitz and Bertagnolli 2009, 
Slattery et al. 2010] 
TSC1 ENSG00000165699 18 3495 Tuberous sclerosis Hamartoma, kidney, 
colorectal PI3K 
[Vogelstein and Kinzler 2004, 
Slattery et al. 2010] 
TSC2 ENSG00000103197 19 5436 Tuberous sclerosis Hamartoma, kidney, 
colorectal PI3K 
[Vogelstein and Kinzler 2004, 
Slattery et al. 2010] 
VHL ENSG00000134086 18 639 Von Hippel-Lindau 
syndrome Kidney, colorectal HIF1 
[ Vogelstein and Kinzler 2004, 
Giles et al. 2006] 
1HGNC 
code        
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4.2.2 Multiple Sequence Alignment (MSA) 
 
The coding DNA sequences of the single gene orthologs were translated and the 
resulting amino acid sequences were aligned using the default parameters in ClustalW 
v2.0.12 (Chenna et al. 2004, Larkin et al. 2007). Using in-house software (‘Mapgap’: 
written in perl), both the original nucleotide sequence files for the orthologous families 
and the translated MSA were taken and gaps added to a DNA alignment file based on 
the position in the amino acid alignment. All alignments were reviewed for quality and 
any poorly aligned regions were manually edited using Se-Al (Rambaut 1996). Se-Al 
does not offer any automation of the editing of alignments. 
4.2.3 Selective pressure analysis using codon models of evolution  
 
Selective pressure analyses were performed using Codeml from PAML version 4.4 
(Yang 1997, Yang and Wong 2005). PAML (Phylogenetic Analysis by Maximum 
Likelihood) is a package of programs for phylogenetic analyses of DNA or protein 
sequences using maximum likelihood (maintained and distributed freely for academic 
use by Ziheng Yang). For our purpose, codonml70(codon-based analysis, codeml for 
codons with seqtype = 1) is used, the main difference between aaml and codonml being 
the unit of evolution in the Markov model, referred to as a ‘site’ in the sequence, is a 
codon in case of codonml while this is an amino acid for aaml.  However, both codonml 
and baseml use similar algorithms to fit models by ML (Yang 2007).  
 
The aligned nucleotide file from Section 4.2.2 (in FASTA file format) is converted to 
(readseq.jar used) Phylip file format and made ready (with some manual editing as 
required by PAML) as an input file for selective pressure analysis using PAML. PAML 
also needs a corresponding tree for each Phylip formatted nucleotide alignment to be 
tested. In this case, pruned species phylogenies were used, as each gene family analysed 
was composed of single gene orthologs, (Benton and Donoghue 2007, Murphy and 
Eizirik 2001). This approach has been taken in PAML analyses in the past (O’Connell 
et al. 2010). To generate the appropriate pruned species tree for each alignment (the 
                                                 
70
 This software assumes that the sequences are pre-aligned codons, the sequence length is an exact 
multiple of 3, and the first nucleotide in the sequence is codon position 1. Introns, spacers and other 
noncoding regions must be removed and the coding sequences must be aligned before running the 
program (PAML documentation).  
 
 Chapter -4                             Evolutionary Analyses of CRC genes 
 
 
57 
 
species present varies slightly from gene to gene), a complete tree is initially generated 
with 21 species involved, using nested parenthesis using treeview software71. This is 
then pruned (using Newick Utilities72) according to the orthologs present in each 
nucleotide alignment. For example, for CDH1 gene, the pruned tree would look like: 
 
(((((((((Human,Chimpanzee),Gorilla),Orangutan),Marmoset),(((Rat,Mouse),Guinea 
Pig),Rabbit)), (((Cow,Pig),Horse),Dog), Elephant),Opossum),Platypus);   
 
Criteria for Selective Pressure analysis: To increase the statistical power of the 
analysis performed, only single gene families containing 6 or more taxa and lengths of 
greater than 500 amino acids, were considered for further analysis. Studies have 
indicated that sequence length, taxonomic representation and divergence depths, all 
have an impact on the power to infer positive selection (Anisimova et al. 2001, Zhang et 
al. 2005). For our analysis, one of the genes, SDHD, is found to have only 3 orthologs, 
so this gene was not suitable for further analysis. 
 
With the sequence data file (in Phylip file format) and treefile (in Newick format), a 
pipeline of analyses was performed using in-house software (under review). This 
software creates (for every model and every starting point on the likelihood plane) an 
appropriate control file, with the appropriate name of the nucleotide alignment data file, 
tree structure file and models parameters and specifications for the analysis, and it does 
this automatically for each gene family we wanted to test. The software also creates 
folders and subfolders for all site-specific models and lineage-site specific models 
(Appendix II, Table B) to be used in PAML analysis so that the output files can be 
retrieved directly to the respective gene family folder per model. In short, the software 
is used to prepare folders for all input files before analysis and to direct the processed 
output to appropriate folders after the selective pressure analyses are completed by 
PAML, and it also performs all appropriate LRTs on the resultant model output. This 
software was designed to reduce the scope for human error in PAML analysis, to 
automate an otherwise complex, involved procedure and to accommodate large-scale 
selective pressure analyses such as the one carried out in this chapter. 
 
                                                 
71 http://taxonomy.zoology.gla.ac.uk/rod/treeview.html  
72 http://cegg.unige.ch/newick_utils  
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Codeml (Codonml here) implements a number of codon-based models in a Maximum 
Likelihood framework that can be used to test alternative and nested evolutionary 
hypotheses. Three different types of codon model were used in this study: (i) a 
homogeneous model (Model 0) - a single ω-value is estimated for the entire alignment; 
(ii) site-heterogeneous models - the sites of the gene sequence are grouped into two or 
more site classes (K parameter), each with its own ω-value estimate; and (iii) lineage-
specific heterogeneous models - a different ω parameter is estimated for different site 
classes in combination with different lineages (Yang 1997, Yang 2007, Murphy et al. 
2001). Seven site-heterogeneous models were used, conventional annotations were 
retained for these models: Model 1 (Neutral), Model 2 (Selection), Model 3 Discrete 
(K73=2), Model 3 Discrete (K=3), Model 7, Model 8 and Model 8a. Two lineage-
specific heterogeneous models were used: Model A and Model A Null. The complete 
set of models used is given in Appendix II, Table B.  
The goodness-of-fit of the different models is assessed statistically using a likelihood 
ratio test (LRT). The LRT compares the log-likelihoods of a null model with the 
alternative model. For hierarchically nested models, the test statistic of an LRT 
approximates the χ2 distribution with degrees of freedom equal to the number of 
additional free parameters in the alternative model compared to the null model. Because 
of this, the critical value of the test statistic can be determined from standard statistical 
tables. If the p-value of the test statistic exceeds that critical value (i.e. if the alternative 
model fits the data significantly better than the null model), then the null model can be 
rejected. For example, if the test statistic of an LRT comparing Model 1 (Neutral) with 
Model 2 (Selection) is greater than the critical value determined from the χ2 
distribution, Model 1 can be rejected. If ω1 > 1 under Model 2, positive selection may 
be inferred. The set of codon models used in this analysis and LRTs used for analysis is 
provided in Appendix II, Table B and Table C respectively. 
The branch/lineage –specific models allow ω to vary among branches in the phylogeny 
and are designed for detecting positive selection acting on particular lineages (Yang 
1998; Yang and Nielsen 1998). The site models allow ω to vary among sites (among 
codons or amino acids in the protein) (Nielsen and Yang 1998; Yang et al. 2000b). A 
                                                 
73
 Site class (Used explicitly in discrete models M2 and M3. However, For Model M0, K=1; for M1 (Neutral) and 
M3(Discrete K=2), it is 2, for M2(Selection) and M3(Discrete K=3), it is 3, for M7(β), K=10 and for M8 (β and ω 
>1) and M8a (β and ω =1), K=11 (Yang and Swanson 2002). 
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number of such models are implemented in codeml. The branch-site models aim to 
detect positive selection that affects only a few sites on pre-specified lineages (Yang 
and Nielsen 2002). The branches under test for positive selection are called the 
“foreground” branches, while all other branches on the tree are the “background” 
branches. The branch-site model used for our analysis is model A. In the LRT, branch-
site model A is an extension of M1 (Test 1 in Zhang et al. 2005) and so it is compared 
to M1 and also to ModelA null (null model of Model A).  
In cases where positive selection is inferred, the posterior probability of a site belonging 
to the positively selected class is estimated using two calculations: Naïve Empirical 
Bayes (NEB) or Bayes Empirical Bayes (BEB). If both BEB and NEB are predicted, the 
BEB results are used preferentially as have been shown to be more robust and account 
for sampling errors in the ML estimates of parameters in the model (Nielsen and Yang 
1998, Yang, Wong et al. 2005).  
PAML output files were then parsed for parameter estimates and log likelihood values 
and LRTs were performed. Where positively selected sites were inferred under a given 
model, these were mapped to the sequence(s) of interest and included in the summary 
file (Table 4.2). Functional annotation of sites under positive selection for each protein 
was obtained from UniProt (UniProt, 2011).  
Recombination analysis also was carried out using GENECONV (version 1.81a) 
(Sawyer 1989), as described in the introduction to this chapter the presence of 
recombination can lead to false positive results in a codeml analysis. Additionally, an 
analysis of human population data was carried out to determine if the selective pressures 
evident at the between species level were also evident in modern human populations 
(Morgan et al. 2012), i.e. if these positively selected amino acids have gone to fixation 
in the human lineage or if there is still large amounts of variation in that position.  
4.3 Results and Discussion 
For recombination analysis, the results are summarized here and the complete set of 
results is provided in Appendix II, Table D. Only the TP53 protein showed significant 
levels of recombination. The regions where recombination was present were compared 
to regions where positive selection was detected. If these regions overlapped - the 
positive selection result was deemed a false positive.  
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For determining selective pressure variation, both site- and lineage-specific selective 
pressure analyses were performed and the statistical significance of all results via LRT 
analyses were assessed to ascertain the codon evolutionary model of best fit. For cases 
with very high value, the notation, ω > > 1 is used throughout the manuscript, as there is 
no biological significance for these extremely large ω values (the precise numbers are 
shown in the codeml results Tables 4.2, for positive results). As the lineage-specific 
analyses are more pertinent to the main question being addressed in this chapter, the 
lineage-specific results have been described in detail in the following section. Site-
specific results are briefly summarised. The model of best fit along with associated 
parameter estimates are described and a summary table for all estimates for each of the 
22 genes is given in Additional file 4 of Morgan et al. 2012. 
 
Analysis of these orthologous datasets revealed significant levels of positive selection. 
A total of 17 of 22 genes were found to be under positive selection in site and/or lineage 
specific positive selection analyses (all positive results are summarized in Table 4.2). Of 
these positive selected genes, 14 are lineage-specific, 5 genes are found to be site-
specific and 2 of these (CDH1 and MUTYH) are both site and lineage-specific. The 
genes found to be positively selected in different functionally important positions  
include: CDH1, PMS1, PMS2, MUTYH and TP53 (Table 4.2).  
 
Lineage-specific models of codon evolution were assessed at multiple phylogenetic 
depths, (i) the extant lineages within the Euarchontoglires clade, and (ii) all ancestral 
lineages leading from the Euarchontoglires to modern mouse and human were also 
tested independently as depicted in Figure 4.2.   
 
Analyses of the lineages within the Euarchontoglires clade resulted in significant 
evidence of lineage-specific positive selection, 6 genes in ancestral lineages and 12 in 
extant lineages (Figure 4.2 and Table 4.2). A total of 14 genes are found to be positively 
selected.  
 
Lineage-specific positive selection was detected in the ancestral Euarchontoglires and 
Hominidae lineages for STK11 and in the ancestral primate lineage for CDH1. The 
ancestral Muridae lineage had evidence of positive selection acting on the TSC1 gene 
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while the ancestral Murinae lineage showed evidence of positive selection for both 
MSH6 and SDHC. The significant finding, therefore, is that for these two genes, SDHC 
and MSH6, the mouse and human orthologs are most likely to have different functions 
and therefore human cancers involving these genes may not be suitable for modelling in 
the mouse system.  
 
Other evidence of positive selection in rest of the extant branches are provided in 
summary Table 4.2 and it is notable here that, neither of the extant human and mouse 
branches show any evidence of positive selection. In this table, the lineage-specific 
positive results for each lineage tested from the Euarchontoglires ancestor to modern 
lineages (see Figure 4.2) are shown in the top panel and the site-specific results are 
shown in the bottom panel. Parameter estimates and number of positively selected sites, 
BEB (Bayes Empirical Bayes) estimations, are also provided. The identified positively 
selected sites (final column) are separated by the posterior probability cutoffs of 0.50, 
0.95 and 0.99. 
 
The analysis is provided in context of their potential functional relevance for those 
genes and was carried out for all genes where functional sites and/or domains have been 
determined/characterised. All sites described were calculated via Bayes Empirical 
Bayes (BEB) analysis (unless otherwise specified). In all cases, the potential functional 
importance of residues based on their sequence position was assessed. There are 
instances where stretches of protein sequence under positive selection are identified and 
there is a possibility that these regions may have very different functions despite their 
sequence position. The corresponding alignments are provided along with the published 
paper in Additional file 2 (The alignments are in nexus file format, 480 pages in word, 
hence not included in this thesis but available at 
http://www.biomedcentral.com/content/pdf/1471-2148-12-114.pdf). The complete set of 
model estimates for the entire dataset are provided along with paper in Additional file 4 
(141 pages in word, hence not included along with this thesis, but available at 
http://www.biomedcentral.com/content/pdf/1471-2148-12-114.pdf). 
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Figure 4.2: Phylogeny of animal species used. The ancestral lineages tested in the analysis are labelled 
with their corresponding names (as used throughout the text). Those lineages where positive selection was 
detected are labelled with filled circles while those lineages tested and producing no evidence of positive 
selection are denoted with an empty circle.     
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 Table 4.2: Summary of parameter estimates and likelihood scores for the model of best fit showing evidence of positive selection. 
 
Gene Model lnL Parameter Estimates Positive Selection 
BEB Positively Selected 
Sites 
Lineage-Specific Analyses 
Euarchontoglires Ancestral Branch 
STK11 modelA -8602.921472 p0=0.93299, p1=0.05633, p2=0.01007, p3=0.00061 ω0=0.03346, 
ω1=1.00000, ω2=197.90897 
Yes 3>0.50, 1>0.95, 0>0.99 
Primate Ancestral Branch 
CDH1 modelA -16658.03484 p0=0.75454, p1=0.23453, p2=0.00834, p3=0.00259 ω0=0.05683, 
ω1=1.00000, ω2=10.20516 
Yes 9>0.50, 1>0.95, 0>0.99 
Hominidae Ancestral Branch 
STK11 modelA -8601.056009 p0=0.93574, p1=0.05920, p2=0.00476, p3=0.00030 ω0=0.03323, 
ω1=1.00000, ω2=44.31709 
Yes 3>0.50, 2>0.95, 1>0.99 
VHL modelA -4263.853291 p0=0.73748, p1=0.25109, p2=0.00853, p3=0.00290 ω0=0.05985, 
ω1=1.00000, ω2=220.34533 
Yes 1>0.50, 0>0.95, 0>0.99 
Chimpanzee Extant Branch 
TSC2 modelA -42659.27711 p0=0.90352, p1=0.09434, p2=0.00194, p3=0.00020 ω0=0.04404, 
ω1=1.00000, ω2=190.09480 
Yes 6>0.50, 2>0.95, 2>0.99 
VHL modelA -4262.098043 p0=0.73571, p1=0.25251, p2=0.00877, p3=0.00301 ω0=0.05976, 
ω1=1.00000, ω2=262.72662 
Yes 3>0.50, 0>0.95, 0>0.99 
 Gorilla Extant Branch 
MSH2 modelA -19485.4338 p0=0.92233, p1=0.06298, p2=0.01375, p3=0.00094 ω0=0.06427, 
ω1=1.00000, ω2=999.00000 
Yes 46>0.50, 34>0.95, 18>0.99   
TSC2 modelA -42569.22884 p0=0.89862, p1=0.08796, p2=0.01222, p3=0.00120 ω0=0.04339, 
ω1=1.00000, ω2=999.00000 
Yes 27>0.50, 14>0.95, 12>0.99   
MSH6 modelA -34009.90221 p0=0.78382, p1=0.18418, p2=0.02591, p3=0.00609 ω0=0.06974, 
ω1=1.00000, ω2=999.00000 
Yes 46>0.50, 34>0.95, 18>0.99   
ATM modelA -69374.08393 p0=0.80673, p1=0.17971, p2=0.01109, p3=0.00247 ω0=0.09745, 
ω1=1.00000, ω2=999.00000 
Yes 48>0.50, 23>0.95, 19>0.99  
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Orangutan Extant Branch 
TSC1 modelA -24068.71106 p0=0.79963, p1=0.18828, p2=0.00978, p3=0.00230 ω0=0.08020, 
ω1=1.00000, ω2=999.00000 
Yes 13>0.50, 6>0.95,5>0.99 
TSC2 modelA -42673.92339 p0=0.90414, p1=0.09295, p2=0.00263, p3=0.00027 ω0=0.04433, 
ω1=1.00000, ω2=40.47366 
Yes 9>0.50, 0>0.95, 0>0.99 
Marmoset Extant Branch 
TSC2 modelA -42616.04524 p0=0.89841, p1=0.09019, p2=0.01035, p3=0.00104 ω0=0.04325, 
ω1=1.00000, ω2=235.10448 
Yes 38>0.50, 9>0.95  
MSH6 modelA -34009.90221 p0=0.78382, p1=0.18418, p2=0.02591, p3=0.00609 ω0=0.06974, 
ω1=1.00000, ω2=999.00000 
Yes 45>0.50, 16>0.95, 12>0.99  
VHL modelA -4262.443441 p0=0.72045, p1=0.22453, p2=0.04195, p3=0.01307 ω0=0.05886, 
ω1=1.00000, ω2=90.26952 
Yes 10>0.50, 0>0.95, 0>0.99 
ATM modelA -69583.23068 p0=0.81640, p1=0.18148, p2=0.00173, p3=0.00038 ω0=0.09939, 
ω1=1.00000, ω2=46.82466 
Yes 2>0.50, 0>0.95, 0>0.99 
Muridae Ancestral Branch 
TSC1 modelA -24126.17894 p0=0.80995, p1=0.18416, p2=0.00481, p3=0.00109 ω0=0.08293, 
ω1=1.00000, ω2=999.00000 
Yes 1>0.59, 0>0.95, 0>0.99 
Murinae Ancestral Branch 
SDHC modelA -3846.690164 p0=0.87666, p1=0.08131, p2=0.03846, p3=0.00357 ω0=0.15340, 
ω1=1.00000, ω2=253.61375 
Yes 9>0.50, 2>0.95, 1>0.99 
MSH6 modelA -34190.13821 p0=0.79911, p1=0.19671, p2=0.00335, p3=0.00082 ω0=0.07057, 
ω1=1.00000, ω2=126.22513 
Yes 3>0.50, 1>0.95, 0>0.99 
Rat Extant Branch 
MADH4 modelA -6092.186945 p0=0.93360, p1=0.01536, p2=0.05021, p3=0.00083 ω0=0.01379, 
ω1=1.00000, ω2=102.33013 
Yes 24>0.50, 11>0.95, 10>0.99  
NF1 modelA -37750.29866 p0=0.96609, p1=0.02476, p2=0.00892, p3=0.00023 ω0=0.02265, 
ω1=1.00000, ω2=999.00000 
Yes 39>0.50, 10>0.95, 10>0.99  
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Guinea pig Extant Branch 
TSC1 modelA -24116.58577 p0=0.80206, p1=0.18611, p2=0.00961, p3=0.00223 ω0=0.08093, 
ω1=1.00000, ω2=284.22603 
Yes 9>0.50, 4>0.95, 0>0.99 
NF1 modelA -37849.50819 p0=0.97375, p1=0.02506, p2=0.00116, p3=0.00003 ω0=0.02414, 
ω1=1.00000, ω2=171.64068 
Yes 3>0.50, 1>0.95, 0>0.99 
Rabbit Extant Branch 
MLH1 modelA -19516.63525 p0=0.80595, p1=0.18541, p2=0.00703, p3=0.00162 ω0=0.05262, 
ω1=1.00000, ω2=7.52747 
Yes 5>0.05, 3>0.95, 0>0.99 
MUTYH modelA -15911.6175 p0=0.61027, p1=0.37605, p2=0.00846, p3=0.00522 ω0=0.07703, 
ω1=1.00000, ω2=998.99697 
Yes 5>0.50, 4>0.95, 3>0.99 
SDHC modelA -3822.683246 p0=0.57771, p1=0.06636, p2=0.31926, p3=0.03667 ω0=0.12047, 
ω1=1.00000, ω2=3.59059 
Yes 51>0.50, 10>0.95, 8>0.99  
ATM modelA -69582.95152 p0=0.81572, p1=0.18045, p2=0.00313, p3=0.00069 ω0=0.09930, 
ω1=1.00000, ω2=7.41594 
Yes 6>0.50, 0>0.95, 0>0.99 
BHD modelA -13523.51719 p0=0.90728, p1=0.05930, p2=0.03137, p3=0.00205 ω0=0.02817, 
ω1=1.00000, ω2=6.50017 
Yes 10>0.50, 7>0.95, 1>0.99  
Site-specific Analyses 
CDH1 m8 -16589.88768 p=0.21848, p0=0.99291, p1=0.00709, q=0.80842 ω=4.53766 Yes 15>0.5, 1>0.95, 0>0.99 
PMS1 m8 -26480.39761 p=0.61337, p0=0.93580, p1=0.06420, q=1.93110 ω=1.32691 Yes 25>0.50, 1>0.95, 0>0.99 
PMS2 m8 -27449.3651 p=0.29104, p0=0.91064, p1=0.08936, q=1.31619 ω=1.28855 Yes 37>0.50, 1>0.95, 0>0.99 
MUTYH m8 -15797.6226 p=0.37255, p0=0.97242, p1=0.02758, q=1.00900 ω=2.44412 Yes 18>0.5, 1>0.95, 0>0.99 
TP53 m8 -8688.19126 p=0.40362, p0=0.94645, p1=0.05355, q=1.77507 ω=1.97385 Yes 13>0.5, 3>0.95, 0>0.99 
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4.3.1 Positive selection in the Euarchontoglires Ancestral branch  
Euarchontoglires ancestral branch (the most ancestral branch tested) resulted in a single 
gene with signatures of positive selection - STK11 (Serine/Threonine-protein kinase 
11). STK11 plays an essential role in G1 cell cycle arrest and acts as a tumour 
suppressor. It phosphorylates and activates members of the AMPK related subfamily of 
protein kinases (Baas et al. 2003, Boudeau et al. 2003). Mutations in STK11 cause 
Peutz-Jeghers syndrome (PJS), a rare autosomal dominant disorder characterized by 
multiple gastrointestinal hamartomatous polyps and an increased risk of various 
neoplasms including gastrointestinal cancer (Hemminki et al. 1998, Nakagawa et al.). 
From the literature we currently know of 17 sites across this gene that when mutated are 
associated with colon-cancer. The Euarchontoglires ancestral lineage has 1.1% of sites 
under positive selection (ω > > 1). Position 206 with a PP (Posterior Probability) = 
0.889 is a hydrophobic Alanine or Valine in Euarchontoglires species or a negatively 
charged Glutamic acid or positively charged Lysine in non-Euarchontoglires species. 
This residue also lies in close proximity to sporadic cancer site A205T and colorectal 
cancer site D208N in Human (Dong et al. 1998). Positively selected position 301 in 
Euarchontoglires (P = 0.885) is present in Euarchontoglires species as an Arginine 
residue and all non-Euarchontoglires as an uncharged Glutamine residue. Site 301 is 
close to R297K and region 303–306, both of which have been implicated in PJS 
(Westerman et al. 1999).  
4.3.2 Positive selection in the Primate Ancestral branch  
 
The branch leading from the Euarchontoglires ancestor towards the primates was 
analysed (termed as the ancestral Primate branch, Figure 4.2). The CDH1 dataset 
consists of 15 taxa and following LRT analysis identified, lineage-specific positive 
selection in 1.1% of sites in the Primate Ancestor (ω=10.21). Positively selected sites 
were compared to human Swiss-Prot entry (P12830) that showed, position 604, with a 
PP of 0.549, falls in close proximity to gastric cancer variant R598Q (Berx et al. 1998). 
At position 604, Primates have a negatively charged Glutamic acid while non-primates 
have a polar uncharged Glutamine.  
4.3.3 Positive selection in the Hominidae Ancestral branch 
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The Hominidae branch (Figure 4.2) also showed evidence of positive selection, in the 
STK11 gene, in 0.51% of sites, or 3 positions, with ω > > 1 (Figure 4.3(a) and Table 
4.2). These positions were then compared to the human Swiss-Prot sequence (Q15831). 
Position 347 represents a radical substitution, as the Hominidae code for an Alanine 
whereas the Murinae lineage encodes an Arginine at this position. For positively 
selected site 378, the ancestral Hominidae lineage encodes the polar residue Serine, 
while the closely related species studied encode Glycine. The functions of these specific 
sites have not been characterised so far in the literature.  
 
A second gene showing evidence of positive selection in the Hominidae ancestral 
branch is the VHL dataset (18 taxa). The VHL gene encodes Von Hippel-Lindaue 
tumour suppressor protein. Mutations in this gene can result in von Hippel-Lindau 
disease (VHDL) - a dominantly inherited cancer syndrome (Latif et al. 1993). VHL 
exhibited weak evidence of positive selection with 1.1% of sites in the ancestral 
Hominidae lineage under positive selection. There was one amino acid that had low 
coverage in the alignment (present only in 6/18 species), so, it is not expanded further.  
4.3.4 Positive selection in the Extant Primate branches  
 
There is also evidence of positive selection in modern non-human primate lineages 
(Chimpanzee, Gorilla, Orangutan and Marmoset). For VHL, positive selection was 
detected in the Chimpanzee lineage with 1.2% of sites (ω > > 1), and also in the 
Marmoset lineage with 5.5% sites (ω > > 1). These positively selected sites were 
compared against human Swiss-Prot entry (P40337), however the region (1–60) was 
only represented by 11/18 species in the alignment and therefore we do not have 
sufficient confidence to explore these sites in more detail.  
 
The MSH6 gene (19 taxa) showed evidence of positive selection in both the Gorilla and 
Marmoset lineages each displaying 3.2% of sites (ω > > 1). Gorilla and Marmoset 
extant lineages were compared against human (P52701) Swiss-Prot entry. No relevant 
functional information could be extracted from positively selected sites in Gorilla, 
however 2/45 positively selected sites in Marmoset fall in close proximity to cancer 
variants. Positively selected site 803 (PP = 0.551) for Marmoset, coincides with CRC 
variants D803G (Kolodner et al. 1999) and V800A (Berends et al. 2002) in Human. 
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Position 803 in Marmoset is a Glutamic acid while in all other mammals it is Aspartic 
acid. Positively selected site 1099 in Marmoset (PP = 0.614) is located between human 
CRC variants R1095H (Kariola et al. 2003) and T1110C (Berends et al. 2002).  
 
Mutation in MSH2 results in HNPCC (Section 4.1.2). Lineage-specific positive 
selection was identified in 1.5% of sites within the extant Gorilla lineage (ω > > 1) for 
MSH2. Positively selected sites were compared to human Swiss-Prot sequence 
(P43246). All 15 sites occur between amino acid position 124–142 which overlaps with 
the region containing variants N127S, N139S and I145M associated with HNPCC1 
(Ollila et al. 2008).  
 
Tuberous sclerosis 2 protein (TSC2) interacts with TSC1 protein, mutations in TSC2 can 
cause tuberous sclerosis type 2 (Tee et al. 2002). Lineage-specific positive selection 
was observed in the following extant lineages, the percentage of sites under positive 
selection in each lineage being shown in brackets, in all cases ω > > 1: Chimpanzee 
lineage (0.2%), Gorilla (1.3%), Orangutan (0.29%), and, Marmoset (1.1%). Positively 
selected sites were compared against human Swiss-Prot sequence (P49815) but the 
functional information was not available.  
 
ATM acts as a DNA checkpoint sensor by activating checkpoint signalling, upon double 
strand breaks (Kishi et al. 2001). Positive selection was detected in the following 
lineages (percentage of the alignment under positive selection shown in brackets): 
Gorilla (1.4%, ω > > 1), Marmoset (0.21%, ω > > 1), and Rabbit74 (0.38%, ω = 7.42). 
BEB significant sites were compared to human (Q13315) and mouse (Q62388) Swiss-
Prot entries. In the Gorilla lineage, positively selected site is 2067 (PP = 0.787), where 
if humans have a substitution of Alanine to Aspartate, it can result in Ataxia 
telangiectasia (AT) which causes weakened immune function and higher disposition to 
cancer (Kishi et al. 2001). No other functionally relevant information was obtained 
while comparing against either Marmoset or Rabbit.  
 
The extant Orangutan lineage also showed evidence of positive selection in the TSC1 
gene for 1.2% of its alignment ω > > 1. Positively selected sites were compared against 
                                                 
74 For ease, discussion of positively selected ATM gene data  for rabbit extant branch is also 
included here. 
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human (Q92574) and mouse (Q9EP53) Swiss-Prot sequences but there was insufficient 
information to elaborate further. 
4.3.4.1 Human population level analysis (using HapMap data) 
 
Genes showing evidence of positive selection in lineages leading to Homo sapiens, i.e. 
the primate and Hominidae lineages (STK11, CDH1 and VHL), were analyzed further to 
determine if there is evidence for any ongoing positive directional selection in modern-
day human populations. The iHS (Integrated Haplotype Score) (Voight et al. 2006), was 
calculated for each SNP in STK11, CDH1 and VHL genes across African Yorubu (Y), 
East Asian (A) and European (C) populations. An iHS score greater than +2 indicate 
that these alleles are segregating at a significant rate within their given populations. One 
intronic SNP in the SDK11 gene, had an iHS score of +2.0385 in European populations. 
For the CDH1 gene, two intronic SNPs with iHS scores of +2.0433 and +2.5838 
respectively, in the East Asian populations. For VHL gene, no population level 
directional selection was identified in modern humans.  
4.3.5 Positive selection in the Ancestral Muridae branch  
 
For ancestral Muridae (MRCA of modern mouse, rat and guinea pig species, Figure 4.2) 
lineage, TSC1 gene (18 taxa) shows positive selection for 0.59% of sites in its alignment 
(ω > > 1). TSC1 interacts with TSC2 and acts as a tumour suppressor gene (Tee et al. 
2002). Defects in TSC1 causes tuberous sclerosis type 1 which is an autosomal 
dominant multi-system disorder. Positively selected sites were compared against human 
(Q92574) and mouse (Q9EP53) Swiss-Prot sequence, however there was insufficient 
information to extrapolate.  
4.3.6 Positive selection in the Ancestral Murinae branch  
 
The ancestral Murinae (MRCA of mouse and rat) lineage shows genes MSH6 and 
SDHC under lineage specific positive selection. The MSH6 mutation is linked to CRC 
(Section 4.1.2). For MSH6 (19 taxa), 0.42% of the sites (3 residues) are under positive 
selection, ω > > 1 (Table 4.2). The corresponding Swiss-Prot sequence (P54276) lacked 
functional details for these positions, thus, potential functional effects remain unknown.  
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SDHC (Succinate dehydrogenase cytochrome b 560 subunit, mitochondrial), with 16 
taxa, acts as a membrane-anchoring subunit for the SDH protein. Defects in this protein 
are reported in paragangliomas and gastric stromal sarcomas (Niemann et al. 2000). For 
SDHC, 4.2% of sites (9 residues) are under positive selection with ω > > 1 (Table 4.2). 
Comparison with the human (Q99643) and mouse (Q9CZB0) sequence from Swiss-Prot 
placed 8 of these sites either in transmembrane or topological domains across the gene, 
with the additional positively selected residue (position 128) neighbouring a metal 
binding site at position 127.  
4.3.7 Positive selection in the Extant Rabbit branch  
 
For extant rabbit lineage evidence of lineage-specific positive selection was observed in 
genes: SDHC, MUTYH, MLH1, ATM (Section 4.3.4) and BHD. The SDHC gene has 
35.59% of sites under positive selection (ω = 3.59). Some 15/51 positively selected sites 
were identified as occurring within 10 amino acid positions of metal binding site at 
position 127 that is also mentioned in the ancestral Murinae analysis. While there are 
extremely high levels of positive selection identified in the rabbit lineage, no other 
relevant functional information could be gathered from the databases at this point. 
 
The MUTYH gene (21 taxa), showed 1.4% of sites (ω > > 1) to be positively selected. 
These sites were compared to human (Q9UIF7) and mouse (Q99P21) Swiss-Prot 
entries, however no relevant functional information could be extrapolated. Radical 
substitutions occurred in all 5 BEB sites in the extant Rabbit lineage, three of which are 
at positions 485–487 in the Nudix hydrolase domain.  
 
The MLH1 gene (linked to CRC, Section 4.1.2), consists of 19 taxa and shows positive 
selection in 0.87% of sites (ω = 7.53). These sites were compared against human 
(P40692) mouse (Q9JK91) Swiss-Prot sequences. At position 120, Rabbit has a polar 
uncharged Serine residue while all other species tested have a hydrophobic Alanine 
residue. This site falls in a region dense with HNPCC2 variants at positions A111V, 
T116K, T117M, Y126N, A128P (Bronner et al. 1994, Pensotti et al. 1997 and 
Kurzawski et al. 2006). Positively selected residues in Rabbit: 209, 478 and 514, each 
fall within 8 amino acid positions of HNPCC2 variants: V213M, R474Q and V506A 
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(Tournier et al. 2008). Also, position 478 identified as under positive selection, lies in 
close proximity to a CRC variant R472I (Kim et al. 2001).  
 
Finally, the BHD gene (20 taxa) shows 3.34% of sites (ω = 6.5) under positive 
selection. Functions of BHD gene are still unknown, although, it is thought that it may 
be a tumour suppressor and may be involved in CRC (Nickerson et al. 2002). BEB 
significant sites were compared to human (Q8NFG4) and mouse (Q8QZS3) Swiss-Prot 
entries. All 10 of the positively selected sites in Rabbit occur in a small region from 
position 61–83 and border a known human cancer variant at position 79 that when 
mutated from Serine to Tryptophan results in sporadic colorectal carcinoma.  
4.3.8 Positive selection in the Extant Rodent (Rat and Guinea Pig) 
 
MADH4 is the co-activator and mediator of signal transduction by TGF-beta. Its defect 
results in pancreatic, colorectal, juvenile polyposis syndrome, juvenile intestinal 
polyposis and primary pulmonary hypertension (Sayed et al. 2002, Sjoblom et al. 
2006). The Rat lineage was identified as being under lineage-specific positive selection 
in the MADH4 gene where 5.1% of sites are evolving with ω > > 1 (number of taxa = 
16). Positively selected sites were compared to human (Q13485) and mouse (P97471) 
Swiss-Prot entries. The majority of positively selected residues in this protein are 
sequential, with 18/24 sites under positive selection in the rat lineage, within 10 amino 
acid positions of the natural human variant 493. When position 493 is mutated from 
Aspartate to Histidine pancreatic carcinoma is induced (Hahn et al. 1996).   
 
NF1 is thought to be a regulator of RAS activity (Ballester et al. 1990). Defects in NF1 
have been shown to cause CRC and breast cancer (Sjoblom et al. 2006).  For NF1 (with 
an alignment containing 17 taxa), there was lineage-specific positive selection identified 
in 0.92% of sites in Rat with ω > > 1 and 0.12% of sites in guinea pig with ω > > 1. 
BEB significant sites were compared to human (P21359) and mouse (Q04690) Swiss-
Prot sequences, however, no functionally relevant information was identified. 
 
TSC1 also shows evidence of positive selection in the extant guinea pig lineage with 
1.2% of the sites with ω> > 1. As before, the positively selected sites were compared 
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against human (Q92574) and mouse (Q9EP53) Swiss-Prot sequences, again, no 
significant information was available. 
4.3.9 Results of site-specific selective pressure analyses  
 
Site-specific results have been summarized in this section as these could be prove to be 
beneficial for those working on rational mutagenesis and/or the identification of 
functionally important regions in the CRC associated genes. These results could also 
add to epigenetic research as links between genetic and epigenetic events have been 
observed (Section 3.2.4). Five genes are identified, that have signatures of site-specific 
positive selection, namely: CDH1, MUTYH, PMS1, PMS2 and TP53, representing 
~23% of the dataset. For each of these five genes, the model of best fit was the site-
heterogeneous model “model 8” (Table 4.2). 
 
For CDH1 (15 taxa) gene, site-specific analysis identified 0.71% sites evolving under 
strong positive selection, ω= 4.54 (Table 4.2). These sites are compared to the human 
Swiss-Prot entry (P12830) to obtain relevant functional information, Figure 4.3 (b). The 
vast majority of positively selected sites (12 sites) in the protein are found within the 
extracellular topological domain (positions 155–709). Many of these positively selected 
are in close proximity to natural cancer variants e.g., position 421 (positively selected) 
which resides within a region (418–423) known to be missing in gastric carcinoma 
samples (Tamura et al. 1996). Positions 457, 465, and 467 are under positive selection 
and map in close proximity to natural variant E463Q found in gastric carcinoma 
samples (Berx et al. 1998). Position 700 resides within the metalloproteinase cleavage 
site (700–701) of CDH1. Position 735 is in close proximity to a gamma-secretase/PS1 
cleavage site (731–732) (Marambaud et al. 2002), and position 553 is in close 
proximity to a glycosylation site (558), essential for the posttranslational modification 
of proteins (Zhou et al. 2008). In the CDH1 gene, the majority of species tested (8/15) 
have hydrophobic residues (Isoleucine, Valine, Leucine) at position 553, the glires 
group (mouse, rat, guinea pig and rabbit) have small residues (Alanine, Serine, 
Threonine), but human, gorilla, and dog have large aromatic residues (Phenylalanine) 
that could significantly alter the protein structure and may affect binding at the 
glycosylation site at position 558. Defects in the CDH1 member of the Cadherin family 
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are linked to hereditary diffuse gastric cancer (Vogelstein and Kinzler 2004, Yoon et al. 
1999). 
 
The MUTYH gene provides instructions for making an enzyme called MYH 
glycosylase, which is involved in the repair of DNA. This enzyme corrects particular 
mistakes that are made when DNA is copied (DNA replication) in preparation for cell 
division75. For MUTYH gene (21 taxa), site-specific analysis identified 18 sites under 
positive selection (ω = 2.44), representing 2.8% of the MUTYH protein (Table 4.2). A 
total of 10 unique sites are reported as natural cancer variants in human (Q9UIF7), 
Figure 4.3 (c). Positively selected sites 406 and 412 are in close proximity to natural 
cancer variants at positions 402 and 411 respectively. Positively selected sites 521, 528 
and 538 also map in close proximity to natural variants, 526 and 531 respectively. Also 
of note are the replacement substitutions observed at Swiss-Prot positions 406 and 412 
that are radical with potential effects on protein structure.  
 
PMS1 (post meiotic segregation increased 1) gene is linked to CRC (section 4.2.1). 
Analysis of PMS1 identified site-specific model of codon evolution model 8 as best fit, 
estimating 25 positively selected sites (6.4% of the alignment) with ω = 1.33 (Table 4.2. 
These sites are compared against human Swiss-Prot sequence P54277. Positively 
selected site 387 resides in close proximity to position 394 - a natural variant (M394T) 
reported in incomplete HNPCC and HNPCC3 (Wang et al. 1999). Due to limited 
functional data it was not feasible to study the remaining 24 sites. However, due to 
PMS1 function in DNA MMR pathway, these positively selected sites could prove as 
ideal candidates for mutagenesis/epimutagenesis studies in the future.  
 
The PMS2 dataset contained 21 taxa and site-specific analysis identified 8.9% of sites 
under positive selection in this protein, ω = 1.29 (Table 4.2). Functional relevance of 
these sites was determined by comparison to Human Swiss-Prot sequence (P54278). 
The vast majority of sites (32) reside within the 430–645 region of the alignment. This 
region of the alignment is highly variable and could not be improved manually. 
Functional characterization for this region is also lacking and therefore it was not 
possible to assess functional relevance. Outside this region, two positively selected 
sites, 402 and 406 (PP = 0.632 and 0.728 respectively) flank a phosphoserine 
                                                 
75 http://ghr.nlm.nih.gov/gene/MUTYH 
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modification site (403) (Beausoleil et al. 2006). Both substitutions are radical and could 
affect the function at position 403.  
 
The TP53 protein (P04637) is 393 residues in length with 343 of these sites reported as 
natural variants that cause/lead to cancer including but not limited to CRC and gastric 
cancers (UniProt, Varley et al. 1995, Guran et al. 1999). In our analysis of TP53 we 
have 16 taxa. Mutations in this gene radically affect function and therefore we would 
expect to find evidence of strong purifying selection across sites and lineages. However, 
results indicate that site specific positive selection is at work with 13 sites under 
positive selection, ω = 1.97, Figure 4.3 (d) and Table 4.2 for detailed analysis. On 
inspection of the 14 sites, it is determined that 11 sites are located within the first region 
of the protein (positions 1–83), a region responsible for interaction with the 
methyltransferase HRMT1L2 and the recruiting of promoters to the TP53 gene (An et 
al. 2004). A cluster of positively selected sites is identified, namely positions 46 and 47, 
along with an additional 7 sites within ten residues 39, 52, 53, 54, 55, 56, and 59 (see 
Additional file 4, Publication). Mutation of position 46 can abolish phosphorylation by 
HIPK2 and acetylation of K-382 by CREBBP (Hofmann et al. 2002). Region 66–110 of 
TP53 is involved in interaction with WWOX protein and two sites are identified (Swiss-
Prot positions: 72 and 81), under positive selection within this region. Positively 
selected position 129, is located within a region reported to interact with HIPK1 (100–
370) and AXIN1 (116–292), and in addition is also located within a region (positions 
113–236) that is required for interaction with FBX042. Positively selected residue 355 
is located within the CARM1 interaction region (300–393), the HIPK2 interacting 
region (319–360), and the oligomerization region (325–356).  
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Figure 4.3 Positive selection analysis for 4 genes: (a) STK11, (b) CDH1, (c) MUTYH, and (d) TP53. The x-axis depicts the gene from start to end of alignment. The Y-axis is the 
posterior probability. The vertical red bars on each graph represent the known cancer causing variants from human populations. The black dots on each graph represent the positively 
selected sites identified in this study. 
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4.4 Conclusion 
The results obtained are indicative of selective pressures acting in a lineage-specific 
manner. In this study, the positively selected sites identified, are found to reside 
frequently in regions of functional importance, such as glycosylation sites, protease 
cleavage sites, and sites known to interact with proteins involved in MMR pathways. 
Also of note, positively selected residues are frequently found to be located at, or in 
close proximity to, known cancer associated sites. However, the statistical significance 
of these occurrences is not conclusive (sample sizes are small). Larger sample sizes 
(more genes) and more complete functional information (from Swiss-prot) would be 
helpful in resolving whether these sites are most likely positioned at variants associated 
with cancer. 
 
While comparing the functional divergence in the extant human and mouse lineages for 
the genes analysed, none were observed in our analysis. However, upon testing the 
lineages leading from the MRCA (most recent common ancestor) of mouse and human, 
i.e. Euarchontoglires, positive selection has occurred on certain branches and in specific 
lineages. In the ancestral lineages from the divergence of primates, rodents and glires 
there is evidence of positive selection in 6 of the 22 genes tested (including weak  VHL 
result, as evidenced by p-values (from Table 4.2). Considering all, including extant 
lineages analyzed, lineage-specific positive selection was detected in total of 64% of the 
genes (i.e. 14/22 genes). Studies on the levels of polymorphism observed in Drosophila 
shows positive selection in ~25% of the genes (Eyre-Walker 2004) while studies for 
primates compared to rodents and in the Hominidae reveal much lower levels of 
positive selection, 5-9% of genes in the genome, (Arbiza et al. 2006, Kosiol et al. 
2008). If these previous analyses of primates were to act as references, then the 
expected number of identified genes under positive selection in our dataset, would be 1. 
However, taking the Drosophila data as the upper bound, ~6 genes with evidence of 
positive selection would be expected. In our case we find 64% of our dataset under 
positive selection in either lineage or site specific manner. The genes taken for study 
here are known CRC genes, and their function and close link with cancer might have 
been the reason for this discrepancy – further supporting cancer as a selective pressure.  
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Further, grouping the CRC genes according to their involvement in functional 
pathways, it is found that the MMR pathway has evidence of positive selection in 3 
components of the pathway – 2 of which are site-specific and one is specific to the 
ancestral Murinae lineage, suggesting a specific selective pressure in this clade for this 
process. The site-specific analyses identified a total of 5 genes that are positively 
selected: CDH1, MUTYH, PMS1, PMS2 and TP53. These results are important for 
contributing to our understanding of fundamental functions of these proteins and have 
provided potential targets for rational mutagenesis. Positive selection sites in MMR 
pathway genes might have some connection with epigenetic silencing of these genes 
(these could be hypermethylation prone) as these genes are known to undergo 
epigenetic silencing and thereby initiating deregulation of MMR pathway. 
 
In general, these results indicate that the function of certain proteins associated with 
colon cancer display distinct lineage-specific patterns of substitution indicative of 
positive selection in the ancestral human and mouse lineages. There are a number of 
selective pressures on any given protein that can contribute to patterns of substitution 
that are “falsely” indicative of positive selection. The necessity to continue to interact 
with protein partners may be strong, driving the evolution of the proteins in this study, 
as many form functional complexes with each other or other proteins (Fraser et al. 
2002). Compensatory mutations may also contribute to elevated levels of ω (Lunzer et 
al. 2010).  The effective population size (Ne) of the species tested in this study varies 
enormously (with estimations for modern human populations in the range of Ne = 7,500 
to 3,100 (Tenesa et al. 2007), while estimations for modern mouse populations range 
from Ne = 58,000 to 25,000 (Salcedo et al. 2007), which might have also contributed to 
the detection of false positives.  
 
A weak evidence for ongoing selective pressure in the human genome on the STK11 
and CDH1 has also been detected, but these may be artefacts of the very small effective 
population size76(Ne) of modern humans. Smaller Ne values are associated with 
increased fixation of slightly deleterious substitutions and subsequent elevated ω values, 
(Eyre-Walker et al. 2002). Such slightly deleterious mutations in turn can lead to 
                                                 
76 the number of breeding individuals in an idealised population that would show the same amount 
of dispersion of allele frequencies under random genetic drift or the same amount of inbreeding as 
the population under consideration 
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additional compensatory substitutions that become fixed. Distinguishing substitutions 
that have become fixed, due to positive selection from slightly deleterious substitutions, 
and small Ne, (Eyre-Walker, Keightley 2009) will aid to a more complete understanding 
of protein evolution in the future. 
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5 Chapter 5 
Exploratory Data Mining and Analysis of StatEpigen Database 
5.1 Exploratory Data Mining and Analysis 
In this chapter, an exploratory data analysis on StatEpigen data has been carried out. An 
exploratory data analysis examines the data for simple correlations or consistent 
occurrences in the data, at the distributions or ranges. This initial analysis also helped to 
evaluate the database contents and checks for quality and consistency. The following 
Figures 5.1, 5.2 and 5.3 look at the occurrence of methylation events at different colon 
cancer stages.  
 
Let’s consider the analysis of MLH1 data depicted in Figure 5.1. The methylation 
frequency values are, number of positive results (for methylation)/number of samples 
taken. Each dot in the plot represents a result of a single experiment for MLH1, e.g. if an 
experiment for MLH1 has 100 samples (patients) and 10 of them are methylated at 
adenoma stage, represented as CC_stage = 7 in the plot, the methylation frequency 
value at Y-axis is 0.1. Similarly, for second experiment, for MLH1, for carcinoma stage 
(CC_stage = 10), if there were 50 samples and 20 of them are methylated, this 
methylation value  is represented as 0.4 on the Y-axis. It is of note that, methylation 
frequency is not ‘degree of methylation’ in this context.  
 
For the exploratory data analysis, StatEpigen data tables, ‘cell-state’ , ‘single relation’ 
and ‘event’ tables (in MySQL) are combined, selecting colon cancer data only (as we 
have some data for other forms of cancer) and methylation event only (as we have other 
events e.g. mutation), and the combined table is further processed (e.g. removing - 
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identical columns and non-methylated rows). Finally, the colon cancer stages are 
numbered (for ease of plotting) as in Table 5.1 as follows: 
 
Table 5.1: Different stages of colon cancer (numbered for ease of plotting) in StatEpigen database 
 
  
SN Stages SN Stages 
1 Adjacent to Polyps 8 Stool- Adenoma 
2 Adjacent to adenoma 9 Premalignant mucosa 
3 Adjacent to Carcinoma 10 Carcinoma 
4 ACF (Aberrant Crypt Foci) 11 Stool- Carcinoma 
5 Polyps, stool 12 Serum - Carcinoma 
6 Polyps 13 CRC 
7 Adenoma 14 Metastasis. 
 
 
The resultant data then is plotted in R, to show methylation frequency (defined as the 
number of methylated samples within each sample used for study, Y-axis), for different 
colon cancer stages, (X-axis) for 3 different genes selected based on their frequency of 
occurence in the current database, these are MLH1 (272 occurences), CDKN2Ap16 (241 
occruences) and MGMT (221 occurences), as shown in Figures 5.1, 5.2 and 5.3 
respectively. It is of note, that, the numbers here (e.g. 272), are instances of data 
introduced in database for MLH1 (the sample/patient numbers could, in each instance 
vary). Database content is clearly subject to updating in future (with addition of more 
data). Also, it is not necessarily the case that these genes occur most frequently in CRC, 
but could be biased due to the selection of papers (during  curation) or due to the 
preference for these genes for experiment by various authors. However, it could also be 
possible that these genes are found to be undergo epigenetic changes more frequently 
during experiments, are hence picked up more frequently in experiments.  
 
It is observed that most of the methylation occurs in carcinoma stage for the selected 
genes (MLH1, CDKN2Ap16 and MGMT), the most common methylation frequency 
being in the range 0.1-0.4 for MLH1 and CDKN2Ap16, and  0.2-0.4 for MGMT, 
indicating that in a random sample, around 10 to 40% of the former and 20-40% of the 
later genes are methylated. Methylation also is seen to be occuring more prominently in 
adenoma and carcinoma stage as compared to other stages (e.g. metastasis) in the genes 
selected. These are clearly initial observations only, given provisions as above and any 
subsequent analyses would require cross checking with other data.  
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Methylation frequency versus stages plot in different genes (single relations): 
 
 
Figure 5.1: Methylation frequency in MLH1 gene versus colon cancer stages (14 metastasis, 10-
carcinoma, 7- Adenoma, 2- adjacent to adenoma). 
 
 
 
 
 
Figure 5.2: Methylation frequency in CDKN2Ap16 versus colon cancer stages (14- metastasis, 10-
carcinoma, 7- Adenoma, 2- adjacent to adenoma). 
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Figure 5.3: Methylation frequency in MGMT gene versus colon cancer stages (14- metastasis, 10-
carcinoma, 7- Adenoma, 2- adjacent to adenoma). 
 
 
These are experimental data and can be traced back if any outliers found. The higher 
variability at early stages might be due to smaller sample size. 
 
This analysis answers the question - which genes are augmented in the database the 
most (as data selection could be due to mere coincidence, author preference or 
constraints on the experiments, or could actually be the most hypermethylated genes, as 
mentioned before). The second question that is addressed here is which stages are 
observed to be hypermethylated (adenoma and carcinoma here, again given conditions 
as mentioned before), according to our current database release. This analysis is one of 
the examples that show the type of questions that can be posed, with the StatEpigen 
database, in order to evaluate its contents. 
 
Provided, these genes occur with high incidence, backed up by the evidence that MLH1 
is mismatch repair gene, the other two genes are also shown  in the literature to be 
involved in the  colon carcinogenesis, and given that literature selecion was not 
determined by any deliberate bias towards any particular gene set,  methylation is seen 
to be occuring more prominently in adenoma stage (after carcinoma stage) as compared 
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to other stages (e.g. metastasis) in the genes selected. In first instance, it implies that 
cancer initiation might be detectable with methylation profiling of the genes involved 
during adenoma stage. These probabilities evidently need to be further investigated.  
 
Similar many other queries, genetic, epigenetic and genetic-epigenetic interactions can 
be dealt with, using StatEpigen. This analysis in brief, signifies the scope of StatEpigen.  
5.2 Data analyses: Future work 
Following is the list of data analyses that can be carried out with StatEpigen in future. 
(1) The genes in StatEpigen database can be grouped into tumour suppressor genes, 
oncogenes and mismatch repair (MMR) gene groups and their methylation data can be 
compared.  
(2) Grouping the entire genes available in StatEpigen into somatic and germline 
mutated genes (for colon cancer) and comparing the methylation data could be another 
way of looking into CRC research. COSMIC database information would help to 
differentiate between somatic and germline mutated genes. COSMIC database is 
designed to store and display somatic mutation information and related details and also 
contains information relating to human cancers. 
(3) Epigenetic analysis with respect to driver and passenger genes in colon cancer and 
the difference in their methylation data would be another useful analysis since different 
driver and passenger genes provide insight on targets for colon cancer medication. 
Currently, few genes are known to be driver genes, with most of those associated with 
colon and other cancers, known as passenger genes. In fact, the key challenge is to 
distinguish driver from passenger genes and to discriminate between these. 
(4) In addition to the above, comprehensive cluster analysis of the colon cancer genes in 
StatEpigen, is currently underway to identify the markers while analysis of gene 
pathways and the timeline for gene involvement is still lacking in any derived network. 
5.3 Data Augmentation in StatEpigen database 
The platform of the in-house developed, database resource, StatEpigen (the knowledge 
management system/ KMS) consists of a database (back-end) and a user interface (front-
end). This resource correlates molecular events (gene expressions and mutations etc.) to 
various colon cancer phenotypes (focus- early stage phenotypes)/ epigenetic events. It 
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presently contains around 5700 records on simple events and 2900 records on 
conditional events (on colon cancer). The objective of this database is to facilitate future 
research in cancer – especially for early diagnosis and risk assessment.  
 
Maintenance and upgrading of the StatEpigen resource needs augmentation of the 
database on a regular basis that currently incorporates manual data curation. Manual 
data curation is described in Section 3.3.1 and is the gold standard, maintaining data 
quality, consistency and accuracy. However, it is costly in effort and very time 
consuming. Approximately 45 papers, 15% of current database content in StatEpigen 
database is due to work done over 12 months. One solution to this labour-intensive 
requirement, is to address the data curation process, such that the system is self-
sustainable in future and the data entry, (curation and augmentation), in the database can 
be carried out in an automatic manner. While providing robustness to the resource, such 
a feature is non-trivial and is discussed in Section 5.4.    
5.4 Future Work 
A major possible upgrade in the current Knowledge Management System (KMS) would 
be to design and construct an automatic data-entry pipeline/module that would act as an 
interface between the (suitable) data source(s) and KMS. A review of the literature leads 
to recognition of MIAME (Minimum Information About a Microarray Experiment) 
compliant microarray data in public repositories, including GEO (Gene Expression 
Omnibus)77 at NCBI (US), Array Express at the EBI (UK)78 and CIBEX at DDBJ 
(Japan)79. These databases aim at storing these high-throughput data in accordance with 
MGED (Microarray Gene Expression Data) recommendations.    
 
The DNA methylation arrays and gene expression arrays in these public repositories 
would be valuable as input source(s) to KMS. The raw data from these resources could 
be downloaded, processed (filtered and normalized) and the results fed into the 
StatEpigen KMS as relational event(s), which are then made available to the webportal. 
The new module could then be used as a data processing tool and as an interface 
initially between KMS and GEO.  
                                                 
77 http://www.ncbi.nlm.nih.gov/geo/ 
78 http://www.ebi.ac.uk/arrayexpress/ 
79 http://trace.ddbj.nig.ac.jp/cibex/index.shtml 
 Chapter-5                           Exploratory Data Mining and Analysis of StatEpigen Database 
 
 
85 
 
 
Data Processing: Processing of methylation array data (for example infinium DNA 
methylation assay considered initially to start with) might include discarding the data 
with p-value >0.05 (for statistical significance), removal of unreliable probe data and so 
on. The β-value (level of DNA methylation at each CpG sites (Chapter 1)) then needs to 
be normalized to eliminate batch effects. 
 
Normalization of data, would be one of the important, as well as challenging, tasks 
during the upgrade process, particularly due to the different platforms (e.g. Affymetrix 
chips, Illumina chips, Beadchips). Different normalization methods are likely to be 
required including least square, lowess, total intensity and so on depending on the 
platform being used (Shakya et al. 2010, Schmid et al. 2010).  
 
Once these data are filtered and normalized, these are subjected to series of statistical 
analysis so that the processed output from these arrays can be incorporated as simple 
and conditional (single and double relational) events in StatEpigen KMS. A schematic 
box diagram and a flow chart (Figures 5.4 and 5.5 respectively below) are provided to 
clarify the initial outline conception of the system. 
 
 
 
 
 
 
 
Figure 5.4: Schematic box illustration of anticipated tool 
 
Anticipated tools to be used 
The following tool base is anticipated to be required.  
1. Biobase , Limma and other tools of Bioconductor package in R. 
2. GEOquery - Tool to access GEO from Bioconductor (Sean and Meltzer 2007)  
3. MySQL and php for StatEpigen Biomedical Resource (Currently used). 
 
GEO 
Raw data 
-Download 
-Process  
(Filter, 
normalize) 
 
StatEpigen KMS 
Webportal  
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An illustration of how the processed data from new input source would appear on the 
web portal is explained below. 
 
There would be a button (left hand pane) below the ‘advanced search’- ‘cell-line’ in the 
home page which will be designated “Search by Arrays”. If this button is clicked, all 
available-processed arrays will be displayed at the right hand pane. When one is 
selected, the respective single or double relations will be displayed in a separate single 
window. A ctrl-select feature will be enabled, which makes it possible for multiple 
relations from the multiple arrays to be displayed in the window. For the initial design 
phase, data on arrays can be kept in separate tables in StatEpigen database and will be 
integrated/ migrated later, once the test-phase migration is successful. A simplified 
flowchart on work-flow for possible upgrade on Knowledge Management System, 
StatEpigen is given in Figure 5.5, below. 
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Figure 5.5: Flowchart (simplified) showing single iteration work-flow for proposed upgrade on 
Knowledge Management System, StatEpigen. 
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Upgrade Advantages and Future Features 
Advantages include: 
1. The scope of StatEpigen would be broadened. The array –input upgrade would 
give StatEpigen a second input source to populate the database in addition to 
data curation information from literature /publications only.  
2. Reduction in the volume of manual curation, as most papers from which data are 
currently extracted have the array information uploaded into GEO or Array 
Express (given introduction of new standards80). 
3. Economy in the data augmentation process.  
4. Timely and regular update of data as new research on colon (and other cancers 
in future) becomes available.  
5. Improved possibilities for data analysis and refinement  
6. A degree of self-sustainability for the KMS and for inputs to modelling 
softwares currently being developed. 
There is also a possibility of extension to other platforms, other cancer forms and other 
resources. 
  
In addition to the automation feature, Integration of the StatEpigen data resource with 
other resources (COSMIC is a targeted example in relation to which some interaction 
has already taken place) can also be a flagged as future work. COSMIC database 
features (somatic and germline) mutation information. Other integrable resources are 
potentially, MethyCancer, MethDB (Section 2.4.6) and useful linkage could also include 
murinae epigenetic database, given the close association with human lineage, and use of 
these species as model organisms for human cancers. Furthermore, there is a 
considerable body of work available in murinae lineage for epigenetic research.  
                                                 
80 http://www.ncbi.nlm.nih.gov/geo/info/MIAME.html  
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6 Chapter 6 
Summary and Conclusions 
The investigations reported here make use of the StatEpigen database resource, which 
incorporates data on genetic and epigenetic factors and statistical information on the 
inter-relationships between them. It is seen as complementary to some of the other 
resources, detailed in chapter 2, with potential for integration with and input-sourcing 
from several others. As a small resource, it has nevertheless been plumbed for data on 
gene lineage shift and robustness of murine models for colon cancer in humans, as well 
as potential epigenetic factors in cancer etiology.  
 
In addition to genetic and epigenetic links in initiation and progression of cancer, as 
discussed in Section 3.2.4, some studies (Sawan et al. 2008, You 2012) suggest that 
genetic- epigenetic interactions are complementary in cancer etiology, some others 
suggest they have synergistic effect (e.g. Ogino et al. 2006, in case of colon cancer). 
Denissenko et al. (1997) have suggested that (cytosine) methylation determines 
mutation ‘hotspots’ in human tumour suppressor gene P53 (indicating the possibility 
that majority of these in human genes are at CpGs). Some notable publications, Rideout 
et al. (1990), Mazin (1994) suggest that methylation events trigger mutation events. In 
contrast, other publications suggest the opposite, i.e. some mutation events can induce 
methylation (Poole et al. 2012, Duncan et al. 2012).  
 
Since positive selection (Chapter 4) also is a form of (advantageous) mutation, 
positively selected genes (identified from selective pressure analysis), may be 
associated with methylation events (they could be methylation prone) or vice-versa. 
Such inter-relationships can be explored further through StatEpigen experimental 
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epigenetic data that links the phylogenetic analysis to the big-picture of genetic-
epigenetic interaction again.  
  
While investigating colon cancer from phylogenetic/ evolutionary perspective, 
identifying positive selection in the primate, Hominidae, Muridae and Murinae lineages 
suggested an ancestral functional shift in these genes between the rodent and primate 
lineages. Our finding that, for SDHC and MSH6 genes, mouse might not be an ideal 
model organism for human colon cancer (as these genes are positively selected in 
Murinae lineage), as well as our identification of 15 other genes that are positively 
selected in different functionally important sites/lineages are significant, as these genes 
can now be targeted for more detailed analyses. The site-specific analyses have 
provided potential targets for rational mutagenesis. The positively selected sites 
identified in this study were found to frequently reside in regions of functional 
importance, such as glycosylation sites, protease cleavage sites, and sites known to 
interact with proteins involved in DNA damage repair pathways, with indications also 
that, positively selected residues are frequently located at, or in close to, known cancer 
associated sites. On grouping cancer associated genes according to their involvement in 
functional pathways, it was determined that the mismatch repair (MMR) DNA damage 
response pathway shows evidence of positive selection in 3 components, 2 of which are 
site-specific and one of which is specific to the ancestral Murinae lineage, suggesting a 
specific selective pressure in this clade (Chapter 4).  
 
The literature survey (Chapter 2) carried out as an initial phase of this research provided 
a background check on the stage of development regarding epigenetics related 
biomedical resources. Epigenetic databases are already found to be numerous and range 
from small to large-scale, with considerable ongoing integration and new links still 
being implemented. Major issues are typical of early-stage development, namely quality 
assurance, effective annotation and overall management. The generation of a centralised 
repository for epigenetics-related data is clearly desirable and is projected for the future 
with many large scale initiatives currently launched. Small scale, specialised databases 
are typically sustainable through integration and compatible targets for StatEpigen 
objectives are to include COSMIC, MethDB, MethPrimerDB, amongst others. The 
biomedical resources, GEO, Array Express and CIBEX are also noted as the potential 
data source for StatEpigen resource after its upgrade.  
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Chapter 3 discussed one of the simplest data curation examples in order to illustrate 
what is involved and highlighted the need for automation, Chapter 5 indicated what is 
involved for automation of the data curation process and provided a schematic diagram 
and initial conceptualization, for future implementation. This chapter also provided 
initial example exploratory data analysis. This simple analysis Section 5.1 noted that a 
significant number  of adenoma stage ‘patients’ showed key genes to be methylated, 
which suggests that  methylation profiling is useful as a screening measure. For early 
stages (e.g. polyp, stage 6), samples are, however, too small to determine what useful 
thresholds can be set.  
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Recent advances in molecular biology and computational 
power have seen the biomedical sector enter a new era, 
with corresponding development of bioinformatics as a 
major discipline. Generation of enormous amounts of 
data has driven the need for more advanced storage 
solutions and shared access through a range of public 
repositories. The number of such biomedical resources is 
increasing constantly and mining these large and diverse 
data sets continues to present real challenges. This paper 
attempts a general overview of currently available 
resources, together with remarks on their data mining and 
analysis capabilities. Of interest here is the recent shift in 
focus from genetic to epigenetic/epigenomic research and 
the emergence and extension of resource provision to 
support this both at local and global scale. Biomedical 
text and numerical data mining are both considered, the 
first dealing with automated methods for analyzing 
research content and information extraction, and the 
second (broadly) with pattern recognition and prediction. 
Any summary and selection of resources is inherently 
limited, given the spectrum available, but the aim is to 
provide a guideline for the assessment and comparison of 
currently available provision, particularly as this relates 
to epigenetics/epigenomics. 
 
Introduction 
 
The Human Genome Project (HGP) in 2003 led to 
identification of more than 20,000 genes and 
determined the three billion chemical base pairs of 
human DNA. With the tremendous advances in 
medical technologies, corresponding development 
in computational power, storage capacity, inter-
connectivity and cost effectiveness, this explosive 
growth has resulted in the generation and collection 
of all aspects of biomedical data and, in the past 
decade, the importance of bioinformatics has been 
 
 
*Correspondence to: Kabita Shakya;  
Email: kabita.shakya@gmail.com 
Submitted: 04/12/12; Revised: 07/11/12; 
 Accepted: 07/13/12 
http://dx.doi.org/10.4161/epi.21493 
recognized. 1 Data warehousing2 as a way of 
dealing with large data set size, combines databases 
across an entire enterprise, whereas independent or 
federated systems seek to integrate multiple 
autonomous databases into a single federation, with 
constituent databases interconnected via a network 
and often geographically decentralised.3,4 One 
example is the many bioinformatics data sources 
linked by the Entrez life sciences search engine.5 
 Biomedical data cover a wide range, from 
patient records to information from pharmaceutical 
studies, specific disease research and different 
“omics” studies, including genomics, proteomics 
and transcriptomics. Resource types can be 
classified by two key features: first, the means or 
method by which access is provided to entities; 
second, the nature of the entities themselves. The 
repository or web service that provides access to 
these data are a vital component of biomedical data 
resourcing. 6 An example is PubMed, the NLM’s 
web-based interface to MEDLINE, the premier 
bibliographic index to journal articles in the life 
sciences. In general, resource providers, such as 
PubMeth and MutationDB, review research papers 
from the domain and mine these for information 
relevant to the scientific audience. Typically, non-
profit research institutes, such as the Sanger 
Institute, University of California Santa Cruz 
(UCSC), National Center for Biotechnology 
Information (NCBI), National Institute of Health 
(NIH), European Molecular Biology Laboratory 
(EMBL) and European Bioinformatics Institute 
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(EBI), among others, make such data publicly 
available over the internet so that these can be 
further analyzed/mined for knowledge discovery.  
 Biological/biomedical resources may be 
one of several types, primary, secondary or 
composite. Examples of primary database 
containing information on biological quantities 
themselves indicate those for sequence or structure, 
e.g., SwissProt, PIR (protein sequences), GenBank 
and DDBJ (genome sequences). Secondary 
resources contain derived information from primary 
sources and examples include eMOTIF (Stanford) 
and SCOP (Cambridge). Composite resources 
typically draw information from a variety of 
different databases, such as those of the NCBI 
genome browser and Genecards.7 The most popular 
genome browsers today are Ensembl, NCBI Map 
Viewer and UCSC, which act as gateways for 
access to genetic and epigenetic information.  
 Following completion of the Human 
Genome Project, increased attention has been paid 
to processes that lead to heritable changes in gene 
expression, during development or across 
generations, without altering the nucleotide 
sequence within the DNA. Both epigenetics and 
epigenomics, the genome-wide distribution of 
epigenetic changes, have become major areas of 
research focus. Principal epigenetic phenomena 
encompass DNA methylation, histone modification 
(methylation/demethylation, acetylation/ 
deacetylation, phosphorylation, ubiquitylation and 
sumoylation), gene silencing, genomic imprinting 
and X-chromosome inactivation. Recently-
launched large-scale initiatives include, among 
others, IHEC (International Human Epigenome 
Consortium),8 which plans to map up to 1,000 
reference epigenomes within a decade, and the 
Human Epigenome Project (HEP),9 which aims to 
identify, catalog and interpret genome-wide DNA 
methylation patterns of all human genes in all 
major tissues.10  
 Epigenetics, cancer and other diseases. 
Epigenetic abnormalities have been found to be 
causative factors of cancer, genetic disorders and 
pediatric syndromes, as well as contributory factors 
of autoimmune diseases and aging.11 The recent 
intensive research on cancer-epigenetics has also 
led to the discovery of many epigenetic markers 
that play an important role in disease initiation. As 
a consequence, cancer-related epigenetic resources 
preponderate over others. Two of the large-scale 
project initiatives for cancer research include ICGC 
(see “ICGC” section below) and TCGA (The 
Cancer Genome Atlas). TCGA has achieved 
comprehensive sequencing, characterization and 
analysis of the genomic changes in various cancers 
and intends to chart the genomic changes involved 
in more than 20 types of cancers.12 All of the 
epigenetic resources are outlined in the following 
sections, with additional assessment of their data 
mining capabilities, intrinsic or externally accessed, 
and their adequacy provided where possible.  
 DNA methylation can induce “epigenetic 
silencing” (or loss of expression) of tumor 
suppressor genes, causing normal cells to be 
transformed into cancer cells and is the first and 
most common epigenetic alteration to be 
observed.13,14 A direct link also exists between 
DNA methylation and histone modification, since a 
number of proteins involved in DNA methylation 
(e.g., DNMTs and MBDs) directly interact with 
histone modifying enzymes, such as histone 
methyltransferases (HMTs) and histone 
deacetylases (HDACs).15 Epigenetic resources 
incorporating methylation signatures are described 
in the “Methylation” section below.  
 
Resources for Epigenetic/Epigenomic 
Signatures  
 
Epigenetic/epigenomic resources are inevitably less 
comprehensive to date but can be broadly 
categorized in terms of type of data content, tools 
and access, and are described below.  
 Methylation. Pubmeth,16 a cancer 
methylation database, provides a sorted, annotated 
and summarized overview of genes, reported to be 
methylated in various cancers, with user query 
based on gene or cancer type. PubMeth draws on 
text-mining of Medline/PubMed abstracts, 
combined with manual annotation of pre-selected 
abstracts. The text mining approach in PubMeth is 
fast and intelligent, enabling search of multiple 
aliases and textual variants of these aliases, and 
querying of multiple keywordlists simultaneously. 
PubMeth also provides the facility to browse a pre-
computed gene list, without having to query the 
database directly.  
 MethDB17 is also a major source for 
experimentally confirmed DNA methylation data 
but is general, more sample-oriented and not 
optimized to cancer-related queries. The database is 
designed to store and annotate information on the 
occurrence of methylated cytosines in DNA. It 
currently contains 19,905 methylation content data 
items and 5,382 methylation patterns or profiles for 
48 species, 1,511 individuals, 198 tissues and cell 
lines and 79 phenotypes. MethDB also has a public 
online submission system available.18 The resource 
forms part of an integrated network of biological 
databases through DAS (Distributed Annotation 
System), enabling the epigenetic data to be viewed 
as a layer in the human genome, and is also 
connected to Ensembl (for DNA sequences with 
available MethDB data aligned to NCBI Refseq).  
 A subset resource, MethPrimerDB,19 is a 
database of primer sequences used in PCR-based 
methylation methods. The database depends on 
submissions by users and administrators that 
guarantee the required quality of the database but 
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not necessarily its completeness. To date, there are 
29 primer sets. In 2006, the MethBLAST feature 
was added to MethPrimerDB oligonucleotide 
sequences. Further updates since 2006, however, 
are not found for this resource.  
 MethyCancer20 is a disease-oriented 
database, specifically of human DNA methylation 
and cancer that aims to integrate methylation 
databases and has developed a meta-data format for 
data standardization, with manual curation still 
used for noisy data. Four main types of data are 
included in MethyCancer, namely, (1) CGI clones 
and global CGI predictions, (2) DNA methylation 
data, (3) cancer information, genes and mutations 
and (4) correlations of DNA methylation, gene 
expression and cancer. MethyView, a visualization 
tool from MethyCancer, is used to facilitate the 
browsing of methylation data in the context of 
existing human genome annotations. A search 
engine to query different data types and interactions 
from the MethyCancer database provides simple 
keyword search and also offers advanced options 
namely, “methylation,” “gene,” “cancer,” “clone” 
and “repeat” searches. For example, Methylation 
search enables the user to specify and combine 
query options, such as methylation type (pattern, 
profile, content and domain), data source (BIG/ 
UHN, MethDB,17 HEP,9 Columbia University), 
experimental methods, sample information (tissue, 
sex, age and phenotype) and chromosomal 
positions.  
 On similar lines, Methylogix21 provides a 
high density DNA methylation database of human 
chromosomes 21 and 22, a CpG island DNA 
methylation database for male germ cells, enabling 
comprehensive analysis of DNA methylation 
variation between and within the germ lines of 
normal males, and a targeted DNA methylation 
database of late-onset Alzheimer disease. Similarly, 
Methtools is a collection of software tools for 
handling and analysis of DNA methylation data, 
generated by the bisulfite genomic sequencing 
method.22  
 Genomic imprinting related resources. 
Genomic imprinting is an important epigenetic 
phenomenon whereby inherited genes are 
“imprinted” due to one copy of the gene being 
epigenetically marked or imprinted in either the egg 
or the sperm. Thus, the allelic expression of an 
imprinted gene depends on whether it is inherited 
maternally or paternally. Imprinted expression can 
also vary between tissues, developmental stages 
and species.23 The Geneimprint database24 includes 
genes and related information on genomic 
imprinting for different animals including humans 
and gathered from NCBI. Genes are listed by 
species and sorted by chromosomal location, name 
and imprinting status and are provided through the 
web-interface. Similarly, an imprinted gene and 
parent-of-origin effect database25 presents 
imprinted genes and related effects. This consists of 
two sections: (1) catalog of current literature on 
imprinted genes in humans and animals and (2) 
catalog of reports of parental origin of de novo 
mutations in humans alone. The addition of (2), 
showing a parent-of- origin effect, expands the 
scope of the database and provides a useful tool for 
examining parental origin trends for different types 
of spontaneous mutations. This second section 
currently includes more than 1,700 mutations, 
found in 59 different disorders. The 85 imprinted 
genes are described in 152 entries from several 
mammalian species. In addition, more than 300 
other entries describe a range of reported parent-of-
origin effects in animals.26 A further resource, 
containing information on mouse gene imprinting,27 
also includes an imprinting catalog, as well as 
chromosome anomalies on mutant mouse lines. 
This represents integration of curated information 
from the MRC Harwell stock resource and other 
Harwell databases, with additional information 
from external data resources such as IMSR 
(International Mouse Stain Resource).  
 Histone and chromatin-related 
resources. The Histone Database,28 of the National 
Human Genome Research Institute, provides a 
complete set of histone protein sequences. 
Nucleosomes, through various core histone post-
translational modifications and incorporation of 
diverse histone variants, can serve as epigenetic 
markers to control processes such as gene 
expression and recombination. The Histone 
Sequence Database is a curated collection, 
assembled from major public databases, of 
sequences and structures of histones and non-
histone proteins containing histone folds. A 
substantial increase in the number of sequences and 
taxonomic coverage for histone and histone fold-
containing proteins is available. The database also 
provides comprehensive multiple sequence 
alignments for each of the four core histones (H2A, 
H2B, H3 and H4), the linker histones (H1/ H5) and 
the archaeal histones. Also included is current 
information on solved histone fold-containing 
structures. The database is thus an inclusive 
resource for the analysis of chromatin structure and 
function.  
 Chromatin.us is another web portal that 
includes information on chromatin proteins, 
histones and nucleosome structures and non-histone 
chromatin protein structures, and provides links to 
the protein data bank (PDB) site, which provides 
further details.29 ReplicationDomain30 is an online 
database for storing, sharing and visualizing DNA 
replication timing and transcription data, along with 
other numerical epigenetic data types. Data are 
typically obtained from DNA microarrays or DNA 
sequencing.  
 Gene silencing. An important epigenetic 
phenomenon, gene silencing, has also attracted 
attention and has been well reported in the 
literature. Collected papers are available on Bio-
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Tech Info- Net.31 Similarly, RNA induced 
epigenetics related papers on imprinting by non-
coding RNAs are collated.32  
 Other epigenetic biomedical resources. 
The evolution of epigenetic resources is still in its 
early stages, with provision associated with several 
specific research efforts and groups. Nevertheless, 
in line with genetic/genomic data examples, efforts 
are being made to connect information, even as 
new targets are emerging. The Epigenetics 
Database33 includes all known epigenetics 
genes/proteins discovered to date. The database is 
arranged in hierarchical format, based upon gene 
ontology. While still in its developmental (ß) phase, 
it is expected that future developments will include 
user-submitted meta-data, which will be freely 
available for use in database and flat file format. 
Some sites, e.g., Epigenie,34 also provide 
bioinformatics tools (e.g., CpG Viewer, CpG and 
GC Plotter and tools for CpG Island detection). 
NCBI supported efforts include the Epigenetics 
Antibody Database,35 providing antibody 
information for researchers working in the field of 
epigenetics/epigenomics, and Unigene,36 containing 
same locus-of-origin transcription sequences, 
protein similarities, gene expression, cDNA clone 
reagents, genomic location and associated 
epigenetic information. NARNA,37 supported by 
Newcastle University, incorporates relationships 
between epigenetic events, DNA methylation, gene 
imprinting and X-chromosome inactivation with 
natural antisense RNAs. Other, locally developed 
or supported, current resources include 
StatEpigen,38 with an initial focus on colon cancer, 
although incorporating some information on other 
pathologies for comparison. Data are provided on 
simple and conditional molecular events, since 
many genetic and epigenetic alterations are 
expected to be mutually correlated and synergistic, 
and drive model input at the micro-layer.39 
Specialized resources also exist for plant data.40  
 
Large-Scale Epigenetic Project Initiatives 
 
European project initiatives including HEP. A 
number of European initiatives exist for centralized 
projects on DNA methylation. The Human 
Epigenome Project (HEP9) will provide an 
epigenetic resource of chromosomal DNA 
methylation reference profiles in human tissues and 
cell lines. Other initiatives include chromatin 
profiling (HEROIC, High-Throughput Epigenetic 
Regulatory Organization In Chromatin), treatment 
of neoplastic disease (EPITRON, Epigenetic 
Treatment Of Neoplastic Disease41) and the 
SMARTER42 initiative, which aims to develop 
small inhibitors of chromatin-modifying enzymes. 
Another effort to provide structure to the epigenetic 
research landscape in Europe is that of the 
Epigenetic Network of Excellence, now known as 
Epigenesys, which aims to advance epigenetics 
toward Systems Biology.43  
 Roadmap epigenomics program. The 
Roadmap Epigenomics Program (also known as 
Epigenomics Roadmap initiative), launched by 
NIH (2008), seeks to create a series of epigenome 
maps to study epigenetic mechanisms, develop new 
epigenetic analytics, generate a repository and 
long-term data archive, standardize procedures and 
practices in epigenomics and support new 
technologies for these. As part of the $190 million, 
five-year initiative, the Roadmap Epigenomics 
Mapping Consortium44 was formed to provide a 
public database for human epigenomics data, the 
Human Epigenome Atlas.45 The current release, 
Epigenome Atlas Release 7, includes human 
reference epigenomes and the results of their 
integrative and comparative analyses. 
 The NIH Roadmap Epigenomics Program 
has also established IHEC (International Human 
Epigenome Consortium),8 which aims to coordinate 
epigenome mapping and characterization 
worldwide, in order to ensure high data quality 
standards, coordination of data storage, 
management and analysis and free access to the 
epigenomes produced. To attain substantial 
coverage of the human epigenome, IHEC aims to 
decipher at least 1,000 epigenomes within the next 
7–10 years. Officially launched in Paris (Jan 2010), 
with an initial (first phase) budget target of $130 
million, IHEC intends to coordinate the mapping of 
epigenomes from not only the NIH’s Epigenomics 
Mapping Consortium but also from international 
efforts such as the European Epigenome Network 
of Excellence, the Danish National Research 
Foundation Centre for Epigenetics, and the 
Australian Epigenetic Alliance. The IHEC web 
portal provides links to databases, such as GEO, 
ARRAYEXPRESS and DDBJ, where epigenetic 
sequencing data will be made available.  
 Another significant large-scale program in 
epigenetics is the Encyclopedia of DNA Elements 
(ENCODE).46 This is supported by the ENCODE 
Consortium, an international collaboration of 
research groups funded by the National Human 
Genome Research Institute (NHGRI). This 
initiative aims to identify all functional elements, 
both at the protein and RNA levels, and regulatory 
elements that control cells and circumstances in 
which a gene is active, in the human genome 
sequence.  
 ICGC. Genomic changes that occur in 
various types of cancer are being investigated by 
the International Cancer Genome Consortium 
(ICGC).47 The goal is to obtain a comprehensive 
description of genomic, transcriptomic and 
epigenomic changes in 50 different tumor types 
and/or subtypes. Many samples from one tumor 
type or subtype will be analyzed in detail so that 
this initiative promises to provide crucial insights 
on genetic-epigenetic links.  
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 Discussion and Conclusions  
 
The biomedical resources relating, primarily, to 
epigenetic data that were surveyed here are 
numerous and range from small to large-scale, with 
considerable ongoing integration and new links still 
being forged. In common with many newly 
identified research targets, early-stage resources are 
often very specific and are supported locally, and 
this is still the case for much useful epigenetic data. 
Many such databases and their software tools are 
publicly accessible from academic/research 
institutions, while others are commercially 
available (Table S1). Major issues remain quality 
assurance, effective annotation and overall 
management, but appropriate analysis must also 
keep pace and is typically uneven (Table S2). 
Clearly, the generation of a centralized repository 
for epigenetics-related data is desirable and 
currently lacking, but new technologies offer 
increased potential for processing solutions down 
the line. Notably, biomedical needs are an 
important focus for federated database 
development, health-grid technology and, of 
course, Cloud computing.  
 Major initiatives to ensure quality and 
standards for genetic and epigenetic research do 
exist and some, such as IHEC and HEP, are 
described in this review. With improved 
technology, these should lead to improved data 
mining tools where those currently available for 
epigenetic/epigenomic analyses are limited and 
predominantly sequence-oriented, ranging from 
identification, through PCR and initial pattern 
matching (Table S2 presents the current summary).  
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    Table S1: Table of available Epigenetic Resources 
Other Epigenetic 
Resources: 
Details: URLs: 
NCBI Epigenomic 
sample browser 
Current most comprehensive collection. http://www.ncbi.nlm.nih.gov/epigenomics/browse  
ChromDB Incorporates 3 types of sequences, genome-based, transcript based and NCBI refseq.  http://www.chromdb.org/  
Zhao lab (NIH) data Genome-wide mapping of histone H3 modifications in human CD4 and T cells, High-Resolution profiling of histone 
methylations in the human genome and combinatorial patterns of histone acetylation and methylation in the human genome. 
http://dir.nhlbi.nih.gov/papers/lmi/epigenomes/ ; 
http://dir.nhlbi.nih.gov/Papers/lmi/epigenomes/hgtcell.aspx ; 
http://dir.nhlbi.nih.gov/papers/lmi/epigenomes/hgtcellacetylation.a
spx  
Young Lab Data 
(MIT) 
Genome-wide map of nucleosome acetylation and methylation in yeast. http://web.wi.mit.edu/young/nucleosome/  
REBASE 
(Restriction Enzyme 
Database) 
Collection of information about restriction enzymes, methylases, the microorganisms from which they have been isolated, 
recognition sequences, cleavage sites, methylation specificity, the commercial availability of the enzymes, and references - both 
published and unpublished observations (dating back to 1952). 
http://rebase.neb.com/rebase/rebase.html  
Rett Syndrome DB An interactive version of the mutation frequency and symptoms databases originally established by Dr. Brian Hendrich and 
Skirmantas Kriaucionis at the University of Edinburgh. Aims to collate and display mutation and symptom information from Rett 
Syndrome patients to allow the analysis of how symptoms correlate with MeCP2 mutation status. 
http://www.mecp2.org.uk/  
Web IRSF MECP2 
Variation DB 
(RettBASE) 
This is constructed by merging mutation and polymorphism data from the published literature pertaining to Rett syndrome and 
related clinical disorders, and by incorporating unpublished mutation and polymorphism data that have been submitted. 
http://mecp2.chw.edu.au/  
CREMOFAC A web-database of chromatin remodelling factors, currently with 64 types of remodelling factors from 49 organisms reported in 
literature. 
 
http://www.jncasr.ac.in/cremofac/  
Antibody Validation 
DB 
Aims to collect and share experimental results on antibodies – aiding researchers in selection and validation of antibodies. Site 
began with 200+ histone antibodies tested as part of the ENCODE and Roadmap Epigenomics projects. Non histone antibodies 
from these projects will also be added. 
http://compbio.med.harvard.edu/antibodies/  
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    Table S2: Table of available Tools for Epigenetic Research 
Tools : Details: URLs: 
CpG Island 
Searcher 
Screens for CpG Islands that meet the criteria listed in the website. http://www.uscnorris.com/cpgislands2/cpg.aspx  
Methylator  Predicts if CpG in a DNA sequence is likely to be methylated or not. http://bio.dfci.harvard.edu/Methylator/  
MethPrimer Online tool for designing bisulfite-conversion-based Methylation PCR Primers. Can design primers for Methylation-Specific PCR (MSP) and 
Bisulfite-Sequencing PCR or Bisulfite-Restriction PCR. The input sequence is DNA sequence in any format. The program returns results in both text 
and graphic view. 
http://www.urogene.org/methprimer/  
BiSearch Provides access to a PCR primer-test and primer-design algorithm that can be used for both bisulfite converted and not modified sequences. Search 
can be carried out on various genomes with the designed primers by a fast ePCR method 
http://bisearch.enzim.hu/  
methBLAST Allows for checking primers for bisulfite converted DNA by blasting them against the unmethylated and methylated genomic sequences of human, 
mouse and rat.  
http://medgen.ugent.be/methBLAST/  
Snake-charmer Tool to select restriction enzymes for COBRA http://insilico.ehu.es/restriction/two_seq/snake_c
harmer.html  
MethTools (ver. 
1.x and 2.x ) 
Software tools for the analysis of bisulfite treated DNA. The software does the comparison between unconverted mother sequences and deaminated 
sequences, generates graphical outputs of methylation patterns and methylation density, estimates the systematic error of the experiment and searches 
for conserved methylated nucleotide-patterns. The software can be used to generate files suitable for the submission to MethDB. 
http://genome.imb-jena.de/methtools/ ; 
http://194.167.139.26/methtools/MethTools2_su
bmit.html 
BiQ Analyzer  Software tool for easy visualization and quality control of DNA methylation data from bisulfite sequencing (Java tool, capable of generating archive 
files that can be directly uploaded to MethDB) 
http://biq-analyzer.bioinf.mpi-inf.mpg.de/  
CpGviewer Simple integrated tool for handling bisulphite sequencing projects. It can process plain text sequences or a variety of electropherogram formats, and 
allows interactive editing of the sequences, aligned to a reference sequence. 
http://dna.leeds.ac.uk/cpgviewer/  
CyMATE  CyMATE (Cytosine Methylation Analysis Tool for Everyone) - a software platform to perform in silico analyses of DNA methylation at cytosine 
sites. Suitable for analyses of sequence data obtained with bisulfite genomic sequencing and hairpin-bisulfite sequencing, i.e. single-strand and double-
strand DNA data. 
http://www.cymate.org/  
BISMA BISMA (Bisulfite Sequencing DNA Methylation Analysis) analyses the bisulfite sequencing data that are derived from sequencing of subcloned 
molecules of a PCR product. 
http://biochem.jacobs-
university.de/BDPC/BISMA/  
EpiGRAPH Software for advanced (epi)-genome analysis and prediction. http://epigraph.mpi-inf.mpg.de/WebGRAPH/  
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Other Epigenetic 
Resources: 
Details: URLs: 
NCBI Epigenomic 
sample browser 
Current most comprehensive collection. http://www.ncbi.nlm.nih.gov/epigenomics/browse  
ChromDB Incorporates 3 types of sequences, genome-based, transcript based and NCBI refseq.  http://www.chromdb.org/  
Zhao lab (NIH) data Genome-wide mapping of histone H3 modifications in human CD4 and T cells, High-Resolution profiling of histone methylations in the 
human genome and combinatorial patterns of histone acetylation and methylation in the human genome. 
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Young Lab Data 
(MIT) 
Genome-wide map of nucleosome acetylation and methylation in yeast. http://web.wi.mit.edu/young/nucleosome/  
REBASE 
(Restriction Enzyme 
Database) 
Collection of information about restriction enzymes, methylases, the microorganisms from which they have been isolated, recognition 
sequences, cleavage sites, methylation specificity, the commercial availability of the enzymes, and references - both published and 
unpublished observations (dating back to 1952). 
http://rebase.neb.com/rebase/rebase.html  
Rett Syndrome DB An interactive version of the mutation frequency and symptoms databases originally established by Dr. Brian Hendrich and Skirmantas 
Kriaucionis at the University of Edinburgh. Aims to collate and display mutation and symptom information from Rett Syndrome patients to 
allow the analysis of how symptoms correlate with MeCP2 mutation status. 
http://www.mecp2.org.uk/  
Web IRSF MECP2 
Variation DB 
(RettBASE) 
This is constructed by merging mutation and polymorphism data from the published literature pertaining to Rett syndrome and related 
clinical disorders, and by incorporating unpublished mutation and polymorphism data that have been submitted. 
http://mecp2.chw.edu.au/  
CREMOFAC A web-database of chromatin remodelling factors, currently with 64 types of remodelling factors from 49 organisms reported in literature. 
 
http://www.jncasr.ac.in/cremofac/  
Antibody Validation 
DB 
Aims to collect and share experimental results on antibodies – aiding researchers in selection and validation of antibodies. Site began with 
200+ histone antibodies tested as part of the ENCODE and Roadmap Epigenomics projects. Non histone antibodies from these projects will 
also be added. 
http://compbio.med.harvard.edu/antibodies/  
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Tools : Details: URLs: 
CpG Island 
Searcher 
Screens for CpG Islands that meet the criteria listed in the website. http://www.uscnorris.com/cpgislands2/cpg.aspx  
Methylator  Predicts if CpG in a DNA sequence is likely to be methylated or not. http://bio.dfci.harvard.edu/Methylator/  
MethPrimer Online tool for designing bisulfite-conversion-based Methylation PCR Primers. Can design primers for Methylation-Specific PCR (MSP) and 
Bisulfite-Sequencing PCR or Bisulfite-Restriction PCR. The input sequence is DNA sequence in any format. The program returns results in both text 
and graphic view. 
http://www.urogene.org/methprimer/  
BiSearch Provides access to a PCR primer-test and primer-design algorithm that can be used for both bisulfite converted and not modified sequences. Search 
can be carried out on various genomes with the designed primers by a fast ePCR method 
http://bisearch.enzim.hu/  
methBLAST Allows for checking primers for bisulfite converted DNA by blasting them against the unmethylated and methylated genomic sequences of human, 
mouse and rat.  
http://medgen.ugent.be/methBLAST/  
Snake-charmer Tool to select restriction enzymes for COBRA http://insilico.ehu.es/restriction/two_seq/snake_c
harmer.html  
MethTools (ver. 
1.x and 2.x ) 
Software tools for the analysis of bisulfite treated DNA. The software does the comparison between unconverted mother sequences and deaminated 
sequences, generates graphical outputs of methylation patterns and methylation density, estimates the systematic error of the experiment and searches 
for conserved methylated nucleotide-patterns. The software can be used to generate files suitable for the submission to MethDB. 
http://genome.imb-jena.de/methtools/ ; 
http://194.167.139.26/methtools/MethTools2_su
bmit.html 
BiQ Analyzer  Software tool for easy visualization and quality control of DNA methylation data from bisulfite sequencing (Java tool, capable of generating archive 
files that can be directly uploaded to MethDB) 
http://biq-analyzer.bioinf.mpi-inf.mpg.de/  
CpGviewer Simple integrated tool for handling bisulphite sequencing projects. It can process plain text sequences or a variety of electropherogram formats, and 
allows interactive editing of the sequences, aligned to a reference sequence. 
http://dna.leeds.ac.uk/cpgviewer/  
CyMATE  CyMATE (Cytosine Methylation Analysis Tool for Everyone) - a software platform to perform in silico analyses of DNA methylation at cytosine 
sites. Suitable for analyses of sequence data obtained with bisulfite genomic sequencing and hairpin-bisulfite sequencing, i.e. single-strand and double-
strand DNA data. 
http://www.cymate.org/  
BISMA BISMA (Bisulfite Sequencing DNA Methylation Analysis) analyses the bisulfite sequencing data that are derived from sequencing of subcloned 
molecules of a PCR product. 
http://biochem.jacobs-
university.de/BDPC/BISMA/  
EpiGRAPH Software for advanced (epi)-genome analysis and prediction. http://epigraph.mpi-inf.mpg.de/WebGRAPH/  
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Table A: Details of the data used in the analysis, the 21 species and their genome coverage. 
Species Assembly1 APC ATM BHD BMPR1A CDH1 MADH4 MET MLH1 MSH2 MSH6 MUTYH NF1 PMS1 PMS2 PTEN SDHB SDHC STK11 TP53 TSC1 TSC2 VHL 
Human GRCh37p2 
                      
Chicken WASHUC2 
                          
Chimpanzee CHIMP2.1 
                      
Cow Btau_4.0 
                      
Dog CanFam_2.0 
                     
Elephant loxAfr 
                        
Frog JGI4.1 
                        
Fugu FUGU4.0 
                          
Gorilla gorGor3 
                      
Guinea Pig cavPor3 
                       
Horse EquCab2 
                      
Marmoset culJac3 
                        
Mouse NCBIM37 
                      
Opossum monDom5 
                         
Orangutan PPYG2 
                       
Pig Sscrofa9 
                              
Platypus OANA5 
                               
Rabbit oryCun2.0 
                         
Rat RGSC3.4 
                        
Zebra Finch teaGut3.2.4 
                             
Zebrafish Zv9 
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Table B: Table with Models used in phylogenetic study. 
 
 
Model Name 
 
Characteristics  
 
Positive Selection 
(ω>1)? 
 
M0 One ω allowed across all sites Allowed  
 
 
Site – specific Models 
 
M1: Neutral  Two classes, ω1 fixed at 0 (ω1 <1 after version 3.14 
PAML/Codeml) and ω2 fixed at 1. Returns the 
proportion p2 of sites in the second category. 1- p2 returns 
p1.  
 
Not allowed  
M2: Selection M1 plus an additional class where ω is estimated from 
the data and can be larger than 1.  
 
Allowed 
M3 : Discrete K 
=2 
Two classes of ω allowed without constraint on either 
value, these values are estimated as their relative 
proportions and ω can be larger than 1.  
 
Allowed 
M3 : Discrete K 
=3 
As M3 (K=2) but with 3 unconstrained classes of ω. 
 
Allowed 
M7: Beta ω is assumed to have a beta distribution between values 
of 0 and 1 inclusive. 10 classes of ω allowed. 
 
Not Allowed 
M8: Beta and ω 
>1 
As model 7 but further ω category is estimated from the 
data and can be larger than 1.  
 
 
Allowed 
M8a: Beta and ω 
=1 
As model 8 but with ω fixed to 1; is the null model of 
M8. 
Not Allowed 
 
 
Lineage – specific Models 
 
Model A  Lineage – specific extension of M1. Four ω classes 
allowed, two of which can vary between the foreground 
and background lineages, one which is unconstrained 
apart from equality for the foreground and background 
lineages, and one which is set ω =1.  
 
Allowed  
Model A Null As Model A but with both the ω classes that are allowed 
to differ between the foreground and background 
lineages set to 1. 
 
Not Allowed 
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Table C: Likelihood ratio tests (LRTs) performed using all evolutionary models used in selection 
analysis. 
 
 
Comparison df ∆l Critical χ2 values 
M0 v M3k2 2 X2 ≥ 5.99 
M3k2 v M3k3 - X1 ≥ 1.00 
M1 v M2 2 X2 ≥ 5.99 
M7 v M8 2 X2 ≥ 5.99 
M8 v M8a* 1 X2 ≥ 2.71 (@5%) 
≥ 5.41 (@1%) 
M1 v Model A 2 X2 ≥ 5.99 
 
Model A v Model 
A1(denoted as model 
a null throughout the 
manuscript) 
1 X2 ≥ 3.84 (@5%) 
 
 
* One degree of freedom for the chi square and comparison using a 50:50 mixture of point mass 0 and χ2, 
so the critical χ2 values are 2.71 at 5% and 5.41 at 1%, and not 10% and 2% respectively. 
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Table D: Full set of recombination test results on a per gene and per species basis 
 
Seq Name Sim  p- value 
BC KA 
Value 
Alignment 
start (nuc) 
Alignment 
End (nuc) Len 
Positively 
Selected Sites 
Removed (AA 
positions) 
       
CDH1             
NA NA NA NA NA NA NA 
PMS1             
NA NA NA NA NA NA NA 
MLH1             
Chicken;Fugu 0.0037 0.00967 1713 1739 27 None 
Horse;Platypus 0.0051 0.01317 952 985 34 None 
Dog;Platypus 0.0093 0.02324 952 985 34 None 
Orangutan;Platypus 0.015 0.03912 958 985 28 None 
Human;Platypus 0.0189 0.04617 958 985 28 None 
Gorilla;Platypus 0.0198 0.04772 958 985 28 None 
Chimpanzee;Platypus 0.0209 0.04931 958 985 28 None 
MSH2             
Zebra_Finch;Frog 0.034 0.10025 1435 1463 29 None 
TSC2             
Orangutan;Zebrafish 0.0392 0.08831 1579 1604 26 None 
MET             
Rabbit;Opossum 0.001 0.00217 2530 2606 77 None 
Human;Opossum 0.0054 0.01115 2530 2606 77 None 
Orangutan;Opossum 0.0054 0.01115 2530 2606 77 None 
Chimpanzee;Opossum 0.0054 0.01115 2530 2606 77 None 
Marmoset;Dog 0.0485 0.11156 2875 3032 158 None 
BMPR1A             
Cow;Dog 0 0.00015 205 362 158 None 
Rabbit;Elephant 0.0027 0.00958 226 284 59 None 
Orangutan;Rabbit 0.0141 0.0455 217 285 69 None 
Chimpanzee;Rabbit 0.0141 0.0455 217 285 69 None 
Human;Rabbit 0.016 0.0494 217 285 69 None 
Gorilla;Rabbit 0.0201 0.05818 217 285 69 None 
Marmoset;Dog 0.0317 0.09429 241 332 92 None 
Marmoset;Rabbit 0.0493 0.14138 226 285 60 None 
MSH6             
Gorilla;Chimpanzee 0 0.00006 1066 1529 464 None 
Human;Gorilla 0 0.00007 1066 1529 464 None 
Zebrafish;Chicken 0.0037 0.00783 532 550 19 None 
Gorilla;Orangutan 0.0073 0.01704 2632 2885 254 None 
SDHB             
NA NA NA NA NA NA NA 
STK11             
Cow;Rat 0.0009 0.00338 379 446 68 None 
Cow;Horse 0.0028 0.00893 890 951 62 None 
Cow;Pig 0.0128 0.0475 895 951 57 None 
PMS2             
NA NA NA NA NA NA NA 
MUTYH             
NA NA NA NA NA NA NA 
VHL             
NA NA NA NA NA NA NA 
                Appendix II 
v 
 
APC             
Elephant;Mouse 0.0003 0.00041 1045 1280 236 None 
Dog;Rat 0.0025 0.00565 994 1157 164 None 
Horse;Mouse 0.0028 0.00724 1105 1307 203 None 
Cow;Rat 0.0032 0.0089 994 1157 164 None 
Horse;Rat 0.0052 0.01403 985 1157 173 None 
Orangutan;Mouse 0.0085 0.02012 1045 1241 197 None 
Cow;Mouse 0.009 0.02047 1105 1280 176 None 
Human;Mouse 0.0105 0.02385 1045 1241 197 None 
Pig;Rat 0.0108 0.02465 994 1157 164 None 
Chimpanzee;Mouse 0.0112 0.02552 1045 1241 197 None 
Cow;Pig 0.0118 0.02559 916 1289 374 None 
Gorilla;Mouse 0.0123 0.0273 1045 1241 197 None 
Mouse;Pig 0.0235 0.05456 1105 1280 176 None 
TP53             
Cow;Guinea_Pig 0.0127 0.07289 927 970 44 317 
MADH4             
Rat;Guinea_Pig 0.0157 0.07756 682 752 71 None 
SDHC             
Cow;Guinea_Pig 0.0127 0.07289 927 970 44 None 
ATM             
Gorilla;Chicken 0.0026 0.00616 3541 3587 47 None 
Gorilla;Chimpanzee 0.0035 0.00819 3049 3793 745 None 
Chimpanzee;Chicken 0.0047 0.01096 3541 3587 47 None 
Human;Chicken 0.005 0.0115 3541 3587 47 None 
Orangutan;Chicken 0.0052 0.01222 3541 3587 47 None 
Human;Gorilla 0.0093 0.01851 4927 5641 715 None 
Rabbit;Chicken 0.0173 0.03145 3547 3588 42 None 
BHD             
Cow;Zebrafish 0.001 0.00282 236 254 19 None 
Marmoset;Zebrafish 0.0011 0.00313 236 254 19 None 
Mouse;Zebrafish 0.0011 0.00313 236 254 19 None 
Opossum;Zebrafish 0.0013 0.00365 238 257 20 None 
Cow;Mouse 0.0048 0.01657 208 266 59 None 
Elephant;Zebrafish 0.0136 0.04138 238 251 14 None 
TSC1             
Orangutan;Horse 0.0242 0.06153 1037 1136 100 None 
Horse;Marmoset 0.0474 0.12863 1030 1136 107 None 
PTEN             
NA NA NA NA NA NA NA 
NF1             
Cow;Mouse 0.0218 0.05108 7390 7445 56 None 
Gorilla;Opossum 0.0448 0.10141 7102 7148 47 None 
Opossum;Orangutan 0.0463 0.10479 7102 7148 47 None 
Chicken;Mouse 0.0464 0.10541 7406 7439 34 None 
Human;Opossum 0.0472 0.10828 7102 7148 47 None 
Chimpanzee;Opossum 0.048 0.11007 7102 7148 47 None 
 
 
Table D: Full set of recombination test results on a per gene and per species basis. The value 
highlighted in yellow for TP53 represents a region where recombination was detected with reasonable 
confidence that also coincided with a positively selected residue (i.e. false positive). 
 
 
